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Abstract 
Haemopoietic stem cells (HSC) in vivo are generally accepted to be quiescent, 
entering cell cycle relatively infrequently. However, their capacity for self-renewal 
and multilineage differentiation renders them a formidable target when 
transformation occurs. Chronic myeloid leukaemia (CML), characterised by the 
presence of the BCR-ABL fusion gene, arises in a pluripotent HSC and also 
features a population of quiescent stem cells. Recent data on the effectiveness of 
a targeted therapy for CML, STI571 (STI), designed to inhibit the tyrosine kinase 
activity of the oncoprotein, has cast doubt on the success and durability of clinical 
responses to this treatment. The work contained in this thesis was aimed at 
isolation of quiescent stem cells from both normal and CML samples and 
characterisation of the properties of these rare populations, the response of CML 
stem cells to STI treatment in vitro was also examined; and finally a microarray 
study was undertaken in an effort to elucidate the gene expression profiles of both 
normal and CML quiescent cells compared to their cycling counterparts. 
To isolate these specific cell populations, enrichment of the stem cell fraction was 
achieved by selection methods based on the stem cell marker CD34. Positive or 
negative CD34 selection yielded up to 99% pure CD34+ cell populations. A 
fluorescent activated cell-sorting (FACS) strategy was developed to allow isolation 
of quiescent and cycling stem cells. Using Hoechst (HST) and Pyronin Y (Py) to 
stain the DNA and RNA respectively and gating on the viable, Propidium Iodide 
(PI)", CD34+ population, it was possible to isolate viable stem cells in GO, G1 and 
S/G2/M phases of the cell cycle. 
Success of the sorting strategy was demonstrated by PCR analysis of differential 
cell cycle gene expression in the sorted populations. Further development of 
FACS methodology allowed the division history and stem cell status, as defined by 
CD34 expression, to be monitored under a range of conditions. By staining cells 
with a non-toxic permanent cytoplasmic dye, carboxyfluorescein diacetate 
succinimidyl ester (CFSE), combined with a sorting strategy to enhance division 
peaks, high resolution tracking of cell division was possible. Growth factor 
independence was established for CML stem cells and was used to identify 
leukaemic stem cell proliferation, as normal cells failed to divide under these 
conditions. 
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Using this experimental strategy, it was shown that a number of CML stem cells 
were able to survive exposure to concentrations of STI in excess of those 
achievable in vivo, and that the surviving cells were undivided or quiescent. A 
range of sensitivities to STI between patient samples was shown, however in all 
cases a population of viable, undivided stem cells was observed. In addition, STI 
was also shown to exhibit antiproliferative activity causing the number of quiescent 
cells to increase following treatment in vitro. It is possible that these observations 
may contribute to the lack of disease eradication in vivo by STI, which is rare with 
most patients harbouring detectable BCR-ABL transcripts, despite significant 
clinical responses. 
In an effort to further characterise quiescent stem cells, the HST/Py FACS strategy 
was used to isolate quiescent and cycling stem cell populations from both normal 
and CML samples, which were then processed for microarray studies. The 
analysis of these very specific stem cell populations has yielded a significant 
amount of new data. 
Firstly, the results have shown a differential gene expression profile between 
normal GO and cycling cells that fully validates the sorting strategy. Significant up- 
regulation of known cell cycle genes was observed between normal GO and 
cycling cells. In contrast, CML GO cells exhibited aberrant expression of a number 
of cell cycle genes in the GO fraction, representing a gene profile closer to that of 
cycling cells. The most significant differential gene expression was in a set of 
chemokine genes, which were up-regulated in both normal and CML GO cells 
compared to cycling cells. This has not been previously reported and represents a 
novel finding. Additional data analysis is ongoing and may, in time, yield 
therapeutic targets for CML disease eradication. 
In summary, isolation of specific CML stem cell populations has enabled the 
identification of a quiescent population of cells that are able to escape the effects 
of a targeted therapy in vitro. These results may have significant clinical 
importance as mechanisms of disease persistence, already observed in vivo, are 
elucidated. Furthermore, identification of gene differences between quiescent and 
cycling cells has validated the FACS strategy for isolation of these rare quiescent 
stem cell populations. In addition, data analysis has identified unique differences in 
gene expression of a set of chemokine genes, up-regulated in quiescent cells, 
from both normal and CML populations. These data will have significant 
importance in our understanding of quiescent HSC behaviour. 
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Chapter 1 Introduction 
1.1 The Normal Haemopoietic System. 
The integrity and functional capacity of the immuno-haemopoietic system is 
maintained throughout the lifetime of an animal by a pool of pluripotent stem cells 
residing in the bone marrow. These cells have the capacity to both self renew and 
to differentiate into all haemopoietic cell types, preserving the stem cell pool and 
sustaining a functioning haemopoietic system. In order to achieve this a 
hierarchical structure exists, which results in progressive lineage commitment of 
haemopoietic stem and progenitor cells with successive division in response to 
demand for mature functional cell types. Simply to maintain the status quo the 
haemopoietic system has to produce around 2x1011 erythrocytes and 1010 white 
blood cells each day. Terminally differentiated cells are generally unable to divide 
further and are continuously replaced by the differentiation and proliferation of 
more primitive progenitors. 
By definition all stem cells, regardless of their origin, must possess the intrinsic 
properties of self-renewal, differentiation and proliferation. HSC are rare (-1 in 105 
total bone marrow cells), relatively quiescent, and are defined as those cells 
whose replicative potential is capable of restoring haemopoiesis after marrow 
ablation, therefore possessing the capacity to generate every cell of the immuno- 
haemopoietic system. Clearly this means that the proliferative potential of these 
cells is immense and must be tightly controlled to prevent excessive numbers of 
cells accumulating in the circulation. The control of the HSC compartment is 
closely associated with the bone marrow microenvironment, where the cells are 
influenced by regulatory factors and adhesive interactions. 
1.1.1 Organisation of the Stem Cell Compartment 
HSCs are closely associated with the bone marrow where stromal cells interact 
with stem cells and transmit signals that influence their behaviour. Two types of 
HSC have been identified; long-term repopulating cells (LTRC) and short-term 
repopulating cells (STRC). STRC's are capable of reconstituting myeloid and/or 
lymphoid haemopoiesis for a short period of time, around 4 months in mice 
(Morrison SJ, Weissman IL. 1994; Morrison SJ, Wandycz AM et al. 1997). In 
Susan M Graham, 2005 Chapter 1,18 
contrast LTRC are capable of rescuing an ablated host for the lifetime of the 
animal and of producing cells that can reconstitute a secondary host (Harrison DE 
and Zhong RK. 1992; Morrison SJ and Weissman IL 1994). The initial 
reconstitution by STRC is thought to be a necessary prerequisite to long-term 
engraftment (Szilvassy SJ, Humphries RK et al. 1990) 
Stem cells give rise to an array of terminally differentiated cells via a pool of 
committed progenitors. The primary function of the progenitor population is to 
vastly increase the numbers of differentiated cells, thereby reducing the 
requirement for extensive proliferation of primitive stem cells, minimising the 
chance of a mutation being perpetuated in a cell with self-renewal capacity 
(Abkowitz JL, Catlin SN et al. 2002; Gordon MY, Lewis JL et al. 2002). As HSC 
divide and move toward lineage commitment their self-renewal capacity is lost. 
Their immediate progeny, although multiipotent, have limited self-renewal potential 
and comprise common myeloid precursors (CMP) and common lymphoid 
precursors (CLP). CMP in turn give rise to committed myeloid progenitors 
including erythrocyte/megakaryocytes and granulocyte/macrophages. CLP give 
rise to B and T lymphocytes and NK cells (Akashi K, Traver D et al. 2000; Hao QL, 
Zhu J et al. 2001). However, the boundaries may not be as clear-cut as first 
thought, as an early T-cell progenitor (ETP) which retained some myeloid potential 
has been identified in the Thymus. This is distinct from the CLP in the bone 
marrow, which has no myeloid potential (Allman D, Sambandam A et al. 2003). In 
addition a bi-potential B-cell/macrophage progenitor has been described as being 
present in small numbers in adult murine bone marrow that has the capacity to 
develop into both lineages under the correct conditions (Montecino-Rodriguez E, 
Leathers H et al. 2001). A diagrammatic representation of haemopoietic cell 
development is shown in figure 1.1. 
Susan M Graham, 2005 Chapter 1,19 
T Lymphocyte 
CLP 
NK Lymphocyte 
Self 
renewal -3º " 
Pluripotent B Lymphocyte Plasma Cell 
Stem Cell 
Erythrocyte 
Megakaryocyte 
(blood clotting) 
Quiescent 
stem CMP 
cell pool IN, ak. 
w Macrophage 
Monocyte 
LTRC STRC ". Granulocytes 
Figure 1-1 A diagrammatic representation of the haemopoietic cell hierarchy. 
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The classic model of haemopoiesis is a stochastic one, where stem cells produce 
progenitors that in turn produce differentiated functionally mature progeny in a 
hierarchical fashion. As cells divide they lose their "sternness" and gain 
characteristics of differentiated cells. It has also been accepted that stem cells are 
largely quiescent residing in the GO/G1 phase of the cell cycle. However, emerging 
evidence has suggested there maybe phenotypic changes related to cell cycle 
position, and more recent models propose an organisation that is more akin to a 
continuum, with cells responding to the environmental stimuli they encounter in a 
way that is dependent upon their cell cycle status. Most assays that examine stem 
cells do not take account of the continuous functioning and adaptation that stem 
cells undergo in the course of their lifespan. 
Studies of stem cells that attempt to evaluate their behaviour over time produce 
some intriguing results. It is estimated that around 90-95% of our multipotent stem 
cells are in GO-G1 at any one time. Analysis of long term repopulating cells 
(LTRC) in mice in the presence of continuous BrdU (which substitutes for 
thymidine in newly synthesised DNA) has shown that in fact 90% of these primitive 
cells had incorporated BrdU into their DNA by 12 weeks. It was calculated that 
these cells cycle around once every 30 days (Bradford GB, Williams B et al. 1997). 
Using a similar strategy Cheshier et al were able to show that by 6 months 99% of 
LTRC had entered cell cycle and calculated that approximately 8% of stem cells 
enter cell cycle daily (Cheshier SH, Morrison SJ et al. 1999). However stem cell 
kinetics in the murine system may not be mirrored for human stem cells, and 
clearly similar experiments in human subjects are not feasible. An interesting set 
of experiments using non-human primates (with similar transplantation kinetics to 
humans) showed that primitive stem cells do enter cell cycle although at a much 
slower rate than those of rodent stem cells (Mahmud N, Devine SM et al. 2001). 
Quiescent cells are not inert; whilst they may not be transiting the cell cycle they 
are transcriptionally active including DNA repair. Synthesis of newly repaired 
fragments of DNA will also incorporate BrdU, albeit at a much lower level than 
replicated DNA, and this should be excluded from measurements of incorporation 
due to proliferation (Pang L, Reddy PV et at. 2003). 
1.1.2 Haemopoietic Stem Cell and Progenitor Assays 
All haemopoietic stem and progenitor assays generally determine two factors; 
differentiation potential and proliferation. This necessitated that each assay was 
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specific for the cell population being measured. Clonogenic assays have been 
designed to identify the progeny of each progenitor and usually take the form of 
cells seeded in semi-solid medium containing growth factors specific for the 
population of interest. The read out from these assays is no longer than 3 weeks; 
therefore they are only capable of measuring progenitor and not stem cell function. 
Clonogenic assays detect more mature progenitors and are normally specific for a 
particular lineage depending on the growth factors included. The cells used to 
establish these assays in semi-solid medium may be un-manipulated bone 
marrow, peripheral blood mononuclear cells or cells generated from assays of 
more primitive stem cells such as LTC-IC, discussed in more detail below. CFU- 
GM, CFU-G, CFU-M, and BFU-e are commonly used to demonstrate the potential 
to differentiate down a particular pathway and colonies containing multiple cell 
types are generally regarded as indicative of multipotency. It is accepted that 
combinations of growth factors are needed to induce stem cell differentiation 
(some of which can only act in synergy) and this in turn produces a variety of cell 
types in clonogenic assays. 
The first haemopoietic stem cell assay was the CFU-S assay described by Till and 
McCulloch (Till JE and McCulloch EA. 1961). This assay measured in vivo stem 
cell proliferation and differentiation based on the observation that transplanted 
stem cells form colonies on the spleen of a lethally irradiated host within two 
weeks of transplantation, and that the number of colonies is directly proportional to 
the number of input cells. The cells contained in these visible colonies have the 
capacity to form colonies in a secondary transplant demonstrating self-renewal 
capability. The CFU-S colonies visible at day 8 contain mostly differentiated cells 
with day 12 colonies containing more multilineage cells, which is a reflection of the 
differentiation status of the initiating cells. However, both of these belong to the 
STRC class of stem cells; accordingly, the terminology pre-CFU-S has been used 
to refer to LTRCs. 
To detect more primitive cells in vitro, cultures that include a supportive stroma are 
required. To proliferate in culture LTRC need to have stromal contact that mimics 
the bone marrow microenvironment. The first stromal assay was developed by 
Dexter (Dexter TM, Allen TD et al. 1977) using mouse whole bone marrow that 
was able to generate mature progeny for several months. Ploemacher and Brons 
further refined the assay by seeding cells onto preformed stromal layers that had 
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been irradiated to prevent proliferation of indigenous cells (Ploemacher RE and 
Brons NC. 1988). This technique allowed the development of the cobblestone area 
forming cell assay (CAFC) in which the cells that form a distinctive cobblestone 
pattern underneath the stromal layer, were subsequently shown to demonstrate a 
maturity which correlated inversely with time, as tested in secondary colony 
forming assays. Day 28 CAFC was shown to be proportional to the expected 
frequency of marrow repopulating cells and day 7 CAFC to be equivalent to D-12 
CFU-S (Ploemacher RE, Van Der Sluijs JP et al. 1989). The sequence of events in 
CAFC, which apparently mirrored in vivo stem cell development, led to this assay 
being utilised for the measurement of drug and radiation sensitivity of various stem 
cell populations (Down JD and Ploemacher RE. 1993) 
Another similar assay is the long-term culture initiating cell (LTC-IC) assay but this 
assay has a different end-point. Cells are seeded onto established irradiated 
stromal layers and colony forming assays carried out at 5 weeks using the non- 
adherent cells from the cultures. It has been reported for human cells that the 
CAFC and LTC-IC assays may give conflicting results in terms of primitive cell 
numbers. This may be explained on the basis of differences in the stromal cells 
used. Whilst these assays give an indication of the proliferative capacity of stem 
cells it must be borne in mind that they give no indication of the in vivo homing 
capability which is crucial for HSC reconstitution. 
The only reliable measure of true stem cell potential is still the in vivo repopulation 
assay, a xenograft model which allows human transplanted cells to analysed. This 
model utilises cells transplanted into a diabetic mouse with severe combined 
immunodeficiency disease (NOD/SCID) mice. These mice were produced by 
crossing SCID (T and B cell defects) and NOD mice (partially deficient in NK cells, 
antigen presentation and macrophage function). Interestingly there was no 
requirement to supplement these mice with human cytokines if >500 cells were 
transplanted (Bonnet D, Bhatia M et al. 1999). Either the mouse bone marrow 
stroma produced the required cytokines or the transplanted cells were able to 
secrete them. 
First described by Kamel-Reid and Dick in 1988, this xenograft model has been 
extensively used to demonstrate homing, proliferation, differentiation and self- 
renewal of human stem cells, and has opened the way for more rational 
investigations of human haemopoietic stem cell behaviour (Kamel-Reid S and Dick 
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JE. 1988). Some mouse strains have been further modified to produce human 
cytokines improving the environment for transplanted human cells. This model 
though one of the most useful is not without limitation. For example, there is a bias 
in the transplanted mice toward B cell development with T cell production being 
less favoured. Engraftment can only be monitored for a short time period (around 
6 months lifespan), which is limiting for a model of long-term human engraftment. 
Other xenograft models have been established, most notably in sheep by Zanjani 
et al, however immune rejection necessitated that human HSC be introduced into 
the developing foetus to induce immune tolerance (Zanjani ED, Flake AW et at. 
1994). This model has allowed transplanted human HSC to be monitored over 
several years, and in addition, no radiation or conditioning of the host environment 
was required, minimising disruptive effects on the stem cell niche. However, there 
are a number of disadvantages in large animal models including expense, 
handling, and long term read out. 
1.1.3 Identification of Haemopoietic Stem Cells 
Due to the relative accessibility of haemopoietic stem cells they are probably the 
most extensively studied of all adult stem cell populations. The remarkable 
similarity between mouse and human haemopoietic systems has allowed much of 
the investigative work aimed at defining markers, to be done in the mouse and 
subsequently confirmed for human stem cells. However, the markers used to 
identify stem cells differ between the two, with in vivo repopulating capacity being 
the ultimate verification of stem cell status. 
1.1.3.1 Stem Cell Markers 
There is no single marker for haemopoietic stem cells; a combination of surface 
markers and lack of lineage specific markers expressed on more mature progeny 
is commonly used to isolate stem cell populations. These populations have been 
shown to contain cells with the ability to rescue an ablated host, therefore by 
inference they must contain multipotent stem cells. Table 1.1 lists the markers 
used most commonly for isolation of both mouse and human cells. Fluorescently 
tagged monoclonal antibodies to these surface antigens allow cells to be identified 
by FAGS and the relative stem cell numbers to be calculated. Using FAGS sorting, 
stem cells can be isolated from whole blood or bone marrow though, given their 
rarity, for practical reasons a prior enrichment step is usually included. 
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Human Mouse 
CD34+ Sca-1' 
c-kit+ cKit+ 
Thy-1 bO Thy-1 tO 
Negative for: - _ CD10 B220 
CD14 CD3,4,8 
CD15 Mac-1 
CD16 Gr-1 
CD19 Ter 116 
CD20 
Table 1-1 Table of surface markers used for identification of human and mouse 
haemopoietic stem cells. 
The most common surface markers used to isolate mouse HSC are Lin" Sca-1 i' 
Thy-1b0 cKIT+. (Spangrude GJ, Heimfeld S et al. 1988) The addition of IL-7Ra as a 
marker has allowed the discrimination of CMP and CLP populations. The IL-7Ra+ 
fraction contains almost all of the common lymphoid progenitors giving rise to T, B 
and NK cells, whereas the common myeloid progenitor is found almost exclusively 
in the IL-7Ra fraction of the Lin' Sca-1+ Thy-1b0 population (Kondo M, Weissman IL 
et al. 1997; Akashi K, Traver D et al. 2000). Murine cells also express CD34, 
however experiments using transgenic mice engineered using P1-based artificial 
chromosomes (PAC-transgenics allow human gene and protein expression in 
mouse cells) have shown that CD34 is expressed differently in mice than in human 
stem cells. CD34 is only expressed on human repopulating cells whereas murine 
CMP and CLP express both human and murine CD34. It has been further 
revealed that elements regulating the gene expression of CD34 are very different 
in human and mouse haemopoietic stem cells (Akashi K, Traver D et at. 2000; 
Okuno Y, Huettner CS et al. 2002; Okuno Y, ). 
Undoubtedly the most important human stem cell marker is CD34, a 
transmembrane glycoprotein expressed on the surface of haemopoeitic stem and 
progenitor cells, which was first discovered in a myeloblastic leukaemia cell line 
(Civin Cl, Strauss CL et at. 1984). The exact function of the CD34 molecule on 
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stem cells is as yet undefined; roles in differentiation and cytoadhesion have 
recently been suggested (Krause DS, Kapadia SU et al. 1997; Hidalgo A, Weiss 
LA et al. 2002). Although it's precise role in haemopoiesis is still under 
investigation, it's importance in selection and purification of HSC for both 
experimental purposes and for human transplantation is indisputable. 
CD34 is expressed on -1-4% of normal bone marrow nucleated cells and on 
<0.1% of the nucleated peripheral blood cells under homeostatic conditions. This 
small fraction of the total white blood cells contains almost all of the cells with in 
vivo repopulating capacity as well as the LTC-IC and CFC, but does not include 
terminally differentiating cells (Saeland S, Duvert V et al. 1992), (Civin Cl, Strauss 
CL et al. 1990). Following depletion of cells expressing lineage markers (Lin) the 
CD34' cell population is still extremely heterogeneous, and in an effort to identify a 
more primitive stem cell population, CD34 has been used in combination with 
other surface markers e. g. CD38, which is expressed on CD34' cells as they 
become more mature. CD34+CD38- cells have the capacity to rescue 
immunodeficient mice following transplantation, whereas the more mature 
CD34; CD38+ cells can only confer short-term reconstitution and have no 
secondary repopulation potential (Hogan CJ, Shpall EJ et al. 2002). 
There is now a considerable body of evidence to suggest that CD34' stem cells 
exist in both humans and mice that also have repopulation capacity (Osawa M, 
Hanada K et at. 1996; Bhatia M, Bonnet D et al. 1998). Sato et at documented that 
murine CD34 expression is inducible both in vitro and in vivo and that it is a 
reversible process (Sato T, Laver JH et at. 1999), (Dao MA, Arevalo J et at. 2003). 
Recently it has been demonstrated that the same is true of human CD34 
expression and that CD34'Lin' cells have marrow-engrafting capacity. Furthermore 
tertiary transplants confirmed that long-term engraftment potential was 
demonstrable for both CD34+ and CD34' cells (Zanjani ED, Almeida-Porada G et 
at. 2003). These observations suggest either that expression of the CD34 antigen 
is not necessary for stem cell function or that phenotypically different cells can 
have similar functional capacity. 
Recent published work by Dooley et al has shown that in vitro modulation of the 
CD34 antigen takes place and that it is associated with proliferation status. These 
experiments illustrated that CD34' cells can regain CD34 expression and that their 
proliferative capacity is similar to CD34+ cells. This modulation was not associated 
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with differentiation. In addition, if CD34+ cells remained undivided i. e. quiescent in 
culture for more than 2 days, they lost CD34 expression, which was reinstated 
when these cells started to proliferate. All of these findings illustrate that the Lin' 
CD34+ population is intrinsically heterogeneous with respect to CD34 expression, 
but still retains repopulation activity in this primitive subset that can be used 
clinically for transplantation (Dooley DC, Oppenlander BK et al. 2004). 
Other possible markers for primitive stem cells include CD133, which is expressed 
on a subset of CD34+ cells. These cells include the repopulating cells and primitive 
progenitors excluding erythroid progenitors. However CD133 is also expressed on 
CD34' human cord blood HSC (Yin AH, Miraglia S et al. 1997; Gallacher L, 
Murdoch B et al. 2000). It is unclear whether CD133 provides any advantage over 
CD34 as a stem cell selection marker. Another recently identified marker for 
human HSC is the vascular growth factor receptor 2 (KDR). It has been reported 
that KDR+ cells are Lin- CD34+CD38' and are highly enriched for SRC (SCID 
repopulating cell) potential, with lineage committed stem cells being CD34+KDR' 
(Ziegler BL, Valtieri M et al 1999). More recently, Danet et at have identified 
ClqRp, (the human homologue of the mouse stem cells antigen AA4) which is 
expressed on both CD34+ and on CD34' stem cells from human cord blood and 
bone marrow as a positive marker of BM repopulating cells (Danet GH, Luongo JL 
et al. 2002). Interestingly, these experiments also showed that C1gRp cells have 
the capacity to develop into human hepatocytes in NOD/SCID mice, indicative of 
stem cell plasticity discussed in more detail below. 
1.1.3.2 Alternative Ways to Identify HSC 
In 1996 Goodell et al identified a new population of mouse stem cells by staining 
with Hoechst 33342 and viewing the dual wavelength UV emission on a FACS 
plot. These cells were designated side population cells due to their position on this 
plot. These cells were subsequently shown to be Lin'CD34' and to contain 
repopulation potential. The SP position of these cells depended on their ability to 
efflux dyes like Rhodamine or Hoechst (Goodell MA, Brose K et al. 1996) The 
efflux of drugs and dyes such as these has since been attributed to the activity of 
P-glycoprotein; an ATP-binding cassette (ABC) transporter expressed on the cell 
surface. When the activity of this transporter pump is inhibited by verapamil the 
numbers of SP cells decrease. However P-gp knockout mice contain SP cells 
indicating that other ABC transporters may contribute to the SP phenotype. 
Susan M Graham, 2005 Chapter 1,27 
Human SP cells were also shown to be Lin'CD34' and highly enriched for LTC-IC 
activity and to express CD34 following stromal cell culture (Goodell MA, 
Rosenzweig M et al. 1997). 
An additional method to purify HSC, which also relies on a functional 
characteristic, involves the activity of the cytosolic enzyme aldehyde 
dehydrogenase (ALDH). Responsible for oxidising aldehydes to carboxylic acids, 
ALDH is found in high concentration in the cytoplasm of HSC rendering them 
resistant to the effects of alkylating agents such as cyclophosphamide. The 
introduction of a fluorescent substrate for ALDH allowed the identification of cells 
with high levels of enzyme to be distinguished and sorted from the rest of the HSC 
population (Storms RW, Trujillo AP et al. 1999). These cells were found to be 
enriched for repopulating cells when introduced into NOD/SCID mice (Hess DA, 
Meyerrose TE et al. 2004). Given that there appears to be some debate regarding 
the surface phenotype of HSC, perhaps isolation methods that rely on biological 
function rather than surface markers may prove to be more reliable. 
1.1.4 Self Renewal of HSC 
In clinical terms, understanding the control of stem cell self-renewal has been the 
ultimate goal for ex vivo stem cell expansion. If stem cells could be induced to self 
renew in culture, the implications for transplantation would be enormous. By 
definition a stem cell is one that can both renew itself and differentiate into multiple 
lineages. In addition, when a malignancy occurs in a self-renewing stem cell it can 
perpetuate the disease limiting the chances of a cure. Factors that control self- 
renewal are still largely unknown, however the recent availability of technology to 
identify gene expression profiles in purified stem cell populations has shed light on 
possible candidates. To date, genes implicated in self-renewal include 
transcription factors, genes involved in chromosomal rearrangements, cell cycle 
inhibitors and signalling pathways. It is not surprising that many of the genes 
involved in stem cell self-renewal identified so far have their origins in 
developmental biology. For an embryo to survive, the early cells must divide and 
retain their stem cell characteristics before differentiating into the cells of various 
organs in due course. 
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HOX genes are highly conserved transcription factors involved in embryogenesis. 
HOXB4 was first shown 10 years ago to cause the selective expansion of primitive 
progenitors when over expressed in HSC and to confer an enhanced repopulation 
advantage over non-transduced cells assessed after several months. Despite the 
expansion of primitive HSC in these repopulation experiments the HSC pool size 
did not exceed that of non-transduced HSC suggesting that overexpression of 
HOXB4 did not influence the regulation of pool size (Sauvageau G, 
Thorsteinsdottir U et al. 1995). 
Further experiments with HOXB4 HSC expanded ex vivo and marked with GFP 
(green fluorescent protein) have shown that the expanded cells were functional 
and able to reconstitute long term haemopoiesis when transplanted. Furthermore 
there was greater expansion in primitive HSC compared to more mature cell types. 
Using a stromal cell line engineered to produce HOXB4, Amsellem et al showed 
that human LTC-IC and SCID repopulating cells were expanded in vitro by >20- 
and 2.5-fold respectively (compared to input numbers) and that this expansion was 
accompanied by increased repopulating ability in vivo (Amsellem S, Pflumio F et 
al. 2003). Thus it would appear that primitive human stem cells could be expanded 
in vitro in response to HOXB4 and still retain their stem cell phenotype. 
Other published work has shown a similar role for HOXC4, where over expression 
in human CD34+ cells induces in vitro expansion of both primitive and committed 
progenitors (Daga A, Podesta M et al. 2000). HOXC4 is a paralog of HOXB4 and 
the similar results obtained with over expression experiments suggest overlapping 
roles for paralogs in the maintenance of the primitive status of HSC. On the other 
hand, more recent studies have shown that HOXB4 deficient mice only have a 
minor proliferation deficiency and sustain comparatively normal haemopoiesis 
(Brun AC, Bjornsson JM et al. 2004). In vitro, the cells from these mice show 
reduced proliferation of primitive cells, which is also observed following 
transplantation. Further analysis revealed that the lack of HOXB4 also appeared to 
influence the expression of other HOX genes as well as some genes associated 
with cell cycle. It was also noted that these HOXB4 deficient mice had reduced 
cellularity in both the bone marrow and spleen, suggesting that although other 
HOX genes compensate for the loss of B4 they do so at a sub optimal level. There 
is a close association with the development of leukaemia and many of the HOX 
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genes, however HOXA4 (a paralog of HOXB4) does not appear to be associated 
with the disease. If HOXA4 plays a central role in stem cell self-renewal, this would 
suggest that augmentation of self-renewal alone is not, in itself, able to cause 
leukaemia. 
1.1.4.2 Polycomb-group Genes 
Recent studies have highlighted another candidate involved in haemopoietic stem 
cell self-renewal, the polycomb-group (PcG) gene Bmi-1. PcG genes play a vital 
role in embryogenesis, cell cycle regulation and lymphopoiesis. They are 
responsible for maintenance of gene silencing and in so doing confer the cell's 
functional identity. Their involvement in malignant transformation has created a 
great deal of interest and subsequent investigation. PcG proteins form complexes 
containing histone deacetylase and methylase activity and are involved in the 
modification of chromatin structure and histone tails (reviewed in (Orlando V 
2003). 
Park et al have demonstrated that adult mouse and human HSC express the 
proto-oncogene Bmi-1 and that bone marrow transplanted from Bmi-1-1" mice was 
able to initiate temporary haemopoiesis only. In addition, there was no evidence of 
self-renewal of adult HSC and gene expression analysis showed that a range of 
stem cell associated genes was altered in the bone marrow of these mice (Park 
IK, Qian D et al. 2003). Lessard et al showed that Bmi-1 has a role in the 
regulation of proliferative capacity in both normal and leukaemic stem cells and 
that endogenous Bmi-1 can rescue cells from apoptosis, growth arrest and 
differentiation (Lessard J and Sauvageau G 2003). A further study by Iwama et al 
has confirmed that increased expression of Bmi-1 promotes HSC self-renewal. By 
transducing HSC with GFP or Bmi-1, culturing single cells and separating the 
daughter cells by micromanipulation, the authors were able to show that forced 
expression of Bmi-1 promoted symmetrical cell division. Each of the daughter cells 
was shown to exhibit similar proliferation potential in colony assays, and the 
probability of symmetrical cell division was significantly higher in the Bmi-1 
transduced cells than in the controls (Iwama A, Oguro H et at. 2004). The 
additional finding that Bmi-1 can extend the lifespan of mammary epithelial cells by 
up regulating the telomerase RT gene (hTERT) could have further implications for 
HSC self-renewal and malignant transformation (Dimri GP, Martinez JL et al. 
2002). 
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1.1.4.3 Notch Genes 
Notch receptors are critical to HSC regulation where they are involved in stem cell 
fate decision i. e. whether a cell self-renews or differentiates. They are also 
involved in specification of T or B lymphocyte development from the common 
lymphoid progenitor cell (Pui JC, Allman D et al. 1999). Notch receptor gene 
knockouts are embryonic or perinatally lethal, demonstrating the importance of 
these genes in development (Xue Y, Gao X et al. 1999), (Jiang R, Lan Y et al. 
1998), (Hrabe de Angelis M, McIntyre J 2nd et al. 1997). There are 4 Notch 
receptors that have partially overlapping functions and share homology in structure 
and in ligand binding. The ligands for Notch receptors are the transmembrane 
proteins Jagged 1, Jagged 2 and Delta. Following binding the intracellular portion 
is cleaved and translocates to the nucleus where it acts as a transcriptional 
activator. 
Varnum-Finney et at have demonstrated, using a retroviral vector, that constitutive 
expression of the intracellular domain of Notch leads to the generation of 
immortalised cell lines from cytokine dependant haemopoietic cells. These cells 
are capable of in vivo repopulation of both myeloid and lymphoid lineages 
(Varnum-Finney B, Xu L et al. 2000). In a series of experiments using the Notch 
ligand Delta 1 immobilised on tissue culture plates in combination with defined 
cytokines, Varnum-Finney et al demonstrated a 4-5 log increase in the number of 
cells capable of short-term lympho/myeloid repopulation in NOD/SCID mice after 
28 days in culture. The significant increases in progenitor cells observed in this 
study are in contrast to other published work where only modest increases in 
primitive cells have been observed using Delta 1 as a soluble factor. The 
considerable expansion seen here is attributed to the immobilised presentation of 
the ligand in combination with the cytokine cocktail (Varnum-Finney B, Brashem- 
Stein C et al. 2003). These results confirm a role for Notch in self-renewal of HSC 
and progenitors. 
More recent studies have identified Notch signalling as indispensable for the 
maintenance of undifferentiated stem cells but not for their survival or cell cycle 
initiation. In transgenic Notch reporter mice, Notch signalling was identified in HSC 
in vivo, and was down regulated as differentiation progressed. In addition when 
Notch signalling was inhibited differentiation was hastened. Furthermore Writ (see 
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below) alone was unable to maintain undifferentiated HSC when Notch signalling 
was absent (Duncan AW, Rattis FM et at. 2005). 
1.1.4.4 Wnt Genes 
Wnt-mediated signalling is implicated in a number of processes in both vertebrate 
and invertebrate development. Wnt proteins have been shown to regulate 
segment polarity in Drosophila and axis specification in Xenopus as well as limb, 
somite and axis configuration in mice. More recently, Wnt signalling pathways 
have been implicated in HSC self-renewal and proliferation. 
There are 19 Wnt genes that encode lipid-modified signalling proteins that serve 
as ligands for the Frizzled family of receptors or the lipoprotein receptor-related 
protein (LRP). In the absence of Wnt signalling, ß-catenin is retained in the 
cytoplasm where it becomes associated with a destruction complex containing 
APC, Axin and GSK-3ß. In the presence of Wnt signalling, GSK-3ß is inhibited by 
Dishevelled and is unable to phosphorylate ß-catenin, which results in its 
stabilization and accumulation in the cytosol. ß-catenin then translocates to the 
nucleus where it forms a complex with the lymphoid-enhancer-binding factor 
(LEF)/T-cell factor (TCF) family of transcription factors, which in turn allows 
induction of specific target genes (Reya T 2003), (Ikeda S, Kishida S et al. 1998; 
Kishida S, Yamamoto H et at. 1998). 
Murdoch et al have demonstrated that injection of Wnt5A into mice transplanted 
with human cord blood haemopoietic cells increased the level of reconstitution and 
output of primitive haemopoietic cells in vivo. Reya et al provided further evidence 
of Wnt induced expansion of HSC, where active ß-catenin (normally produced as a 
consequence of Wnt signalling) was constitutively over expressed in retrovirally- 
transduced stem cells resulting in the proliferation of HSC populations in the 
absence of differentiation. It was estimated that ß-catenin caused an 8-80-fold 
increase in HSC number after just 1 week in culture. Conversely, engineered 
expression of soluble Frizzled receptor (which inhibits Wnt signalling), or 
intracellular expression of Axin (involved in ß-catenin degradation) caused a 
reduction in the proliferation and survival of primitive HSC in vitro. Interestingly, 
these experiments also revealed that Wnt activation produced an increase in 
expression of HOXB4 and Notch 1, previously associated with HSC self renewal. 
(Reya T, Duncan AW et al. 2003). 
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1.1.4.5 p21 and p27 
Stem cells are comparatively quiescent, entering cell cycle relatively infrequently 
compared to progenitor cells, whose expansion is rapid and extensive. Cyclin 
dependant kinases (CDK) and inhibitors (CDKI) control cell cycle progression, with 
the CDKIs serving as checkpoints limiting progression through the different cell 
cycle phases. There are two families of CKIs; the CIP/KIP family which includes 
p21c'P'waf (p21), p27Kip (p27), and p57K'p2, and the INK4 family including p161nk4, 
p151nk4b, p18i"kac and p19I"k4d. The two families are distinguished by the CDKs they 
inhibit; the INK4 members act on CDK4 and CDK6 and the CIP/KIP family acts on 
a number of CDKs but particularly on CDK2. p27 is distinct from p21 in its C 
terminus and is not a target for p53. Most CDKIs are regulated at the post- 
transcriptional level, however p27 is also subject to post-translational regulation. 
It has been shown that the bone marrow of p21'' mice contain increased numbers 
of HSC and show increased HSC cell cycling, however exhaustion of stem cells 
was observed under conditions of stress. (Cheng T, Rodrigues N et al. 2000). p27 
was shown to have a similar effect, however this was observed in a more mature 
progenitor population. Recent studies by Yuan et al have demonstrated that 
deletion of p181nk4c results in vastly improved engraftment of murine stem cells, 
largely due to an increase in self-renewal divisions (Yuan Y, Shen H et al. 2004). 
These observations suggest that different CDKIs have diverse effects depending 
on cell context and activation status. 
1.1.4.6 Others 
Maintenance of telomeres is critical to self-renewal. Telomeres are guanine-rich 
repeat sequences at the ends of chromosomes that act to preserve genomic 
stability. In the absence of telomerase (an RNA/protein complex that extends 
telomeres) DNA is not fully replicated and as a result progressive shortening of the 
chromosome ends occurs. Progressive telomere shortening leads to replicative 
senescence and ultimately to cell death. A feature of many malignant cells is the 
up-regulation of telomerase, and thus escape from senescence and preservation 
of division potential. Telomerase is expressed in HSC with self-renewal capacity 
and declines as cells become more differentiated (Morrison SJ, Prowse KR et at. 
1996). Despite the intrinsic telomerase activity in HSC, their telomeres continue to 
shorten with division in vivo. Accelerated shortening of telomeres in transplanted 
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HSC compared with donor HSC is observed initially, however the differences 
reach a level that does not change after around a year post-transplant 
(Brummendorf TH, Rufer N et al. 2001). Serial transplants in mice are limited to -4 
rounds suggesting that HSC cannot self-renew indefinitely, however stresses on 
transplanted cells in terms of homing and establishment of cell interactions within 
the bone marrow niche may influence their long term stability (Harrison DE and 
Astle CM. 1982). 
Yet another candidate implicated in stem cell regulation has its origins in 
embryogenesis; the Hedgehog (Hh) family of proteins is involved in the 
organisation and specification of early mesoderm and embryonic tissues. The 
group comprises Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert 
Hedgehog (Dhh), and two transmembrane receptors Patched (Ptc) and 
Smoothened (Smo), with Ptc being the primary receptor. When Hh binds Smo the 
subsequent signalling events modulate expression of genes such as Writ 
(described above) and the bone morphogenic protein (BMP)-4 specific inhibitor 
Noggin. BMP-4 is a member of the transforming growth factor (TGF-ß) superfamily 
and has been shown to enhance stem cell survival at high concentration (Bhatia 
M, Bonnet D et al. 1999). Shh, Ptc and Smo gene expression has been identified 
in primitive HSC. Bhardwaj et al have shown that addition of anti-Hh inhibited the 
cytokine-induced proliferation of HSC; in contrast treatment with Shh induced 
expansion of primitive human HSC in transplanted mice. In addition Noggin was 
able to inhibit the mitogenic effect of Shh showing that Shh acts through BMP-4 
(Bhardwaj G, Murdoch B et al. 2001). 
1.1.5 The Stem Cell Niche 
Central to the behaviour of stem cells are the environmental influences to which 
they are subject. The bone marrow stroma consists of a variety of cell types 
including endothelial cells, fibroblasts and osteoblasts as well as extra cellular 
matrix (ECM) components, which include collagen, fibronectin, laminin and 
proteoglycans. The cell-cell interactions between these and HSC are mediated 
through a variety of specific molecular targets within this niche, which act to control 
stem cell behaviour. The ECM can bind growth factors produced by stromal cells 
creating distinct "pockets" that accumulate HSC. The ECM can also bind to 
glycoproteins expressed on HSC. Stromal cells are known to secrete or present in 
bound form a variety of cytokines important for HSC survival and proliferation. 
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These include IL-1, -6, -11 and certain colony stimulating factors e. g. stem cell 
factor (SCF), flt3 ligand (FL), tumour necrosis factor a (TNFa) and TGFI (Sensebe 
L, Deschaseaux M et al. 1997). 
Adhesive interactions also play a critical role in HSC regulation by the BM 
microenvironment. Numerous receptors on HSC are involved in adhesion to 
stroma, including very late antigen-4 (VLA-4) and VLA-5 receptors for fibronectin, 
CD44, the receptor for hyaluroinc acid (a component of the ECM), and a number 
of stromal cell surface receptors such as intracellular adhesion molecule (ICAM) 
and vascular adhesion molecule (VCAM), a ligand for VLA-4. In fact, blocking 
VCAM with monoclonal antibody in vivo leads to an increase in circulating HSC, 
suggesting that these cells are unable to efficiently adhere to molecules within the 
BM stroma (Kikuta T, Shimazaki C et al. 2000). Studies of BM CD34+ cells 
cultured with and without stroma, fixed stromal layers or integrin binding FN 
fragments showed increased preservation of LTC-IC and ELTC-IC with or without 
associated cell division in the presence of stroma or FN fragments (Bhatia R, 
Williams AD et al. 2002), reinforcing the significance of stromal interaction with 
stem cell behaviour. 
More recently two groups have identified a population of osteoblasts in the BM that 
appear to influence HSC behaviour. In the study by Calvi et al, mice were 
genetically altered to produce active parathyroid hormone PTH/PTHrP receptors 
(PPRs) controlled by an osteoblast specific promoter. They were able to show that 
not only was there an increase in the number of osteoblasts in response to PPR 
but this was accompanied by a 2-fold increase in HSC (but not progenitor cells), 
and that the effect could be reproduced in normal mice by injection of PTH. 
Significantly these changes were also associated with increased production of the 
Notch ligand, Jagged 1 by osteoblasts and increased Notch activation in vivo, that 
could be negated by specific inhibition of Notch (Calvi LM, Adams GB et at. 2003). 
Using a different approach Zhang et al demonstrated that mutant mice with an 
increased endosteal bone surface and reduced BM cavity also show around a 2- 
fold increase in HSC. In addition, they also show that long-term HSC are 
preferentially attached to the N-cadherin+ osteoblasts. N-cadherin forms a complex 
in tissue cell junctions and also forms active signalling complexes with ß-catenin, 
recently shown to play a role in HSC self-renewal (Zhang J, Niu C et al. 2003). 
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1.1.5.1 Stem Cell Homing and Mobilisation 
As detailed in the previous section, stem cells have an intimate relationship with 
the BM microenvironment and with specific cell types. Tracking transplanted stem 
cells stained with CFSE (a permanent non-specific stain) demonstrated that more 
primitive cells selectively migrated to the endosteal region whereas more mature 
cells lodged in the central bone marrow region and that this migration occurred 
rapidly within 5-15 hours post-transplant. Non-ablated hosts were used in this 
study to eliminate the possible influence of a damaged stromal environment 
(Nilsson SK, Johnston HM et al. 2001). 
Central to the success of BM and peripheral blood stem cell (PBSC) 
transplantation is the ability of stem cells to locate and colonise the host stem cell 
niche. These processes are likely to be regulated by a combination of adhesive 
and chemokine receptor-ligand interactions. Adhesive interactions play a central 
role in homing and in particular VLA-4 (discussed in detail previously) has been 
shown to be a crucial factor. Preincubation with anti-VLA-4 antibody decreased the 
engraftment of human CD344' cells in the BM of fetal sheep, with a corresponding 
increase in human cells in the peripheral blood (Zanjani ED, Flake AW et al. 
1999). Also key to the homing process is the chemoattractant interaction between 
stromal-derived factor-1 (SDF-1 also known as CXCL12) and its receptor CXCR4 
expressed on stem cells. SDF or CXCR4 knockouts have multiple lethal defects 
including impaired haemopoiesis (Nagasawa T, Hirota S et al. 1996; Ma Q, Jones 
D et al. 1998). However CXCR44 fetal liver cells are capable of engraftment in the 
BM of wild type mice albeit with defects in retention of B-lymphoid and granulocytic 
lineage precursors in the BM (Ma Q, Jones D et al. 1999). These results suggest 
SDF-IICXCR4 interactions can act in combination with other mediators of homing 
and engraftment. Nonetheless SDF-1 has been shown to be a potent 
chemoattractant for human stem cells in vitro and addition of antibody to CXCR4 
abolished these effects (Jo DY, Rafii S et al. 2000). Lack of engraftment in vivo by 
treatment with anti-CXCR4 and successful engraftment of CD34+ cells induced to 
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express CXCR4 illustrate the importance of this receptor-ligand interaction in HSC 
reconstitution (Peled A, Petit I et al. 1999). 
One of the most important aspects of stem cell transplantation is the movement of 
repopulating cells out of the BM niche and into the circulation termed mobilisation. 
Stem cell mobilisation can be stimulated by administration of cytotoxic drugs such 
as cyclophosphamide, hydroxyurea or 5-fluorouracil and by certain cytokines 
including G-CSF, GM-CSF, IL-11, IL-3, IL-8 FIt3L etc or by a combination of both 
cytotoxic drugs and cytokines. By far the most commonly used regimen utilises G- 
CSF. Although the kinetics of mobilisation are relatively slow (peak at 5-6 days), 
the benefits include minimal toxicity and relative ease of administration (IV 
injection, dose based on weight). Not surprisingly, many of the factors involved in 
BM homing also play a part in mobilisation. For example, in mice treated with 
cyclophosphamide/G-CSF, expression of VLA-2 and VLA-4 is reduced on 
mobilised peripheral blood HSC. Also, treatment with anti-VLA-4 antibodies 
induces mobilisation of CFC and long-term repopulating cells (Craddock CF, 
Nakamoto B et al. 1997). 
More recent data have described the cleavage of the N-teminus of CXCR4 on 
HSC in the BM and on those mobilised into the circulation in response to GCSF. 
This leads to a reduction in the chemoattractant interactions of CXCR4 and SDF- 
1, which was further shown to involve a decrease in SDF-1 concentration in the 
BM, accompanied by an increase in proteases able to cleave SDF-1 (Levesque 
JP, Hendy J et at. 2003). Petit et al have further shown G-CSF stimulated 
mobilisation by reducing SDF-1 in the BM, and that the gradual reduction was due 
to degradation by neutrophil elastase. Reduction in SDF-1 was associated with 
increased mobilisation, which was reduced by inhibition of neutrophil elastase. 
(Petit I, Szyper-Kravitz M et al. 2002). A recent report from Broxmeyer et at has 
demonstrated that in vivo (mouse and human), treatment with a CXCR4 
antagonist can produce mobilisation of HSC and can act in synergy with G-CSF to 
increase stem cell mobilisation. They also showed that the mobilised cells were 
primitive HSC able to repopulate a secondary host (Broxmeyer HE, Orschell CM et 
at. 2005). 
One of the notable aspects of cytokine-induced mobilisation is that most of the 
circulating HSC are quiescent (in GO or G1 phases of the cell cycle), however it 
was not known if quiescent cells were preferentially released into the circulation or 
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if the cells had divided prior to release (Ponchio L, Conneally E et al. 1995; 
Donahue RE, Kirby MR et al. 1996; Uchida N, He D et al. 1997). In an interesting 
study by Wright et al, mice were treated with cyclophosphamide/G-CSF and BrdU 
(which is incorporated into dividing cells) and assessed for the presence of divided 
and undivided stem cells. The results indicated that almost all of the LT-HSC had 
entered cell cycle prior to release from the BM and that cells enter the blood in the 
post mitotic M phase of the cell cycle (Wright DE, Cheshier SH et al. 2001). It is 
known that the proportion of cycling cells in the BM is greater than in mobilised 
peripheral blood, which could be explained by these findings. 
1.1.6 Stem Cell Plasticity 
No discussion on stem cells would be complete without some mention of plasticity 
or the apparent ability of stem cells to develop alternative fates. The demonstration 
of fate switching in B-lineage cells from Pax-5-deficient mice to different 
haemopoietic cell types has indicated that plasticity may be a genuine feature 
(Rolink AG, Nutt SL et al. 1999). Kondo et al have also demonstrated that the fate 
of common lymphoid progenitors could be redirected to the myeloid lineage by 
stimulation through IL-2 receptor, suggesting that the fate of individual cells can be 
influenced by cytokine stimulation (Kondo M, Scherer DC et al. 2000). A body of 
evidence existed that HSC could switch to a non-haemopoietic fate, particularly at 
the site of injury for example to muscle or heart or following transplantation. 
However, more recent studies have cast doubt on the interpretation of these 
results. Studies using parabiotic mice (surgically joined to develop a common 
circulatory system) and GFP/GFP" cells showed that haemopoietic but not non- 
haemopoietic chimerism existed suggesting that "transdifferentiation" was rare if at 
all possible (Wagers AJ, Sherwood RI et al. 2002), reviewed in (Wagers AJ and IL. 
2004). It has also been noted that cell fusion may have been misinterpreted as 
plasticity when high levels of cell fusion were found in liver cells following HSC 
transplantation in mice (Vassilopoulos G, Wang PR et al. 2003). 
1.2 Chronic Myeloid Leukaemia 
Chronic myeloid leukaemia (CML) is a stem cell disease originating in a pluripotent 
haemopoietic cell that acquires a defined chromosomal abnormality. CML was first 
identified clinically in the mid 1800s when three physicians independently 
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described patients with massive splenomegaly and lethal leukocytosis not 
associated with documented conditions (Virchow R 1845; Bennett JH 1845; 
Craigie D 1845). A major breakthrough was the pioneering discovery of the 
Philadelphia chromosome (Ph) by Nowell and Hungerford in 1960. They noticed 
that in all CML samples there was an abnormally small chromosome 22 not 
observed in other leukaemias (Nowell PC and Hungerford DA 1960). This was the 
first chromosomal abnormality to be linked to a human cancer. It took a further 13 
years to elucidate that the Ph chromosome was the result of a translocation 
between the long arms of chromosomes 9 and 22 (Rowley JD 1973). In 1984 
Groffen et at showed that the translocation event involved the ABL proto-oncogene 
on chromosome 9 and a new "break point cluster" gene (BCR) on chromosome 22 
(Groffen J, Stephenson JR et at. 1984). It was confirmed some time later that in 
fact the translocation was reciprocal also producing ABL-BCR (Melo JV, Gordon 
DE et al. 1993). 
1.2.1 Clinical Features of CML 
CML accounts for -15-20% of all leukaemias with an incidence of 1 in 100,000 of 
the general population. It can occur at any age, however incidence increases with 
age and the median age at diagnosis is around 60. There are no predisposing 
factors to the development of CML, though survivors of the atomic bombs in Japan 
showed an increased incidence 4-10yrs following radiation exposures from 
explosions. It has also been suggested that the proximity of BCR and ABL genes 
in haemopoietic cells during interphase is related to cell cycle and differentiation, 
with a closer than predicted position observed for BCR and ABL in more primitive 
cells. This could facilitate the opportunity for chromosome rearrangement in some 
cells which may be enhanced by their cell cycle position (Neves H, Ramos C et al. 
1999). 
There are typically 3 distinct phases of disease: chronic phase (CP), which lasts 
-4-6 years, accelerated phase (AP), which lasts up to 1 year and blast crisis (BC), 
which lasts around 3-6 months. CP is characterised by the accumulation of 
excessive numbers of mature and functional blood cells produced from a 
transformed pluripotent stem cell (Fialkow PJ, Jacobson RJ et al. 1977). There is a 
marked expansion of myeloid lineage cells at the expense of erythroid cells. AP 
lasts upto lyr and is characterised by an increase in more primitive cells 
proportional to mature cells. Disease progression is inevitable and results in a fatal 
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BC, which resembles an acute leukaemia, and may happen suddenly without an 
intervening AP. An accumulation of more immature cell types and increased 
resistance to therapy in BC leads to mortality in -3-6 months (Thijsen S, 
Schuurhuis G et al. 1999). Around 30% of these acute leukaemias are acute 
lymphoblastic leukaemia (ALL) and the rest are acute myeloid leukaemia (AML) or 
acute undifferentiated leukaemia (AUL). As yet the mechanism of progression 
from CP to BC is undefined but additional genetic events have been associated 
with development of BC. These include trisomy 8, loss of p53 function, alterations 
in the retinoblastoma gene, p16 gene rearrangements, amplification of the c-Myc 
gene and alterations in RAS signalling (Ahuja HG, Jat PS et al. 1991; Feinstein E, 
Cimino G et al. 1991; Sill H, Goldman JM et al. 1995; Jennings BA and Mills KI. 
1998; Voss J, Posern G et al. 2000). 
1.2.1.1 Treatment Options 
Historically the main aim of treatment for CML was to reduce the excessive 
numbers of circulating white blood cells. This was achieved using various cytotoxic 
drugs, which prolonged life for -3-5yrs following diagnosis of CP. Treatment with 
a-interferon (IFN) prolonged survival by a further 12 months compared to cytotoxic 
drug treatment and in a small percentage of cases (6-20%) induced a complete 
cytogenetic remission (Silver RT, Woolf SH et al. 1999). However, BCR-ABL 
transcripts could still be detected in patients in cytogenetic remission using 
sensitive RT-PCR techniques. IFN is also relatively toxic and can result in severe 
side effects, in addition some patients either cannot tolerate the drug or their 
leukaemia does not respond to it. The only curative therapy for CML is an 
allogeneic BM transplant. However, many patients are outwith the transplant age 
limit of <55yrs. In addition, only around one third of patients have a suitable donor. 
In effect this means that the majority of patients have chemotherapy as their only 
treatment option. The quest to find more effective drugs lead to the development 
of targeted therapy for CML in the form of ST1571 (or Glivec), which will be 
discussed in more detail later. Figure 1.2 shows time lines of therapeutic and 
scientific landmarks for CML relevant to the following discussion. 
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CML Landmarks 
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Figure 1-2 Time lines of scientific observation and treatment options for CML. 
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1.2.2 Ph+ Stem Cells 
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It is generally perceived that CML develops when a pluripotent stem cell acquires 
the Ph" chromosome with the BCR-ABL fusion gene. Fialkow et al demonstrated 
that CML was a clonal disease by examining X-linked polymorphic genetic loci in 
female CML patients in chronic phase and identifying the same genetic markers in 
different cell types (Fialkow PJ, Jacobson RJ et al. 1977). CML stem cells are 
morphologically indistinguishable from normal stem cells. The demonstration by 
FISH and cytogenetics that Ph+ cells were found in granulocyte, erythroid, 
megakaryocyte and B and T precursors confirmed that the genetic lesion arose in 
a pluripotent stem cell. More recently, evidence of the presence of Ph'' endothelial 
cells in CML BM has indicated that an earlier stem cell with endothelial and 
haemopoietic potential may be the CML initiating cell (Gunsilius E, Duba HC et al. 
2000). 
CML progenitors are able to generate LTC-IC similar to normal stem cells; 
experiments culturing CML BM showed that normal haemopoietic progenitors 
coexisted alongside their leukaemic counterparts. Interestingly, on further long- 
term culture, the leukaemic progenitors rapidly disappeared whereas the normal 
progenitors could be detected for 2-3 months (Coulombel L, Kalousek DK et at. 
1983). A similar observation was made by Udomsakdi et al using CML peripheral 
blood or BM. This study also showed that the number of LTC-IC in CML BM was 
significantly decreased compared to normal BM, and that CML LTC-IC in the 
peripheral blood were significantly increased to >10 times that of normal 
(Udomsakdi C, Eaves CJ et al. 1992). These data suggest that CML progenitors 
have limited capacity for self-renewal, and exhibit an increased tendency towards 
maturation. This may seem at odds with the idea of CML as a stem cell disease 
with uncontrolled proliferation. However, emerging evidence is of a complex series 
of interactions, with the suggestion that bcr-abl may exert effects on cell behaviour 
that vary with maturation, cell cycle and microenvironment. It has been 
demonstrated previously, that whereas normal and CML mature cells have similar 
responses and proliferation patterns to cytokines, more primitive progenitors 
display altered responses (Reviewed in (Clarkson B and Strife A 1993; Clarkson 
B, Strife A et at. 2003). Strife et at have also demonstrated that primitive CML cells 
display an increased sensitivity to single cytokines and that this may allow 
accelerated maturation, and thereby facilitate an accumulation of committed 
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progenitors. In support of this theory Buckle et at have shown that CML primitive 
progenitors comprise a lower proportion of the stem cell compartment compared to 
normal primitive progenitors and that there was an increased proportion of more 
mature cells in CML (Buckle AM, Mottram R et at. 2000). Ultimately, leukaemic 
stem and progenitor cells replace normal haemopoeisis and disease progression 
is associated with an accumulation of more primitive CML cells in the circulation. 
It has been documented that CML stem and progenitor cells display altered 
adhesive interactions with BM stroma, and this could account for the increased 
number of progenitor cells in the circulation (Verfaillie CM, McCarthy JB et al. 
1992). CML cells, like normal cells, express integrins, however CML cells exhibit 
significantly decreased adhesion to fibronectin (Verfaillie, McCarthy et al. 1992). 
Recent work by this group has demonstrated that binding of integrins in normal 
cells causes up regulation of the proliferation inhibitor p27kip, preventing cell cycle 
entry (Jiang Y, Prosper F et al. 2000). Further studies by the same group have 
revealed that although CML cells bind integrins, binding does not inhibit cell cycle 
progression. They also found that in contrast to normal cells, p27 kip is found mostly 
in the cytoplasm where it is unable to bind CDK2 and inhibit proliferation (Jiang Y, 
Zhao RC et al. 2000). In addition Bhatia et al have recently demonstrated that ß1 
integrin-fibronectin interaction preserved normal primitive progenitors by 
decreasing proliferation, and enhanced preservation of dividing primitive 
progenitors, possibly by preventing differentiation. In contrast, CML cells showed 
abnormal ß1 integrin-mediated adhesion and impaired signalling following contact 
with FN or stroma (Bhatia R, Williams AD et al. 2002). It has also been 
demonstrated that the effects of impaired integrin function are bcr-abI associated 
since they can be reversed by inhibition of bcr-abl or induced in normal cells by 
expression of the BCR-ABL gene (Bhatia R and Verfaillie CM 1998; Zhao R, Fan 
E et al. 1999). Other studies have shown that both BM and PB CML CD34+ cells 
display lower migration responses to SDF-1 compared with normal CD34+ cells 
and that this was not a result of receptor (CXCR4) down-regulation (Durig J, 
Rosenthal C et al. 2000). More recently, it has been shown that CML 
CD34''CXCR4+ cells show lower migratory responses to SDF-1 than normal 
CD34+CXCR4+ cells from the same patient (Peled A, Hardan I et al. 2002). These 
data indicate that altered adhesive interactions almost certainly play a role in 
mobilisation of CML progenitors into the circulation and possibly affect retention of 
leukaemic stem and progenitor cells in the BM. 
Susan M Graham, 2005 Chapter 1,43 
1.2.2.1 Stem Cell Kinetics 
The molecular basis for the proliferative advantage of CML cells is not fully 
clarified. There is continuing debate regarding the importance of apoptosis in the 
CML phenotype. Some studies have shown that CML cells have an innate 
resistance to apoptosis and suggest that could account for the expansion of the 
leukaemic clone (Bedi A, Zehnbauer B et at. 1994). Conversely, in studies using 
serum deprivation, X-rays or glucocorticoids to induce apoptosis, Amos et al found 
no difference in survival of normal and CML myeloid progenitors or in more mature 
colony-forming cells (Amos TAS, Lewis JL et at. 1995). A more recent study has 
shown that non-dividing CML progenitor cells are more resistant to drug induced 
apoptosis, which may have implications for treatment (see discussion chapter 7) 
(Holtz MS, Forman SJ et at. 2005). 
Differences in cell cycle position between normal and CML CD34+ cells have been 
observed. Traycoff et at have demonstrated that there are fewer BM CML stem 
cells in the GO/G1 cell cycle phases compared to normal CD34+ cells. They also 
observed that upon stimulation with cytokines, CML cells exit GO/G1 more rapidly, 
suggesting CML cells exhibit greater cell cycle activation. Furthermore, in the 
absence of cytokine stimulation, CML cells were able to enter cell cycle, unlike 
normal stem cells (Traycoff CM, Halstead B et at. 1998). Experiments using 
exposure to tritiated thymidine have shown that a higher proportion of CML LTC-IC 
and CFC are in S-phase of the cell cycle, with most being killed following 
exposure. In the case of normal LTC-IC, only around 5% were killed in this suicide 
assay, indicating that normal LTC-IC are largely quiescent (Ponchio L and Eaves 
CJ 1995). In a further study by Bhatia et al using staining techniques to evaluate 
division history, these authors show that most CML LTC-IC were generated from 
CD34+ cells that had previously undergone division, whereas normal LTC-IC 
originated from undivided stem cells (Bhatia R, Munthe HA et al. 2000). It has 
been demonstrated that, unexpectedly, a population of quiescent CML stem cells 
exists in CP. Holyoake et al have isolated GO and G1/S/G2/M cells from CML 
patients by FAGS and shown that, when transplanted into NOD/SCID mice that 
are also ß-microglobulin', some quiescent CML cells can exit GO and effect 
engraftment (Holyoake T, Jiang X et at. 1999). The finding that a quiescent stem 
cell population existed in CML has raised the question of how to target therapy, 
when historically, cytotoxic drug treatment was aimed at eliminating the cycling 
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population. This very important issue will be addressed in the experimental and 
discussion chapters as a central theme in this work. 
1.2.3 The Molecular Biology of CML 
The majority of CML cases are associated with the presence of the Ph 
chromosome, the result of the reciprocal translocation between chromosomes 9 
and 22. The molecular consequence of this translocation is to place the ABL gene 
in close proximity to the BCR gene, creating the BCR-ABL fusion gene. The 
properties of the individual genes and the fusion gene are discussed below. 
1.2.3.1 c-ABL 
The ABL gene on chromosome 9 is the human homologue of a gene formerly 
recognized in a murine oncogenic virus, the Ableson murine leukaemia virus (A- 
MuLV). The ABL gene family encodes highly conserved intracellular non-receptor 
tyrosine kinases with similar features to the SRC family of kinases (Laneuville P 
1995). c-ABL is universally expressed with 2 isoforms, la and 1b, which result 
from alternative splicing of the first exon. Several functional domains on c-ABL 
have been identified including 3 SRC homology domains (SH1-SH3), positioned 
near the NH2 terminus. The SH1 domain contains the tyrosine kinase function 
whereas the other two SH domains are involved in interactions with other proteins. 
Nuclear localisation signals, actin-binding and DNA-binding motifs are located 
closer to the COOH end. Until recently the mechanism of c-abl control of was 
speculated to involve a cellular inhibitor. However, a series of experiments by Pluk 
et al have demonstrated that in fact c-abI is controlled by autoinhibition and the 
elements involved in control are absent in bcr-abl. By testing the kinase activity of 
mutant forms of the protein, they identified 80 residues at the N-terminal that bind 
intramolecularly and are critical for regulation of c-abl. These residues are 
encoded by the first exon of ABL, which is always absent in fusion proteins formed 
with BCR (Pluk H, Dorey K et al. 2002). 
The function of c-ABL is not completely understood but conservation and 
expression in different species suggest developmental importance. In addition, 
ABL knockouts display a number of developmental abnormalities such as 
abnormal eyes, runtedness, and defective spermatogenesis (Schwartzberg PL, 
Stall AM et al. 1991). c-abl protein is located in both the cytoplasm, where it co- 
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localises with F-actin, and in the nucleus, where it is bound to chromatin. abl 
proteins associated with transformation are exclusively cytoplasmic where they are 
bound to F-actin. Roles for c-abl in cell cycle regulation, integrin signalling and 
stress response have been suggested. (Reviewed in (Van Etten RA. 1999). 
1.2.3.2 BCR 
The BCR gene on chromosome 22 has 23 exons and produces a 160kd protein, 
which is also ubiquitously expressed. It contains several structural motifs including 
GTPase activity for Rac, a small GTPase of the Ras superfamily. BCR can also be 
phosphorylated on several tyrosine residues, particularly 177, which binds the 
adaptor molecule Grb-2, involved in the Ras pathway. The function of BCR as yet 
remains undetermined, and given that BCR knockout mice are viable, argues for 
at least a degree of redundancy in function (Voncken JW, van Schaick H et al. 
1995). Interestingly, recent data has suggested a possible role for bcr in the 
regulation of c-abl. Work by Ling et al has shown that BCR overexpression inhibits 
cytoplasmic c-abl and that sequestration of bcr releases c-abl from the complex 
with bcr, which in turn, leads to oncogenic transformation as a result of c-abl 
activation (Ling X, Ma G et al. 2003). These data indicate that autoinhibition of c- 
abl as described above may not be the only mechanism of c-abl regulation. 
1.2.3.3 BCR-ABL 
The breakpoint on the ABL gene can occur over a relatively large area (>300bp) of 
the 5 end, most commonly between exons Ia and 1b, although breakpoints either 
side of these exons have been observed (Melo J 1996). The mRNA product 
invariably lacks exon 1a even if the breakpoint is anterior of this exon, probably as 
a result of mRNA splicing. In contrast, the breakpoints in BCR occur over a large 
variable region of >5kb, which spans exons 12-16 and is described as the major 
breakpoint cluster region or M-bcr. Alternative splicing within this region, generates 
two fusion transcripts containing either b2a2 or b3a2 junctions. Both mRNAs 
produce a 210kd oncoprotein commonly labelled p210BCR. ABL.. As well as the M-bcr 
there are two other breakpoint regions named m-BCR (minor breakpoint cluster 
region) and p-BCR. Breakpoints in these regions produce p190 and p230 
oncogenic bcr-abl proteins respectively. p190 is associated with Ph* ALL (acute 
lymphocytic leukaemia) and only rarely with CML, and p230 with rare Ph' chronic 
neutrophilic leukaemia. Breakpoints in other regions associated with ALL and CML 
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have been identified in rare cases. For the classic b2a2 and b3a2 junctions in CML 
there appears to be no correlation between breakpoint and prognosis or time to 
disease progression (de Braekeleer M 1987; Rozman C, Urbano-Ispizua A et at. 
1995). Figure 1.3 details the position of the breakpoints and the resultant fusion 
products. 
c-ABL gene 
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Figure 1-3 BCR and ABL breakpoints and fusion products. 
The presence of the BCR-ABL transcript is not in itself sufficient to cause disease. 
Using sensitive RT-PCR, BCR-ABL mRNA transcripts were detected in a very 
small number of white blood cells in healthy individuals. Many of the transcripts 
were found to encode non-functional proteins, however transcripts encoding 
functional bcr-abl protein were identified (Bose S, Deininger M et al. 1998). The 
potential to develop CML disease may depend on the cell type in which the 
translocation arises and/or the microenvironmental stimuli encountered by the cell. 
It is possible some cells that acquire the translocation are eliminated by the 
immune system, or that these cells have limited division/differentiation potential, 
and are therefore are unable to sustain disease. 
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1.2.3.4 Oncogenic Activity of BCR-ABL 
Following the identification of the Ph chromosome and its translocation partners, 
investigations into the mechanism of transformation gained momentum. The 
association between ABL and transformation had previously been established by 
studies of the Ableson leukaemia virus (A-MuLV), which had been shown to cause 
transformation of NIH 3T3 cells and lymphoid cells in vitro (Rosenberg N, 
Baltimore D et al. 1975; Scher CD and Siegler R 1975). In a series of elegant 
experiments using antibodies to various parts of the protein, it was established that 
the transforming ability of the A-MuLV was associated with a chimeric protein 
GAG-ABL. The GAG sequences were of viral origin and the ABL sequences of 
cellular origin, and both proteins were associated with transformation (Witte ON, 
Rosenberg N et al. 1979; Witte ON, Rosenberg NE et al. 1979). The observation 
by Collett and Erikson that the protein kinase activity of the Rous Sarcoma Virus 
(RSV) was associated with its transforming ability, lead to the question of whether 
other oncoproteins possessed similar enzymatic activity (Collett MS and Erikson 
RL 1978). The finding that GAG-abl had kinase activity, and that variants of the A- 
MuLV with no kinase activity did not possess transforming capability, confirmed 
the importance of this enzymatic activity in transformation (Witte ON, Goff S et al. 
1980). Further studies showed that the protein kinase activity specifically 
phosphorylated tyrosine residues, and subsequently, that abnormal tyrosine 
kinase activity was associated with a number of malignancies (Hunter T and 
Sefton BM 1980). 
The demonstration that the ABL gene mapped to chromosome 9 and that it was 
involved in the translocation that generated the Ph chromosome, lead to the 
identification of abl as part of the protein product of BCR-ABL (Bartram CR, De 
Klein A et al. 1983). These findings were confirmed in cell lines expressing BCR- 
ABL and in cell lysates of primary CML cells (Konopka JB, Watanabe SM et al. 
1985). Antisera generated from Gag-Abl studies, discussed previously, was used 
to show that p210BCR-ABL had comparable tyrosine kinase activity to Gag-Abl and 
that a mutation in the protein that inactivated the kinase activity impaired its 
transforming ability. These observations confirmed the necessity of the abl 
tyrosine kinase in malignant transformation (Konopka JB, Watanabe SM et al. 
1984; Pendergast AM, Gishizky ML et al. 1993). 
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One of the most significant differences between c-abl and bcr-abl proteins is their 
location within the cell. bcr-abl is found exclusively in the cytoplasm despite it 
containing three nuclear localization signals (NLS) and a nuclear export sequence 
(NES) (McWhirter JR and Wang JY 1993; Wen ST, Jackson PK et al. 1996). In 
contrast c-abI shuttles between the nucleus and cytoplasm, and exerts a 
proapoptotic effect in its nuclear form (Taagepera S, McDonald D et al. 1998). It 
has been documented that bcr-abl exerts an antiapoptotic effect (discussed more 
fully below) and elegant experiments by Vigneri and Wang have shown that this 
can be reversed to a proapoptotic effect. Inhibiting the tyrosine kinase activity of 
bcr-abl with STI (see below) caused bcr-abI to enter the nucleus and the addition 
of Leptomycin B (blocks nuclear export) trapped it there. Removal of STI and 
subsequent reactivation of the bcr-abl tyrosine kinase then induced an apoptotic 
cell death (Vigneri P and Wang JY. 2001). 
1.2.3.5 Model Systems To Study BCR-ABL Effects 
Daley et al demonstrated that BCR-ABL was the genetic element responsible for 
CML by infecting murine BM with retrovirus encoding p210BCR-Asp and using these 
cells to transplant irradiated animals. The result was a range of malignancies 
including a myeloproliferative syndrome that closely resembled CP CIVIL The 
leukaemic cells were shown to express viral BCR-ABL and it was possible to 
transplant the disease into secondary recipients, confirming the target cell for 
leukaemic transformation was a HSC (Daley GQ, Van Etten RA et at. 1990). 
Attempts to develop a BCR-ABL transgenic model of CML have proved extremely 
difficult largely due to embryonic lethality (Heisterkamp N, Jenster G et at. 1991). 
Some of these problems were partially overcome using conditional promoters such 
as tetracycline (Huettner CS, Zhang P et at. 2000). A further problem was that 
these mice seldom developed myeloid leukaemia and acute lymphoid leukaemias 
were much more common, which did not resemble CML-like disease (Heisterkamp 
N, Jenster G et al. 1990). A new transgenic model has been developed recently 
using targeted BCR-ABL expression in murine stem and progenitor cells, which 
produces a biphasic disease in mice, with many of the characteristics of human 
CML (Koschmieder S, Gottgens B et at. 2005). However this model has yet to be 
fully tested in other experimental systems. Recent advances in transduction and 
transplantation efficiency have been able to generate more robust murine models 
of CML disease, however death in experimental animals from complications not 
associated with the human disease, continues to be a problem (Pear WS, Miller 
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JP et al. 1998; Zhang X and Ren R 1998). Models like these still represent 
important tools for studying BCR-ABL induced leukaemogenesis. 
Established cell lines offer greater flexibility in terms of time frame and 
convenience but it is difficult to faithfully represent a chronic disease that 
progresses to an acute disease in vitro. Many studies employ BCR-ABL-positive 
cell lines such as K562, produced in 1975 by Lozzio and Lozzio from blast crisis 
CML (Lozzio CB and Lozzio 1975). Whilst a useful model, it does not mirror CP 
CML, possessing multiple copies of BCR-ABL and being derived from the more 
acute BC phase. In addition, cells that have undergone multiple passages in 
culture are likely to have acquired other mutations. This may affect their responses 
to different conditions; therefore caution is warranted when extrapolating data to in 
vivo CML. Furthermore, many studies employ BCR-ABL inducible on/off or 
overexpression systems to compare cell behaviour. However, it must be 
appreciated that in CML where BCR-ABL is constitutively activated this may not 
represent a true picture, i. e. the cellular effect of suddenly turning on BCR-ABL 
may be very different to one of long-term continuous exposure. 
Studies using primary cells from CML patients and comparable material from 
normal individuals are likely to yield the most relevant information. One of the most 
difficult factors is the inherent patient-to-patient variability observed in CP CML, 
which can result in less robust statistics. The selection of defined cell populations 
such as CD34+ cells may help to reduce some of the variability. As discussed 
earlier, the contribution of co-existing normal cells in CML has to be eliminated 
from experimental data to ensure comparison of the relevant cell populations. 
1.2.3.6 BCR-ABL Interactions 
The documented cellular processes and pathways influenced by bcr-abI are 
continuously increasing. A comprehensive review of all of the candidates is out 
with the scope of this discussion, however some of the most interesting, at least 
from a clinical standpoint, are worthy of mention. (Reviewed in (Melo JV and 
Deininger MW. 2004). The functional domains/motifs on the bcr-abl oncoprotein 
facilitate interactions with a number of other cellular proteins. Interactions with 
mitogens, cytoskeletal components, anti-apoptotic proteins, cell cycle proteins, 
cytokines and adaptor proteins have been reported. 
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The interaction of bcr-abt with members of the RAS pathway has been 
documented. Protein-protein interactions combine bcr-abl with members of the 
RAS-MAPkinase signalling complex including Grb2, SHC and Crkl (Puil L, Liu J et 
al. 1994; Goga A, McLaughlin J et al. 1995; Senechal K, Halpern J et al. 1996). It 
has been shown that bcr-abl, through autophosphorylation of tyrosine 177 in the 
bcr component, stabilizes RAS in its active conformation, leading to constitutive 
activation. In contrast, inactivation of RAS by inhibitors significantly suppresses the 
cellular transformation by bcr-abI (Peters DG, Hoover RR et al. 2001). To become 
activated, RAS proteins undergo posttranslational modification, the first of which is 
farnesylation of their C-terminus catalysed by famesyl transferases. Studies using 
farnesyl transferase inhibitors (FTI) have shown that bcr-abl induced 
leukaemogenesis can be inhibited by FTIs, and these compounds have now 
reached clinical trial (Reichert A, Heisterkamp N et al. 2001). Indications are that 
activation of the RAS pathway is critical to bcr-abl induced leukaemogenesis. 
The JAK/STAT pathway involves three families of genes, JAK (Janus tyrosine 
kinases), STAT (signal transducers and activators of transcription) and SOCS 
(suppressor of cytokine signalling). The JAK/STAT pathway is involved in 
transduction of signals from cytokine receptors to the nucleus, where stimulation of 
JAKs produces STAT transcription factor activity. In bcr-abt transformed cell lines 
a demonstrable activation of STAT5 and to a lesser extent STATs 1 and 3 have 
been observed (Ilaria RL Jr and Van Ellen R 1996). It has also been demonstrated 
that STAT 5 induces the expression of the antiapoptotic protein Bcl-xl and through 
this mechanism may promote survival of malignant cells (Horita M, Andreu EJ et 
al. 2000). CML patient cells and bcr-abl; cells exhibit similar biological 
characteristics to IL-3 stimulated cells or those with engineered IL-3 
overexpression. It has been further demonstrated in CML CD34+ cells that 
increased STAT5 phosphorylation is a consequence of bcr-abl induced IL-3 
stimulation and that IL-3 is in fact produced through an autocrine mechanism in 
BCR-ABL+ cells (Jiang X, Lopez A et al. 1999). 
P13 kinase activity has been shown to be a requirement for transformation of bcr- 
abi expressing cells (Skorski T, Bellacosa A et al. 1997). bcr-abl complexes with 
P13K and adaptor molecules which activate P13K, and requires the intact SH2 
domain on bcr-abl. This in turn activates the downstream effector Akt kinase in 
bcr-abl-positive cells. A kinase deficient Akt mutant was unable to effect 
transformation of murine cells in vitro and suppressed leukaemia in SCID mice 
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(Skorski T, Bellacosa A et al. 1997). However, more recent data has suggested 
there may be a degree of redundancy in both the STAT5 and Ras signalling 
pathways in bcr-abl transformed cells (Hoover RR, Gerlach MJ et al. 2001). 
Although as mentioned previously RAS inhibitors can suppress transformation by 
bcr-abl, it is clear from the apparently conflicting evidence that bcr-abI and its 
associated tyrosine kinase activity exert a myriad of effects on downstream 
pathways that have a range of consequences for cell behaviour. The model 
systems and cell populations used in various studies may yield different results, 
and this must be considered when comparing data. BCR-ABL expression has 
been shown to influence different pathways depending on a variety of factors 
including cell type, cell cycle status, maturation status and cell context. 
1.2.4 The Development of an Inhibitor of BCR-ABL 
It had been demonstrated that it was possible to design a Tyrosine 
Phosphorylation Inhibitor (tyrphostin) with specificity for a particular tyrosine kinase 
(Yaish P, Gazit A et al. 1988). AG490 was the first synthetic tyrosine kinase 
inhibitor to reduce leukaemic cell proliferation in vitro and in vivo with no effect on 
normal cells (Meydan N, Grunberger T et al. 1996). Scientists at Ciba-Geigy (now 
Novartis) began high throughput screening of a range of small molecule inhibitors 
and identified a platelet derived growth factor receptor inhibitor (PDGF-R), CGP 
53716. Unexpectedly this compound was also shown to inhibit Gag-abl tyrosine 
kinase activity. Following some minor modifications to its structure CGP57148B 
(STI1571) was generated and shown to selectively inhibit the tyrosine kinases of 
PDGF-R, KIT, ABL, and ARG (Reviewed in (Traxler P, Bold G et al. 2001). 
1.2.4.1 Development of ST1571/Glivec 
ST1571 (STI now known as Glivec or Imatinib Mesylate) is a small molecule 
inhibitor that competes for the ATP binding site of the tyrosine kinase of bcr-abl, 
rendering it unable to phosphorylate downstream targets. However, more recent 
data have suggested that direct competition for the ATP binding site may not be 
the exact mode of action. Elucidation of the crystal structure of the abi catalytic 
domain and comparison of the binding of STI and another closely associated 
molecule (PD17355), has shown that STI only occupies part of the binding pocket 
of abl and may act by stabilising bcr-abl in its inactive conformation such that it is 
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unable to bind ATP (Nagar B, Bornmann WG et al. 2002). (See 1.2.4.3 on STI 
resistance). 
In vitro, STI was shown to be effective at micromolar concentrations. A number of 
bcr-abl+ cell lines were tested and an IC50 (50% inhibitory concentration) in the 
range 0.1 - 0.5pM was established for inhibition of kinase activity. Similar IC50 
values were calculated for the inhibition of proliferation of bcr-abl+ cells with little 
effect on bcr-abl' cells. Cells isolated from CML patients also showed selective 
inhibition of progenitor colony formation, and proliferation in liquid culture. 
Eradication of human BCR ABL+ cells injected into nude mice confirmed the 
efficacy of STI in vivo (Le Coutre P, Mologni L et al. 1999). In addition, normal 
haemopoiesis was shown to be relatively unaffected at concentrations of up to 
1pM STI (Druker BJ, Tamura S et al. 1996; Deininger MW, Goldman JM et al. 
1997). These promising results prompted the commencement of clinical trials in 
the USA. 
1.2.4.2 Clinical Studies with ST1571 
STI reached the clinic in 1998 and was the first drug specifically targeted to 
counteract the effects of a cellular oncoprotein. Initially only patients who had 
failed interferon-a (IFN) in CP were approved for the trial. The toxicity was 
comparatively low level and the drug was well tolerated. In this first trial 53 out of 
54 patients achieved a complete haematological response (CHR) at doses of 
300mg and, at this level or above, 31% of patients achieved a cytogenetic 
response, which was complete in 13% of cases. Pharmacokinetic data revealed 
that at 300mg/day, the level in the plasma was equivalent to 1 NM, shown to be 
effective in the in vitro studies. On the basis of these results the study was 
expanded to include patients in BC phase of the disease. However, most of these 
patients relapsed within a few months of therapy indicating that the drug was much 
less effective in BC. Phase II and III trials followed, including patients at diagnosis, 
at all stages of disease and with combinations of conventional drugs versus STI. 
Overall the STI treated patients showed improved survival and, due to its lack of 
toxicity, better quality of life (Kantarjian HM, O'Brien S et al. 2003). Although these 
results lead to confidence that an effective treatment for CML at least in CP had 
been found, there were certain observations that were cause for concern. One of 
the most significant was that in patients who achieved a completed cytogenetic 
response, detectable BCR-ABL transcripts were shown in samples analysed by 
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sensitive RT-PCR, indicating that molecular remissions were rare (Hughes TP, 
Kaeda J et al. 2003). It has also been shown, in work included in this thesis, that 
quiescent BCR-ABL+ stem cells are resistant to the effects of STI in vitro and have 
the potential to cause relapse (Graham SM, Jorgensen HG et al. 2002). These 
observations have increased doubts over the durability of responses to STI 
therapy. 
1.2.4.3 Resistance to STI 
The less favourable responses of CML patients in AP and BC to STI therapy, 
together with the existence of low level BCR-ABL transcripts in treated patients in 
CP, prompted investigations into the possible mechanisms of resistance. It is clear 
from the clinical data that resistance may be acquired i. e. patients respond initially 
and then fail therapy, or resistance may be inherent i. e. little or no response is 
observed. The mechanism of resistance may be associated with disease status 
and progression, and may be different for both. 
As early as 1997, Deininger et al had found that small numbers of Ph+ colonies 
could be grown in the presence of 1pM STI (Deininger MW, Goldman JM et at. 
1997). Le Coutre et al demonstrated that a BCR-ABL+ cell line, LAMA84, could be 
induced to develop resistance to STI by culturing cells with increasing 
concentrations of STI over a period of time. They also showed that resistant cells 
contained a higher level of bcr-abt expression and phosphorylation, and that this 
was associated with gene amplification (Le Coutre P, Tassi E et at. 2000). The 
observation that removal of STI from cultures could restore sensitivity to the drug 
in cell lines, indicated that two populations of cells coexisted i. e. a sensitive and an 
insensitive one each prevailing under the correct conditions (Tipping AJ, Mahon 
FX et at. 2001). These results raise the possibility that patients who have become 
resistant may regain sensitivity by brief withdrawal of the drug. It is not clear what 
implications these observations may have in the therapeutic context. 
Drug resistance is most commonly associated with reactivation of bcr-abl signal 
transduction and recent data have indicated that the most frequent mechanisms of 
resistance to STI are point mutations in the kinase domain of bcr-abl or gene 
amplification at the transcript or genomic level (Gorre ME, Mohammed M et al. 
2001). Mutations in the kinase domain may interfere with STI binding or may 
change the conformation of the protein such that drug binding is reduced. 
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Investigations have shown that there is a range of sensitivities to STI associated 
with particular mutations (Corbin AS, Buchdunger E et al. 2002). Recent work by 
Bhatia's group has shown that kinase mutations can be detected in CD34+ stem 
cells from patients in CCR on STI therapy, raising the possibility that therapy itself 
may lead to a selective advantage for the mutant clone and subsequent relapse 
(Chu S, Xu H et at. 2005). The finding that point mutations could be found in 
patients prior to STI therapy argues for a pre-existing mutant clone that gains 
prevalence as its sensitive neighbours are eliminated (Shah NP, Nicoll JM et al. 
2002). 
Other possible mechanisms for resistance to STI therapy include overexpression 
of the MORI gene, which encodes the P-glycoprotein pump, and was shown to 
inhibit the entry of STI into K562/DOX cells (resistant to doxirubicin by MDR1 
expression). Retroviral transfection of BCR-ABL+ cells with MDR1 reduced their 
sensitivity to STI, which could be restored by inhibition of Pgp with verapamil 
(Mahon FX, Belloc F et al. 2003). Using C14-radiolabelled STI it has been shown 
recently that both uptake (by hOCT1) and efflux (by MDRI) are active transport 
processes that can be inhibited by verapamil. Both transporters were expressed in 
primary CML cells and in cell lines. This observation may mean that resistance is a 
result of disparity in expression between the two transporters (Thomas J, Wang L 
et al. 2004). Another recent report has documented the first cellular effect of Pgp 
modulation in the treatment of a Ph* ALL patient with STI (Illmer T, Schaich M et 
al. 2004). In contrast, other studies have shown overexpression of MDRI in BCR- 
ABL+ K562 cells did not protect them from the effects of STI (Ferrao PT, Frost MJ 
et al. 2003). The importance of MDR1 in clinical resistance to STI has yet to be 
established. 
To try to overcome the problems of STI resistance other approaches in the 
treatment of CML include, dose escalation of STI, other bcr-abl inhibitors, 
combinations of other cytotoxic drugs and STI and inhibitors of downstream 
targets of bcr-abl. Undoubtedly, STI has had a major impact on both the clinical 
management of CML and on the laboratory investigations into this fascinating 
disease. Whether resistance to STI is a feature that has to be overcome with 
additional therapy or whether there are (quiescent) cells that are genuinely able to 
evade therapy, will be elucidated in time to come. 
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1.3 Microarrays 
Recent technological advances together with the success of the Human Genome 
Project have given researchers the tools to investigate gene expression on a 
genomic scale. The data generated from numerous studies have changed the 
focus of research in many areas, not least cancer. A complete review of the 
technology is outwith the scope of this discussion, which will focus on the areas 
most relevant to this study. 
1.3.1 Types of Arrays 
The most common formats for microarrays are cDNA arrays and oligonucleotide 
arrays: 
1. cDNA arrays use gene sequences, which are normally PCR products derived 
from cDNAs that are robotically spotted onto either glass slides or nylon 
membranes. Labelled single stranded cDNA is produced from RNA samples using 
reverse transcriptase and hybridised to the array, in a typically competitive 
reaction. The two samples to be compared are labelled with different dyes, most 
commonly Cy3 and Cy5, and the arrays are then scanned at two different 
wavelengths to detect the relative transcript levels for each sample. The main 
advantages of this type of array are, a) they can be generated in house, b) they 
can be customised to suit samples and investigation, and c) they are relatively 
inexpensive. However, the main disadvantages are that managing large cDNA 
libraries is an onerous task and even the best labs are prone to errors. The 
reproducibility in array manufacture is variable and the format is limited to a 
smaller density of spots, largely due to limitations in the robotics. A further 
drawback of this type of array is the possible failure to detect closely related genes 
if there is a large degree of sequence homology. 
2. Oligonucleotide arrays such as Affymetrix GeneChip® arrays are the gold 
standard in array technology and are made by synthesising oligonucleotides on 
the chip by a process known as photolithography. There are 11-16 probe pairs or 
sets for each gene and hybridisation is non-competitive. A pair consists of a 
perfectly matched sequence of 25 oligos and partner containing a single mismatch 
base at position 13. Biotin tagged RNA produced by in vitro transcription is applied 
to the chips and the signals obtained from the perfect match and mismatch probes 
Susan M Graham, 2005 Chapter 1,56 
compared. The use of multiple short sequences allows splice variants and 
sequences of up to 90% homology to be identified. The probe mismatch strategy 
helps to minimise non-specific and background signals. In addition, Affymetrix 
chips contain a number of probe sets with known expression levels, which serve 
as internal controls for signal and background normalisation. This method of 
manufacture means that at least 12,000 genes can be represented per chip and 
the sample can be recovered following the first hybridisation and applied to 
another chip. There are a number of disadvantages of this system, 1) it requires 
specialist equipment and expertise to operate it, 2) it is very expensive especially if 
multiple samples are to be included, and 3) the expense of custom chips makes 
this impractical for even small experiments. 
3. Recently, oligonucleotide arrays using 60-mer sequences (or longer) have 
become available. This format offers an increased level of sensitivity over the early 
oligonucleotide arrays together with the option of custom gene sets at a 
reasonable cost. One of the main advantages is that these arrays do not require 
expensive equipment to process the slides and, due to advances in spotting 
technology, now offer a high level of reproducibility. Comparisons of 
oligonucleotide and Affymetrix array formats have shown good correlation of 
expression values for comparable samples (Barczak A, Rodriguez MW et al. 
2003). 
Samples for application to microarrays can be from any source providing there are 
enough cells from which to extract intact RNA. Often clinical samples especially 
from solid tumours or biopsies yield very small amounts of material. It is possible 
to amplify the RNA prior to application to the arrays. Linear amplification is based 
on reverse transcription with primers containing a bacteriophage RNA polymerase 
promoter sequence and cDNA is amplified by in vitro reverse transcription using 
the appropriate bacteriophage RNA polymerase (Baugh LR, Hill AA et al. 2001). 
The results are reproducible and allow as little as 1-50ng of total RNA to be used 
as starting material, equivalent to 100-5000 cells. Recent data has validated this 
amplification protocol for small amounts of starting material, showing that similar 
differential gene expression profiles were generated from both amplified and non- 
amplified RNA (Patel OV, Suchyta SP et al. 2005). 
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Microarray experiments by their nature generate vast amounts of data. The task of 
analysing this data to produce meaningful results is complex and time consuming, 
requiring input from specialist bioinformatians. Initially the image data from the 
array scans has to be normalised to subtract background noise and non-specific 
signals. In the case of Affymetrix Genechips the controls are internal to the chips 
giving more robust data. The next level of analysis is aimed at identifying relevant 
changes in gene expression, usually comparing one sample with a control sample. 
Specialist array programs are employed at this stage to deal with complexity and 
quantity of data. One such program is GeneSpring® (Silicon Genetics, USA) and 
was the one used for the initial analysis in this work. Normalised data from the 
array chips are imported into the program, which allows the data to be 
manipulated in various ways. The first step is typically to look at the fold change 
either up or down between samples. This gives an indication of the number of 
genes that are changed between experimental groups. Utilising the numerous 
analysis tools in the program allows generation of gene lists with defined 
parameters i. e. fold change set at 2,3, etc or overlapping genes in data sets using 
Venn diagrams. Further data analysis to determine statistical significance is 
required to confirm results. Clustering analysis identifies gene groups that are 
changed between samples and more sophisticated analysis can generate a 
genetic "fingerprint" for a particular condition or disease, which could be used to 
predict outcome or identify suitable treatment (Reviewed in (King HC and Sinha 
AA. 2001). 
1.3.3 Confirmation of Microarray Results 
Due to the way in which large amounts of data are generated in microarray 
experiments, confirmation by independent analysis is required. Separate samples 
other than the ones used for the arrays increases the validation of results. 
Normally another experimental platform is used to corroborate array data. This is 
commonly quantitative real time PCR such as Taq-man (Applied Biosciences) or 
Light Cycler (Roche), which can measure relative expression levels in matched 
samples. Ultimately, the most relevant biological validation is variation in cellular 
protein levels, although for technical reasons this may not always be possible. It 
must be appreciated that although microarrays are a powerful tool they only give a 
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snapshot of the transcription levels in a cell in that time frame. Moreover, they do 
not discriminate post-translational or post-transcriptional modifications, which may 
be just as relevant to the cell's biological state. 
1.3.4 Microarrays and Stem Cell Biology 
Microarrays have been used in a number of studies in an effort to unlock the 
genetic program of stem cells. However, numerous investigations have failed to 
yield consistent gene sets. This is perhaps not surprising given the variations in 
studies between cell populations, selection methods, array formats, and 
bioinformatics. A vast amount of data has been generated, however much of it is 
not directly comparable due to the variations listed above. The ability to examine 
the gene expression profile of HSC has led to a variety of microarray studies in the 
search for a "molecular signature" that could be used to define these rare cells, 
and thus separate them from the general population. Phillips et at have reported a 
microarray study of murine HSC, which identified gene differences between 
primitive and more differentiated stem cells. The analysis recognised thousands of 
known and unknown genes as differentially expressed between the cell types, 
which were used to construct a stem cell database (Phillips RL, Ernst RE et al. 
2000). The results illustrate the problems inherent in these types of experiments 
i. e. vast amounts of data are generated and it is difficult to identify the most 
important gene expression differences. Even in studies where similar methodology 
has been used, microarray results can generate different gene sets. This was 
illustrated recently when two independent groups used gene profiling to try to 
identify a molecular signature of "sternness". Both groups examined the 
expression profile of mouse embryonic, neural and haemopoietic stem cells, and 
produced a list of genes associated with a common stem cell profile. However, 
analysis of both data sets by an independent group revealed that there was very 
little overlap in the gene sets identified, in fact only 6 genes were common to both 
gene sets. These data emphasise the importance of strictly defined cell 
populations and caution in interpretation of analysis (Ivanova NB, Dimos JT et at. 
2002; Ramalho-Santos M, Yoon S et at. 2002; Evsikov AV and D. 2003). 
The problems highlighted can be minimised to some degree by using very defined 
cell populations, such as sorted cells, although this inevitably means small 
amounts of starting material. Other microarray studies have confirmed the 
importance of recognised gene differences and subsequently, increased the 
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significance of these observations. In a recent report, Steidl et al compared the 
expression profiles of BM and circulating CD34+ cells and confirmed the increased 
cycling status of BM CD34+ cells compared with G-CSF mobilised PB CD34+ cells 
(Steidl U, Kronenwett R et al. 2002). It is clear that this technology has facilitated 
our understanding of some important pathways and interactions, and has become 
an important tool in stem cell research. 
1.3.5 Clinical Impact of Microarrays 
One of the first applications of successful gene profiling, in the context of 
leukaemia, was used to distinguish acute lymphoblastic leukaemia (ALL) and 
acute myeloblastic leukaemia (AML). Although the two diseases were 
distinguishable through the application of various specialist criteria, there was no 
single test that was sufficient to separate them. Treatment for each disease is 
markedly different and critical to success. Although both diseases will respond to 
the corresponding treatment regime, lower cure rates and unnecessary toxicities 
are observed. Golub et al used the two diseases as a test case to measure the 
success of a gene profiling strategy for disease classification. They were able to 
define a class predictor (50 genes) for the AML/ALL distinction and further 
determined that it could have been automatically discovered without prior 
knowledge of the biology (Golub TR, Slonim DK et al. 1999). 
More recently, gene profiling identified a newly classified leukaemia distinct from 
ALL or AML. A subset of human leukaemia with a particularly poor prognosis was 
known to possess a chromosomal translocation involving the mixed-lineage 
leukaemia gene (MLL). The morphology of the disease is lymphoblastic leading to 
its classification as ALL. However, unlike classic childhood ALL, relapses post 
chemotherapy were common and the cells exhibited distinct immunophenotypic 
differences from ALL, including lack of early lymphocyte antigen and the tendency 
to express myeloid antigens. The gene expression profiles showed that ALLs with 
the MLL rearrangement displayed a uniform and distinct pattern distinguishing 
them from conventional ALL and AML (Armstrong SA, Staunton JE et at. 2002). 
There are many more studies that have successfully employed microarray 
technology to clinical advantage. The possibility of routine diagnosis by gene 
profiling is a little way off, however there is no doubt that this technology 
represents a major step forward in clinical investigation and in targeted therapy. 
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Quiescent HSC remain relatively uncharacterised. The existence of quiescent 
leukaemic stem cells in CML and their potential for disease persistence, presented 
an attractive target for investigation. The initial experiments were aimed at 
developing the methodology to select these rare stem cells from the rest of the 
HSC population. A FAGS sorting strategy was developed to isolate pure 
populations of quiescent and cycling stem cells from both normal individuals and 
CML patients. 
Further FACS sorting methodology was utilised to investigate the differences 
between normal and CML HSC in vitro in the presence and absence of growth 
factors. Additional experiments were aimed at examining the effects of a 
specifically targeted therapy, ST1571, on CML stem cells in vitro. Finally, FACS 
sorting methodology was used to isolate populations of normal and CIVIL HSC in 
different phases of the cell cycle, in an effort to identify the transcriptional profile of 
normal and CML quiescent and cycling cells by microarrays . 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Tissue Culture Supplies 
Baxter Healthcare Gammagard human i. v. immune 
Northampton, UK globulin 
Sterile water 
Isolex stem cell selection kit 
Becton Dickinson Hypodermic needles 
Plymouth, UK Luer lock syringes 
Falcon tubes 
Bibby-Sterilin Suspension culture dishes 35mm 
Staffordshire, UK 
Chugai Pharma, rHU G-CSF 
London UK 
Costar, Cell scrapers 
Cambridge, MA, USA 
Corning, 24 well tissue culture plates 
Bucks, UK 
Gibco BRL, 2-mercaptoethanol 
Paisley, UK 
Millipore, Millex-OR single use filter (0.2pm) 
Watford, UK 
Nalge Nunc International, 50ml Tissue culture flasks 
Roskilde, Denmark Cryotubes 
Novartis, ST1571 
Surrey, UK 
Roche Products Ltd Recombinant human Dnase 
Welwyn Garden City, UK (Pulmozyme®) 
Scottish Blood Transfusion Service, 20% Human serum albumin (HSA) 
Glasgow, UK 4% Human serum albumin (ALBA) 
Human immunoglobulin 
Sigma Aldrich, Acetic acid 
Dorset, UK Ammonium chloride 
Dimethyl sulphoxide 
Dulbecco's phosphate buffered saline 
(w/o Ca2+ and Mgt+) (PBS) 
Foetal calf serum (FCS) 
Glutamine 
Low density lipoprotein 
Iscove's modified Dulbecco's medium 
(IMDM) 
Methanol 
Penicillin/streptomycin 
Potassium chloride 
Tri-sodium citrate 
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Trypan blue solution (0.4%) 
Isopropyl alcohol 
Pol -L-I sine 
Stem Cell Technologies, BIT (serum substitute) 
British Columbia, Canada rHU FLT3L 
rHU IL-3 
rHU IL-6 
rHU Stem cell factor (SCF) 
Methocult 
Stem cell mix + erythropoeitin 
Progenitor enrichment cocktail 
Biotinylated anti-CD15 
StemSep columns 
Sterilin Ltd 90mm petri dishes 
Hounslow, UK 30mm triple vent dishes 
15ml centrifuge tubes 
PES filter system (0.2pm) 
50ml centrifuge tubes 
5ml sterile disposable pipettes 
10mi sterile disposable pipettes 
25ml sterile disposable pipettes_ 
Tayside Pharmaceuticals, Magnesium chloride 
Dundee, UK 
Vysis-Abbott, FISH Dual fusion probe (bcr/abl) 
Maidenhead, UK 
2.1.2 FACS Reagents 
Becton Dickinson, Oxford Human anti-CD34 FITC antibody 
UK Human anti-CD34 PE antibody 
Human anti-CD38 PE antibody 
IgG FITC isotype control 
IgG PE isotype control 
Mid range FL1 rainbow alignment 
particles 
Calibrite FITC/PE beads 
FAGS flow 
FACS safe 
FACS rinse 
Cambridge Biosciences, CFSE 
London, UK UV alignment beads 
Hoechst 33342 
Sigma Aldrich, Propidium iodide 
Dorset, UK ronin Y 
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2.1.3 Molecular Biology Reagents 
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Abgene, ReddyMix PCR Master Mix 50µI 
Surrey, UK reaction tubes 
Ambion, DNA-free Kit 
Texas, USA 
Beatson Laboratory Stock, DH5a E. Coli 
Glasgow, UK 
Invitrogen, Superscript II kit 
Paisley, UK TRlzol reagent 
TOPO TA kit 
MWG, PCR Primers 
London, UK 
Qiagen, QlAquick PCR Purification Kit 
West Sussex, UK QlAquick Nucleotide Removal Kit 
QlAquick Gel Extraction Kit 
QlAprep Miniprep Kit 
Rneasy Mini Kit 
Sigma Aldrich, Ampicillin 
Poole, UK Chloroform 
Dimethyl formamide (DMF) 
Isopropyl alcohol 
Trizol reagent 
X-gal 
Ethidium bromide 
Hyperladder IV 100-1000b 
2.1.4 Primers for RT-PCR 
Actin: forward: TCC ATC ATG AAG TGT GAC GT 
reverse: TAC TCC TGC TTG CTG ATC CAC 
CD34: forward: CTG CTA CCA CGG AGA CTT CTA CAC AAG G 
reverse: ATG GCA CTC GGA GCA GAA GAT GAT 
MCMS; forward: GCA GAG GCG CTT CAA GGA GTT CC 
reverse: ATG TTG GTG AGG GTG TTG CGC CAG 
PCNA: forward: TCA ACG AGG CCT GCT GGG ATA TTA G 
reverse: TGG CTG AGA TCT CGG CAT ATA CGT G 
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ABL: forward: TTCAGCGGCCAGTAGCATCTGACTT 
reverse: GGTACCAGGGTGTTTCTCCAGACTG 
BCR-ABL: forward: CAGGGTGCACAGCCGCAACGGCAA 
reverse: GTCCAGCGAGAAGGTTTTCCTfGGA 
2.2 Media and Solutions 
2.2.1 Tissue Culture Media 
2.2.1.1 Serum Free Media 
77.8m1 IMDM 
20m1 BIT (serum substitute) 
Im( L-Glutamine (200mM) 
1 ml Penicillin (5000u)/Streptomycin (5mg/ml) 
200p12-Mercaptoethanol (200mM stock) 
40pg/mI Low density Lipoprotein 
2.2.1.2 Growth Factor Cocktail for Serum Free Media 
IL-3 20ng/mI 
IL-6 20ng/ml 
h-SCF lOOng/m( 
FLT-3L IOOng/ml 
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G-CSF 20ng/mi 
2.2.1.3 IMDM 2% FCS 
98m1 Iscove's modified Dulbecco's medium 
2m1 Foetal calf serum 
2.2.2 Tissue Culture Solutions 
2.2.2.1 PBS 2% FCS (PBS/2%) 
98ml Dulbecco's modified phosphate buffered saline w/o Ca + and 
2m1 Foetal Calf Serum 
2.2.2.2 PBS 20% FCS (PBS/20%) 
80ml Dulbecco's modified phosphate buffered saline w/o Ca + and 
20m1 Foetal Calf Serum 
2.2.2.3 PBS+ 
327ml Dulbecco's modified phosphate buffered saline w/o 
0.5m1 magnesium chloride 
and 
2.5m1 
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500ml Dulbecco's modified phosphate buffered saline w/o Ca and M 
75m1 Tri-sodium citrate 
25ml Human serum albumin 
l ml Magnesium chloride 
5m1 
2.2.2.5 ALBA 20% DMSO 
80ml Human serum albumin 
20m1 dimethylsulphoxide 
2.2.3 Molecular Biology Solutions 
2.2.3.1 TAE Buffer 
40mM Tris-acetate 
1mM EDTA 
Reagents were dissolved in distilled water and pH adjusted to 8.3 with glacial 
acetic acid 
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2.2.4 Bacterial Culture Reagents 
2.2.4.1 SOC Medium 
2% (w/v) bactotryptone 
0.5% (w/v) yeast extract 
10mM NaCl 
2.5mM KCI 
20mM MgCI2 
20mM MgSO4 
20mM glucose 
2.2.4.2 Luria-Bertani (LB) Broth and Agar Plates 
lg tryptone 
15g yeast extract 
lOg NaCI2 
950m1 deionised water 
15g Agar (FOR PLATES) 
All the ingredients, except the agar were added, and the pH adjusted to 7 using 
NaOH. The final volume was increased to 1 litre and the solution autoclaved 
before use. To make bacterial culture plates, agar was added at 15gf to the LB 
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broth and autoclaved, before the addition of 50pg/ml ampicillin. Approximately 
1 Oml of the solution was poured into 90mm petri dishes to solidify. 
2.2.4.3 X-Gal Stock Solution 40 mg/ml 
400mg x-gal 
10mi dimethylformamide 
X-gal was dissolved in dimethylformamide and stored as a stock solution at -20°C 
protected from light. Before addition to the agar plates, the plates were warmed to 
37°C and 40pl of the stock solution added to each plate and spread evenly with a 
sterile spreader. The plates were dried for 15 minutes and protected from light, for 
use within 24 hours after the addition of x-gal. 
2.3 Methods 
2.3.1 General Cell Culture 
2.3.1.1 Cell Counts 
Cell counts were performed on a Beckman Coulter T660 analyser, which required 
120µI of sample. For counting small cell numbers or for cell viability counts, a 
haemocytometer counting chamber was used. 
2.3.1.2 Cryopreservation of Cells 
Sorted or selected cells were stored frozen in liquid nitrogen where appropriate for 
further use. For cryopreservation, a cell suspension was made not exceeding 
1x107 cells/ml in appropriate medium to which was added an equal volume of 
ALBA + 20% DMSO, to give a final concentration of 10% DMSO. The cryotubes 
were placed in a freezing container (Mr Frosty) that included isopropyl alcohol and 
placed in a --80°C freezer overnight. This allowed a controlled reduction in 
temperature of approximately 1°C/minute. before placing into long-term liquid 
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nitrogen storage. For some CD34+ selected CML and normal samples used, this 
was performed by either Dr Michael Alcom or Mrs Linda Richmond. 
2.3.1.3 Recovery of Frozen Samples 
To recover the maximum number of viable cells from cryopreservation it was 
necessary to exercise extreme care when thawing patient samples, particularly 
CML samples. On removal from liquid nitrogen, the vials were immediately thawed 
in a 370 C water bath until all of the ice crystals had disappeared. The cells were 
transferred to a sterile 15ml centrifuge tube on ice and 10ml of ALBA was added 
drop-wise over a 15-20 minute period. The tubes were centrifuged at 400g for 10 
minutes. The cells were washed twice by adding 10ml of PBS/2% and centrifuging 
as before. After discarding the final wash supernatant, the cells were resuspended 
in appropriate medium, counted and assessed for viability. 
2.3.1.4 Assessment of Viability 
Routinely viability was determined using the trypan blue exclusion method. The 
cell suspension was diluted to an appropriate number and trypan blue solution 
added at a ratio of 1: 4 trypan blue to cells. The cell suspension was placed in a 
haemocytometer counting chamber and at least 200 cells were counted under a 
light microscope at 40x magnification. The blue stained cells were scored as dead 
and the unstained cells as live. The percentage of viable cells was calculated by 
dividing the number of viable cells by the total cell count x100. 
2.3.1.5 Red cell Lysis by Ammonium Chloride 
For most experimental purposes it was necessary remove red cell contamination 
from leukapheresis products. This was achieved by lysis of the red cells with 
ammonium chloride solution 0.083%w/v in distilled water, added at a 1: 10 cell 
suspension to NH4CI and incubated in a 37°C water bath for 10 minutes. The cells 
were recovered by centrifugation at 400g for 10 minutes followed by a further 
wash in PBS/2%. If red cell lysis was incomplete the above procedure was 
repeated. 
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2.3.1.6 Removal of Red Cells by Density Gradient Centrifugation 
An alternative method for effectively removing red cells from samples used 
lymphoprep, a density gradient medium. The cell samples were diluted in PBS2% 
to give a working cell concentration of less than 5x107/ml. 6-10mis of cell 
suspension was carefully layered over 4ml of lymphoprep avoiding mixing the two 
phases. The tubes were centrifuged at 800g for 20 minutes during which the red 
cells moved through the lymphoprep to the bottom of the tube and the 
mononuclear cells remained at the interface. Following recovery from the 
interface, the cells were washed twice in PBS2%. 
2.3.1.7 Removal of Platelets 
When using leukapheresis products it was necessary to remove contaminating 
platelets before commencing cell separation. This was done by centrifuging the 
sample in 50ml tubes at 200g for 10 minutes and stopping the rotor without the 
brake activated. The supernatant was removed by aspiration and the above step 
repeated with the addition of PBS++ (section 2.2.2.4) to each tube. The 
supernatant was discarded and the cell pellet resuspended in appropriate medium. 
2.3.1.8 Committed Progenitor Assay 
As a measure of functionality, cells were cultured in semi-solid medium in the 
presence of stimulatory cytokines in CFU-GM/CFU-BFUE assays. Methocult, a 
commercial ready- made methylcelluose, was supplemented with stem cell mix + 
erythropoietin (custom cocktail from Stem Cell Technologies). 2.3ml of 
supplemented methocult was aliquoted into falcon tubes and stored at -20°C until 
required. After thawing the tubes, the cell suspension was added in a final volume 
of 0.2ml in IMDM/2%FCS to each tube and shaken vigorously to mix. Iml of the 
suspension was placed in each of two 35mm suspension culture dishes. The 
dishes were placed in a 90mm petri dish together with a dish of sterile water to 
prevent drying, and incubated for 12 days at 37°C in a humidified incubator in 5% 
CO2. The plates were counted on day 12 and GM colonies scored as having >40 
cells, and each erythroid burst scored as a single colony. Duplicate dishes for 
each of the cultures were scored and the counts averaged. 
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2.3.2 Stem Cell Selection 
2.3.2.1 Primary Human Cells 
All CML cell samples used were leukapheresis products from patients who were 
undergoing this procedure as part of their clinical management to reduce 
peripheral white cell counts. Normal cells were obtained from allogeneic donors 
mobilised with rhG-CSF collected by leukapheresis. Informed consent was 
obtained from all patients and donors prior to the procedure, and only material 
surplus to clinical requirement was available for research purposes. All consents 
were in accordance with ethical approval from the Local Research Ethics 
Committee. 
2.3.2.2 Negative Stem Cell Selection 
Stem cells are a relatively rare proportion of mobilised peripheral blood products 
and therefore need to be selected from the whole population. This can be done in 
two ways, either by labelling and selecting the population of interest i. e. positive 
selection (see below) or by removing most of the other cells leaving the stem cell 
fraction i. e. negative selection. The resultant product for each type of selection is 
intrinsically different although both contain stem cells. For some applications such 
as microarrays it was essential that the samples to be compared had been 
selected in the same way. 
Putative stem cells were selected from CML patient samples, using Stem-Sep 
negative selection according to the manufacturer's instructions. All dilutions and 
column washes were done in PBS++. Briefly, the cell suspension at a 
concentration of 2-8 x107cells/ml in PBS++ (after removal of red cells) was 
incubated with an antibody cocktail containing CD2, CD3, CD14, CD16, CD19, 
CD24, CD56, CD66b and Glycophorin A for 15 minutes at room temperature (RT) 
on a roller mixer. Then 60pl of magnetic colloid/ml of cells was added for a further 
15 minutes at RT on a roller mixer. The number of columns required was 
dependent on the total cell number. The maximum number of cells was 1 x108- 
1.5x109 per column. Four columns could be run simultaneously and the whole run 
was repeated if all of the cells could not be accommodated in a single run. 
Columns were primed with PBS only and washed with PBS++ before being slotted 
into the magnet prior to addition of the cell suspension. The eluted cells were 
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collected in three column volumes of PBS++ and centrifuged at 400g for 10 
minutes, before resuspension, counting and FACS (detailed in chapter 3). The 
selected cell numbers were adjusted to -1x107/ml for cryopreservation in ALBA 
+10%DMSO. 
2.3.2.3 Positive Stem Cell Selection 
For CD34-positive selections, the cells were labelled with an anti-CD34 antibody, 
which was subsequently bound to a magnetic bead and used to isolate the CD34+ 
cells with a magnetic column. For this procedure, stem cells were enriched using 
the Isolex® kit and IsolexN 50 automated system. This was essentially a clinical 
processing kit scaled down for smaller cell numbers and which used a smaller 
processing machine, the Isolex 50 (procedure detailed in chapter 3). Briefly, 
following removal of the platelets as described, the cells were resuspended in 
30ml PBS++ to a concentration of 1-5x101/ml and 5ml human immunoglobulin (Hu 
Ig) added for 15 minutes at RT with mixing. Anti-CD34 antibody (0.5pg/NI) was 
added at I NI/1 x106 cells and incubated at RT with mixing, for 30 minutes. The cells 
were loaded onto the column and the automated procedure for washing and 
release of target cells was followed using the Isolex 50 apparatus. The cells were 
collected at the end according to the instructions and FACS analysis performed to 
establish the purity and recovery of the CD34+ cells. Some of the samples used in 
the CFSE experiments (chapter 5) were processed by Dr Michael Alcorn or Mrs 
Linda Richmond. 
2.3.3 FACS and Cell Sorting 
2.3.3.1 FACS Sorter Alignment and Set-up 
The machine used was a Becton Dickinson FACS Vantage incorporating an 
enterprise argon laser for excitation at 488nm and using a beam splitter to give 
excitation at 340nm in the ultra violet range. The laser required to be aligned 
before each use. If the UV was to be used it had to be aligned separately. The 
optical alignment was done using mid-range FL1 Rainbow beads for the primary 
laser and UV beads for ultra violet beam. The integrity of the alignment was 
checked using histogram plots with markers indicating the CV (coefficient of 
variation) values for each parameter. The percentage CV range for forward scatter 
and FLI was 2-4%, and for UV in FL4 was 1-3% on linear scales. The 
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parameters for sorting were defined by choosing the sort mode. There were 4 
options with varying purities and counter accuracies depending on the desired cell 
population. The differences in sort modes defined how the machine dealt with 
aborted events and were operator controlled. The gating strategies used for 
sorting defined cell populations are detailed in the relevant results chapters. Once 
the gating was set the sample differential was adjusted to allow a total event rate 
of 3000/sec, which was the maximum this particular sorter could deal whilst 
maintaining acceptable cell recoveries. The most critical parameter for sort purity 
was the drop delay setting, which was adjusted according to the parameters 
described in the manual, and constantly monitored throughout the experiment. 
Following laser alignment, activation of the drop drive caused the stream 
containing the cells to be broken into droplets and depending on the settings, the 
drops were charged positively or negatively and sorted left or right into the 
collection tubes containing PBS/2%. Digital counters allowed the number of 
threshold, left, right and aborted events to be monitored. The proportion of cells in 
each parameter gave constant indication of the sorting process and allowed 
inspection of the sorting procedure. 
2.3.3.2 Antibody Staining 
All antibodies were titrated to determine the appropriate concentration for use. The 
concentrations used were the minimum amount of antibody that gave reliable 
staining and good separation of cell populations. As well as reducing the cost, 
lower intensity of antibody facilitated compensation in multi-parameter FAGS 
experiments. For standard antibody staining a reaction mix of 200pl PBS 2%, cells 
and antibody was used. Controls consisted of the same reaction volume with 
matched isotype and fluorescent label. i. e. if anti CD34-FITC antibody was used 
and it was an IgG1 antibody the control tube contained IgG1-FITC. Isotype 
controls were included for all antibody staining. 
2.3.3.3 CFSE Staining 
The cells to be stained were recovered from liquid nitrogen as described. After 
resuspension in PBS2%, 2x106 cells were removed for unstained controls. The 
remainder of the cells were incubated in 1 pM CFSE for exactly 10 minutes at 
37°C. 10x volume of ice cold PBS 20% was added to stop the reaction and the 
cells centrifuged at 400g for 10 minutes. The supernatant was removed and the 
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cells washed in PBS2%. The stained cells and the unstained control cells were 
then cultured overnight in serum free medium with or without the addition of a five 
growth factor cocktail as described to allow excess dye to leach out. The cells 
were incubated overnight on 90mm sterile non tissue culture treated petri dishes 
or in suspension flasks at a concentration of 2x107/ml. The following day the cells 
were recovered from the flasks or plates using a cell scaper, and washed in 
PBS2%. After removal of a sample of cells for FAGS controls, the remaining cells 
were stained with anti-CD34-PE antibody and incubated at RT for 15 minutes 
before being washed twice in PBS2%. The second wash contained PI at a 
concentration of 1 pg/ml in all tubes. These cells were now ready for CFSE sort I 
as described below. 
2.3.3.4 FACS For CFSE Experiments 
The unstained/isotype control cells were run first to check the position of the 
negative population, and if necessary the detectors were adjusted to place the 
negatives in the first log decade. The viable gate was set around the PI' 
population. Following gating on the viable cells, the CD34+ stained cells were 
identified and a further gate set around this population. The cells stained with 
CFSE/CD34/Pl were then run and the compensation adjusted to give the same 
percentage of CD34+ events as for the CFSE /CD34+/PI' sample. Considerable 
levels of compensation were required as the CFSE stain was very bright and the 
spectral overlap into other channels was significant. For CFSE sort 1, the object 
was to obtain a homogenously stained cell population, which would allow the 
resolution of the peaks of cell division after 3 further days in culture. Two narrow 
markers of 19-21 channels, with 5 channels between, were set on the 
CFSEma"/CD34+/PI' cell population and sorted left and right. The two populations 
of sorted cells were kept separate for all further experiments. During sorting all 
cells were kept on ice and in the dark. All the left-sorted cells were pooled and 
similarly all the right-sorted cells pooled for counting and subsequent culture. 
Following a further three days in culture under various conditions, (as described in 
the relevant results chapters), the cells were sorted again (sort 2), into divided and 
undivided populations. Gates were set around the viable (PI') cells that were 
CD34+ (PE Bright). To set gates for divided and undivided cells, the position of the 
undivided peak was identified using the same cells (left- or right-sorted) cultured in 
the presence of 100ng/ml colcemid. Markers were set on a histogram plot to sort 
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the undivided population to the left and all of the divided cells to the right. To 
preserve cell viability and maximum fluorescence in stained cells during lengthy 
sorting experiments, all cells were kept on ice in the dark. 
2.3.3.5 Hoechst and Pyronin Staining 
In order to identify the GO, G1 and S/G2/M phases of the cell cycle, DNA was 
stained with Hoechst 33342 (HST) and RNA was stained with Pyronin Y (Py). 
Hoechst was used at a final concentration of 10pM and the cells incubated in a 
37°C water bath for 90 minutes. Without washing, Pyronin Y was added at a final 
concentration of 0.5pg/ml for 45 minutes. Anti-CD34-FITC was then added 1: 25v/v 
again without washing for 15 minutes at RT. The cells were then washed in PBS 
2% containing the same concentration of HST and Py. A further wash in the same 
buffer was done with the inclusion of PI at a final concentration of 1 pg/ml. At each 
stage cells were removed for FACS controls. For antibody stains, a matched 
isotype control was run prior to the positive samples to verify the position of the 
negative population.. 
2.3.3.6 FACS For Hoechst and Pyronin. 
FACS was carried out using the BD FAGS vantage equipped with UV laser. The 
position of the positively stained cells was verified using a combination of 
unstained, single and multiple stained controls. The positively stained cells were 
gated as follows: PI" / CD43+/ HST'O/PVO (GO) and PI' /CD34+ /HSTb"9nt / pyb"9ht 
(G1/S/G2/M). The gating is shown in detail in chapter 3. 
2.3.3.7 FISH on sorted cells 
Approximately 1x103 sorted cells were placed in 0.2ml tubes in 50pl of PBS/2% 
and centrifuged at 4000rpm in a microfuge for 5 minutes. The supernatant was 
removed by aspiration, without disturbing the pellet. The cell pellet was 
resuspended in 50pl of pre-warmed hypotonic solution containing 0.075M 
potassium hydroxide. Aliquots of 20pl were placed in wells of a poly-L-lysine 
coated slide and incubated for 20 minutes at RT before the hypotonic solution was 
removed. The cells were fixed by the addition of 20pl freshly prepared 
methanol: acetic acid (3: 1) to each well and incubated at RT for 5 minutes. This 
fixation step was repeated before air-drying the slide overnight. The slides were 
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stored at -20°C wrapped in parafilm until FISH was performed using the bcr/abI 
Dual Fusion probe according to the manufacturers instructions. Interphase nuclei 
were evaluated using a Leitz fluorescence microscope with a triple-band pass filter 
for DAPI, Spectrum Orange and Spectrum Green. All FISH slides were processed 
and read by Mrs Elaine Allan. 
2.3.4 Molecular Biology 
2.3.4.1 Primer Design 
Relevant primers were designed using Oligo/Exe program. First the gene coding 
sequence was identified by a Pubmed nucleotide search, and the sequence used 
to search for appropriate primers of between 20 and 25 base pairs (bp) with similar 
melting temperatures and no internal loops or palindromes. The forward primer 
was typically around 50bp into the coding sequence and the reverse primer was 
around 300bp downstream. All primers were diluted to alOpM stock and used at 
final concentration of 0.2pM. 
2.3.4.2 Generation of Total RNA 
Cell samples were spun down to a pellet and most of the supernatant removed by 
aspiration. Up to 1ml of TRlzol® was added depending on the number of cells. 
After vortexing the samples were frozen at -80°C until required. The RNA 
extraction was as per the Trizol protocol, briefly the samples were thawed at room 
temperature and 0.2ml of chloroform added per I ml of Trizol and shaken for 15 
seconds. The volumes of reagents were adjusted if the volume of Trizol was less 
than 1 ml. The samples were centrifuged at 10,000rpm in a microfuge for 15 
minutes at 2-8°C. The colourless upper aqueous phase (containing the RNA) was 
transferred to a fresh tube and 0.5ml isopropanol/ml (of original Trizol volume) was 
added for 10 minutes at RT and centrifuged at 10,000 rpm, 2-8°C for 10 minutes. 
The supernatant was removed and discarded. The pellet was washed in 1ml of 
75%( v/v) ethanol per ml of Trizol in original preparation, by vortexing thoroughly 
and spinning at 5000rpm for 5 minutes at 2-8°C. After discarding the supernatant 
the pellet was air dried briefly and resuspended in RNA-free water. The pellets 
were incubated at 55-60°C for 10 minutes to ensure total dissolution. 
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Following the protocol for the superscript kit II, briefly, for each sample a mix was 
prepared which included 5.51I RNA, 0.5µI oligo DT, 3µI random hexamers, 1µl 
DNTP and incubated at 65 °C for 5 minutes before being transferred to ice for I 
minute. A reaction mix containing 2µI of 10x RT buffer, 4µI of 25mM MgCI2,2µI of 
0.1 M DTT, 1 µl RNAse Out was added to each sample tube and incubated at 42°C 
for 2 minutes. 1µl of Superscript 11 RT enzyme or DPC water (-RT control) was 
added to each tube and incubated at 42°C for 50 minutes, then at 70°C for 15 
minutes. The tubes were transferred to ice and 1µl of RnaseH was added to each 
sample for 20 minutes at 37°C. All reagents were supplied with the kit. 
2.3.4.4 Removal of DNA from RNA Samples 
Contaminating genomic DNA was removed from RNA samples using the DNA-free 
kit from Ambion, briefly 0.1 volume of 10x DNase buffer 1 and 1µl of DNase (2 
units) were added to a maximum of 100µI of RNA. The samples were then 
incubated for 20 minutes at 37°C. After resuspension, 0.1 volume of DNase 
inactivation reagent was added and mixed thoroughly. Following 2 minutes at RT, 
the samples were spun at 15,000rpm in a microfuge for 1 minute. The supernatant 
containing the RNA was removed to a clean tube. The resultant DNA 
contamination was typically <0.1 %. 
2.3.4.5 PCR 
Using the Reddymix tubes from Abgene, 1 pl of each primer at 1 0µM was added to 
the 50µl tube together with 51iI of cDNA. Control tubes included H2O and minus RT 
samples. The PCR machine was set up to go through 35 cycles with each cycle 
consisting of 92°C for 2 minutes, 58°C for 30 seconds and 72°C for 1 minute. 
When 35 cycles were completed the tubes were heated to 72°C for 10 minutes 
before being cooled to 4°C until removed from the machine. 
2.3.4.6 Analysis of PCR Products 
The PCR products were run on electrophoresis gels that allowed visualization of 
the bands. Briefly, a 2% agarose gel was made using 2g of agarose powder in 
I00ml of TAE buffer which was melted in a microwave for 2 minutes at full power. 
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To this 1.2µI of ethidium bromide stock was added at 10mg/ml and mixed. The gel 
was then poured into a cast containing a comb to create sample wells. This was 
done in a cold (4°C) room and left to set for approximately 15 minutes. The sample 
comb was then removed and the gel placed in the gel tank containing 1x TAE 
buffer before the samples were loaded. 15-20µl of PCR product was loaded into 
each well. Hyperladder IV (100-1000bp) was included as a reference. Gels were 
run N 15OmV constant voltage. The gels were viewed on a UV transilluminator and 
photographed. 
2.3.4.7 Extraction of Gel Bands 
Whilst viewing on a transilluminator, bands were cut from the gel using a scalpel, 
minimising the amount of agarose extracted with each band. The DNA was then 
extracted using the Qiagen QlAquick gel extraction kit (which contained all 
reagents) and protocol. Briefly, the gel slices were placed in Eppendorf tubes and 
weighed. 3x volume of buffer QG was added and the tubes placed in a 50°C water 
bath for 10 minutes to melt the agarose. After adding one gel volume of 
isopropanol, the samples were applied to QlAquick spin columns and centrifuged 
for 1 minute in a microfuge at full speed. The eluate was discarded and the 
columns washed with 750pl of buffer PE. The DNA was eluted in 50pl of distilled 
water. 
2.3.4.8 Cloning of DNA Fragments with TOPO TA® 
The PCR products were ligated into pCR® 2.1-TOPO® using the TOPO®TA kit 
from Invitrogen. According to the manufacturer's instructions 0.5-4p1 of PCR 
product was added to I pl of salt solution and 1 pl of TOPO® and the reaction mix 
made up to 6p1 with sterile water. The tube was mixed gently and incubated at RT 
for 5 minutes. The reaction was placed on ice for between 5 and 30 minutes. 2p1 of 
this mix was added to I vial of One Shot chemically competent DH5a E. coli, which 
were then heat-shocked at 42°C for 30 seconds and immediately transferred to 
ice. 250pL of SOC medium at RT was added to each tube and incubated at 37°C 
for 1 hour in a shaker at 200rpm. LB agar plates were prepared by adding 1.5% 
agar to prepared LB medium and autoclaving before pouring into 90mm petri 
dishes. When the agar had cooled and solidified, 40pl of x-gal at a concentration 
of 40mg/ml in dimethylformamide (DMF) was added to the surface of each plate, 
spread with a sterile spreader and dried for 15 minutes. 
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Following incubation at 37°C, 10-50pl from each transformation was spread evenly 
on an LB agar plate prepared (as detailed 2.2.4.2) and incubated overnight at 
37°C. White colonies containing insert were picked from the plate and cultured 
overnight at 37°C in LB medium containing 50pg / ml ampicillin. 
2.3.4.10 Isolation of Plasmid DNA 
DNA was isolated from plasmid preparations using the QIAPprep miniprep kit 
which is based on the alkaline lysis of bacterial cells, adsorption of DNA onto silica 
in the presence of high salt, followed by elution in low salt buffer. Only DNA is 
adsorbed on to the membrane all RNA, cellular protein and metabolites are found 
in the flow through. Briefly, the bacterial cells were pelleted and the supernatant 
removed by aspiration before the addition of 250pl of buffer P1 (containing RNase 
A). The solution was transferred to Eppendorf tubes and 250pl of buffer P2 added 
with gentle mixing. 350pl of buffer N3 was added and the tubes mixed by 
inversion. The tubes were centrifuged for 10 minutes at 15000rpm in a microfuge. 
The supernatants were applied to QlAprep spin columns in a 2ml collection tube 
and centrifuged for 30-60 seconds and the flow through discarded. The columns 
were washed by adding 750pl of buffer PE and centrifuging for 30-60 seconds and 
discarding the flow through. The columns were centrifuged for a further 1minute to 
remove residual wash buffer. The DNA was eluted by the addition of 50NI of 
distilled water, letting it stand for 1 minute and centrifuging for 1 minute at 
15000rpm. 
2.3.4.11 Verification of DNA Sequence 
The amount of DNA from each extracted band was measured using a 
spectrophotometer. A known amount was processed through the ABI sequencer 
by Mrs Christine Lang and the results recorded. The sequences were compared 
with the gene coding sequences and the primer: gene specificity verified. 
2.3.4.12 Sample Preparation For Microarrays 
Cells positively selected for CD34 were recovered from liquid nitrogen as 
described and sorted for GO and dividing (G1/S/G2IM) cells according to the 
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protocol described for HST and Py. Cells sorted on the same parameter were 
pooled following sorting, centrifuged and placed in Eppendorf tubes, where most 
of the PBS2% was removed by aspiration. Trizol was added and the volume 
adjusted depending on the number of sorted cells. The amount of Trizol added 
was: 1 ml per 106-107 cells, 0.5ml per 105-106 cells and 0.2ml per 104-105 cells. 
The tubes were vortexed and placed immediately in the -80°C freezer until all of 
the samples had been acquired. Generation of total RNA was as described and it 
was crucial for the microarray study that all samples were processed at the same 
time to reduce the possibility of disparity in preparation. 
2.3.5 Statistics 
Statistical analysis was performed by either the student's t-test or the wilcoxon- 
signed rank test. 
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Chapter 3 Results I- Identification and Isolation of 
Stem Cells in Different Phases of the Cell Cycle 
3.1 Introduction 
Chronic myeloid leukaemia is a stem cell disease, which is characterised by 
excessive numbers of circulating intermediate progenitors and mature 
granulocytes (Eaves CJ and Eaves AC 1987). Stem cells are intrinsically resistant 
to damage by either cytotoxic drugs or radiation, and diseases that originate in a 
stem cell are difficult to eradicate. CML has three distinct phases of progression, 
an initial chronic phase, during which large numbers of relatively mature 
granulocytes exist with a typical time scale of 4-6 years (see figure 3.1), is followed 
by the onset of accelerated phase, which can last up to 1 year, and culminates in 
blast crisis, where the numbers of immature white cells increase proportionately to 
mature cell types (Sawyers CL 1999). At this stage the disease becomes much 
more resistant to therapy and almost certainly involves further acquired mutations. 
Patient mortality is 100% within 3-6 months of onset of blast crisis if untreated 
(Spiers ASD 1977). 
Variable duration 
Chronic Phase 
4-6 years 
Accelerated Phase 
<1 year 
Blast Crisis 
3-6 months 
Mature>immature Immature>mature 
Figure 3-1 A schematic diagram of the progression of CML disease. 
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If an appropriate therapy could be found for the treatment of CML in chronic 
phase, progression to fatal blast crisis could be arrested. Since chronic phase 
offers the best opportunity for successful therapy, the work described in this thesis 
focuses exclusively on this stage of the disease. In an effort to identify possible 
targets, which could be exploited for therapeutic purposes, some of the properties 
of normal and CML stem cells in vitro have been investigated. 
Normal stem cells are known to be largely quiescent, residing in the GO phase of 
the cell cycle, where they can be recruited into division in response to appropriate 
stimuli (Bradford GB, Williams B et al. 1997), (Ponchio L, Conneally E et at. 1995). 
This has been demonstrated by introducing quiescent cells into NOD/SCID mice, 
where some cells can exit GO and repopulate the haemopoietic system of the 
mouse. It was an unexpected finding that alongside the actively cycling malignant 
population in the chronic phase of CML, there also coexisted a quiescent stem cell 
fraction. These cells were primitive, expressing the stem cell marker CD34 and 
were part of the leukaemic clone, as verified by FISH (fluorescence in-situ 
hybridisation) and RT-PCR (Holyoake T, Jiang X et al. 1999). It has been 
established that cells expressing CD34, but lacking lineage markers, are primitive 
and able to generate progeny of different phenotypes. However, there is also 
some evidence that an earlier stem cell exits which does not express CD34 or 
lineage markers and is able to repopulate the haemopoietic system of a 
myeloablated host (Bhatia M, Bonnet D et al. 1997). CD34' cells have been used 
successfully for clinical transplantation and the presence of this marker is currently 
used as an indicator of stem cell dose for peripheral blood stem cell 
transplantation. For the experiments presented in this thesis identification of 
CD34+ cells was used as an indicator of stem cell status. 
In order to compare the properties of normal and CML stem cells, it was necessary 
to separate them from the rest of the circulating blood cells, prior to subsequent 
experimentation. Using CD34 as a stem cell marker the cells were enriched by 
either positive or negative stem cell selection. The following describes the 
selection process in detail with representative numbers and FACS plots for each 
system and for normal and CML cells. All of the CML cells used in this study were 
collected from patients in chronic phase at diagnosis and before treatment. 
Susan M Graham, 2005 
3.2 Stem Cell Selection 
Chapter 3,83 
Stem cells represent a very rare fraction of the circulating progenitors, around 
0.1 %, and in order to study these cells, it was necessary to significantly enrich the 
stem cell fraction, before FAGS sorting specific cell sub-populations. This was 
achieved by either positive or negative stem cell selection. The starting cell 
population was collected from CML patients during leukapheresis, which is 
primarily performed to reduce excessive numbers of circulating white blood cells, 
or to store autologous material for future treatment. The procedure was performed 
using a dedicated leukapheresis machine, which allows red blood cells and 
plasma to be returned to the patient, after removal of a large number of the white 
cells. Leukapheresis products that are surplus to clinical requirement can be used 
for research with appropriate patient consent. Within the CML patient group, there 
was a large variation in the starting CD34+ percentage from 0.3-50%, the median 
being approximately 3%, characteristic of a stem cell disease (Richmond U, 
Alcorn MJ et al. 2002). 
For normal stem cell collections, donors receive G-CSF (granulocyte stimulating 
factor) for 4-6 days before collection to boost the number of circulating progenitors. 
There can be large differences in the effectiveness of G-CSF mobilisation, leading 
to differences in both the percentage of CD34+ cells in the starting fraction, from 
0.3-1.7%, and in total white cell numbers harvested. The dose required by the 
patient for a stem cell transplant at this institution was calculated as 6x106 CD34" 
cells/kg and, with consent, a proportion of the remainder could be used for 
research purposes. The leukapheresis machine settings were operator controlled 
and the purity of the stem cell collections obtained, influenced by the settings. For 
this reason, and because of differences in effectiveness of mobilisation, there 
could be a significant variation in the starting CD34' number, and subsequent 
recovery of stem cells following selection. 
The stem cell populations derived from positive or negative selections are 
intrinsically different. There is some evidence that a more primitive cell than a 
CD34 expressing cell exists within the stem cell compartment that can in turn 
generate CD344* cells (Goodell MA, Rosenzweig M et at. 1997). A negative 
selection would retain these cells since they would also lack lineage markers. A 
positive selection would exclude these cells since it only targets cells expressing 
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the CD34 marker. The method of choice was dependant on the final experiments 
to be performed. Throughout the studies presented in this thesis, it was necessary 
to freeze cells following stem cell enrichment. Both types of selection involved a 
considerable time input and further cell sorting required at least 12 hours, including 
staining and cell culture post-sort. 
3.2.1 Positive stem cell selection 
In a positive selection, the cells of interest are removed from the rest of the 
population by labelling with antibody, magnetic beads and selecting using a 
magnetic column. For the positive selections described here the Isolex® 50 system 
was used. This was a commercial method used for clinical stem cell selections, 
which was scaled down using a smaller magnetic column for research samples, as 
the number of total cells/column was critical to cell recovery and purity. 
The cells were labelled with a mouse anti-human monoclonal antibody against the 
CD34 antigen, and further labelled with a sheep anti-mouse antibody bound to a 
magnetic bead. The cells were then passed through a magnetic column such that 
the unlabelled cells were eluted first before a stem cell releasing agent was added 
in order to detach the bound cells. The releasing agent contained a nano-peptide 
(PR34®) with a similar sequence to the CD34 antigen, which competed for binding 
of the active site, and due to the excess of nano-peptide, the antigen-bound cells 
were released from the magnetic column. 
3.2.2 Example of a CML and a Normal Positive Cell Selection 
A diagram of the labelling and selection procedure is shown in figure 3.2. Stem 
cells were released with the CD34 antigen intact and available for further labelling. 
The selected cells were assessed by flow cytometry for CD34 purity and plots of 
the pre-column and post-column samples for both normal and CML are shown in 
figure 3.3. 
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Figure 3-2 Isolex CD34 stem cell selection method. 
Cells are labelled and selected as described in the text. 
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Using side scatter (SSC) to discriminate cells on the basis of their granularity 
(lower granularity indicates less differentiation) and including a marker for CD34, 
the more primitive cells can be identified. Figure 3.3 shows that the proportion of 
CD34 positive cells has increased in the CML sample from 31.8-98%, and in the 
normal sample from 1.59-83%. The cells were a99% viable post selection for both 
normal and CML examples and these were representative for most selections. The 
final percentage of CD34 positive cells obtained using this method varied between 
53-98% for both CML and normal, with recoveries ranging from 36-71 % in normal 
samples and 69-98% for CML samples. The quality of the starting population both 
in terms of total cell number and percentage of CD34+ cells influenced the 
efficiency of the selection. 
1. Sensitization with 
anti-CD34 mAb 
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Figure 3-3 FACS plots of normal and CML positive stem cell selections. 
The plots show CD34 versus SSC, the gated populations shown are low in 
SSC and high in CD34 expression. The regions indicate the percentage of 
CD34' cells pre- and post-selection for both normal and CML samples. 
The plots in figure 3.3 illustrate there is little qualitative difference in post-selection 
samples between normal and CML. The number of CD34+ cells recovered and the 
final purity of the sample (as shown in table 3.1) were dependent on the starting 
cell population and not on the disease status of the patient. 
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S g 
Starting Starting 
` 
Final % Rec Total 
+ Type of ell 
% of 
` 
CD34 % 
+ 
of 
'' 
CD34 
selection number 
CD34 cell CD34 CD34 cells 
cells number cells cells recovered 
Isolex 
positive 1.2X1010 1.53 1.8x108 85 62 1.12x108 
Selection 
Stem-Sep 
negative 1.75x1010 0.64 1.12x108 60.2 82 9.2x107 
selection 
CML 
Starting S Starting Starting + 
Final % Rec Total 
+ Type of cell 
% of CD34 % of CD34 
selection number 
CD34+ cell CD34 CD34 cells 
cells number cells cells recovered 
Isolex 
positive 7.3x109 4.72 3.4x108 94 53 1.84x108 
Selection 
Stem-Sep 
negative 4.5x109 5.6 2.5x108 77.5 47 1.17x108 
selection 
Table 3-1 Table of selection numbers for normal and CML representative examples. 
The numbers are shown for both Isolex positive and StemSep negative 
selections described in the text. 
Table 3.1 shows an example of the cell numbers obtained from positive stem cell 
selections for normal and CML representative samples. The total cell starting 
number in the normal example was 1.2x1010 and the total number of CD34 
positive cells available was 1.8x108, based on the CD34 starting percentage of 
1.53%. The selection produced a cell population which was 85% CD34; and 62% 
of the available CD34 cells were recovered from the column giving a total of 
1.12x108 cells, which were then frozen in liquid nitrogen in aliquots of 20x106/vial. 
In the CML example, the stem cell selection produced an increase in CD34+ 
percentage of 4.72 to 94% with a recovery of 53% of the available CD34+ cells, 
(which were a total of 3.44x108) giving a final number of 1.84x108 selected stem 
cells, which were frozen in liquid nitrogen at 20x106/vial. As the selection system 
used was a unique scaled down clinical system there were no published numbers 
using this method, however the recoveries and enrichments were within the limits 
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published for the full clinical system, using the same antibody cocktail and 
methodology but a different magnetic column (Farley TJ, Ahmed T et al. 1997). 
3.2.3 Negative Stem Cell Selection 
In negative stem cell selections, cells expressing lineage markers were labelled 
with a panel of mouse anti-human antibodies including CD2, CD3, CD14, CD16, 
CD19, CD24, CD56, CD66b, and glycophorin A, then further labelled with a sheep 
anti-mouse antibody bound to magnetic colloid. The unbound stem cells were 
eluted from the column separating them from the bound cells, which remained 
attached. Table 3.2 shows the antibodies contained in the progenitor enrichment 
cocktail and their relevant target cells. 
Antibody Target cell 
CD2 T cells, NK cells 
CD3 T cells, 
CD14 Monocyte/macrophage 
CD15 (CML) Granulocytes/basophils 
CD16 NK cells, granulocytes 
CD19 B cells 
CD24 B cells 
CD56 NK cells, 
CD66b Granulocytes 
Glycophorin A Erythroid cells 
Table 3-2 Table of antibodies in the StemSep progenitor enrichment cocktail. 
A schematic outline of the selection procedure is shown in figure 3.4. The method 
was modified when CML cells were processed by the addition of biotinylated anti- 
CD15 to the cells before the addition of the other antibodies described and anti- 
biotin included with the magnetic colloid. This step facilitated the removal of the 
excessive number of granulocytes characteristic of this stage of CML disease. The 
cells were then passed through a magnetic column where the unlabelled cells 
were eluted and the labelled lineage+ cells remained attached to the column. The 
CD34+ purity and recovery of the selected cells was assessed by flow cytometry, 
in the same way as the positively selected cells i. e. by calculating the percentage 
of CD34 strongly positive cells that were also low in side scatter before and after 
selection. 
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Figure 3-4 Diagrammatic representation of StemSep negative selection. 
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3.2.4 Example of a Normal and a CML Negative Selection 
y 
In the normal example shown in figure 3.5 the number of CD34 positive cells has 
increased from 1.23 to 76.2% and in the CML sample the percentage of CD34 
positive cells has increased from 5.9 to 86%. Since this population also contains 
cells that do not express lineage markers or CD34 it would not be expected that 
the percentage of CD34+ cells would be as high as in the positive selection. In 
practice, negative selections produced a lower percentage of CD34+ cells, typically 
from 40-88%, compared to 53-98% for positive selections. The FACS plots in 
figure 3.5 show that, as in the case of the positively selected cells, there was little 
difference between the normal and CML samples in terms of stem cell purity. The 
addition of anti-CD15 in the CML sample maximised the purity of the CD34+ cells 
in the selected fraction by removing the large excess of granulocytes typical of 
CML in chronic phase. 
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Figure 3-5 FACS plots of normal and CML StemSep negative selections. 
The regions show the percentage of CD34+ cells pre- and post-selection for a 
representative normal and CML sample. 
In the negatively selected normal example in table 3.1, a starting cell number of 
1.75x1010, with a starting CD34 percentage of 0.64, giving 1.12x108 available 
CD34 cells, yielded 9.2x107 CD34+ cells. The yield from the column was 82%. In 
the CML example, from 2.5x108 available CD34+ cells, 1.17x108 were recovered, 
indicating a recovery of 47%. Comparing these examples of positive and negative 
selection for normal cells, the negatively selected example has a better recovery of 
stem cells 82% compared to 62% in the positive selection. However in the CML 
examples, there was little difference in recovery between positive and negative 
selection 53-47%. A possible explanation for the CML examples was that all of the 
stem cells were not labelled in the positive selection, or that they were not 
completely released from the column. Due to the nature of the processing in both 
situations involving multiple wash steps, antibody labelling, columns and sample- 
to-sample variation, there were differences in the final recovered cell numbers. 
Also, there were insufficient amounts of any sample to enable direct comparison of 
selection methods with the same sample. For all of the samples, the recoveries 
and yields were within the limits suggested by the manufacturers. The rationale for 
doing the stem cell selections was to enrich for primitive progenitors to facilitate 
isolation of rare quiescent stem cells. Given that CML is a disease that originates 
in a pluripotent stem cell and that normal stem cells are largely quiescent, the 
overall aim was to compare the characteristics of normal and CML stem cells, in 
Pre-selection 
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relation to their cell cycle position. To do this, a method of isolating quiescent and 
cycling, viable stem cells was required. 
3.3 Hoechst and Pyronin Y staining 
There are a number of fluorescent stains available, which allow discrimination of 
the different phases of the cell cycle, however few allow the isolation of viable 
cells. The choice of staining protocol is also limited by the excitation and emission 
spectral capacity of the sorting instrument, in this case the FACS Vantage cell 
sorter. For these reasons the choice of stain was Hoechst 33342 (HST) for 
staining DNA and Pyronin Y (Py) for staining RNA, which allowed discrimination of 
the cell cycle compartments. By combining these stains with anti-CD34-FITC as a 
stem cell marker and propidium iodide (PI) for exclusion of dead cells, it was 
possible to sort viable quiescent and cycling stem cells. 
HST is a DNA selective, UV excited, blue fluorescent bisbenzimidazole dye 
originally synthesized by Loewe (Loewe H and Urbanietz J 1974) as an anti- 
protozoal drug for Hoechst and was first used in flow cytometry in 1974 by Latt 
(Latt SA 1974). HST dyes bind to sequences of three A-T base pairs in DNA, 
binding to the minor groove of the DNA helix, rather than by intercalation. Their 
affinity for DNA is sufficiently strong that they will displace bound molecules of 
intercalating dyes (Loontiens FG, Regenfuss P et al. 1990). Binding of dyes like 
HST has been shown to exhibit a certain level of toxicity (Durand RE and Olive PL 
1982), which is relative to cell type. For this reason it was necessary to confirm 
that the staining process did not adversely affect the viability or functional capacity 
of the cells. 
Py is a homologue of acridine orange (AO) which has been used for the 
assessment of cell cycle for a number of years. Py diffuses into the cell and allows 
staining of RNA whilst permitting the cells to remain viable, unlike AO, which 
requires fixing and permeabilisation of the cells. Py binds to RNA with a 
preference for G-C rich regions and although DNA staining by Py has been 
documented in some cases, it is not likely to confuse DNA/RNA based sorting 
using this protocol as pre-incubation with the HST stain blocks access of Py to 
binding sites on DNA (Ladd AC, Pyatt R et al. 1997). 
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Due to the variability of DNA and RNA staining it was necessary to determine the 
concentration of the combined stains, which would allow discrimination of the cell 
populations by FACS, whilst preserving cell viability. This was done by staining 
cells with different concentrations of each stain and measuring, staining efficiency, 
viability and colony forming capability. The availability of stem cell enriched patient 
samples was very limited, however it was important to use representative 
examples of experimental cells, to ensure comparable results. The number of cells 
required to set up the initial experiments limited the replicates to one normal and 
one CML. 
3.3.1 Comparison of Colony Forming Capacity Following 
Hoechst and Pyronin Y Staining 
Plating cells in a clonogenic assay gives a measure of the colony forming capacity, 
which in turn gives an indication of functionality. The objective was to determine if 
the combination of stains required to produce good FACS profiles had a 
deleterious effect on the capacity of the cells to divide and form colonies. The cells 
used were CD34+ selected cells, either CML or normal, recovered from frozen and 
incubated overnight in a5 growth factor cocktail containing IL-3, IL-6, FLT3L, 
hSCF and G-CSF to allow recovery from frozen. If the cells were used immediately 
following recovery from cryopreservation, cells dying as a result of thawing could 
interfere with the data relating to toxicity of the dyes. By incubating overnight in a 
growth factor rich cocktail, recovery of viable cells was maximised. The following 
day the cells were removed from petri dishes or flasks, washed in PBS/2% and 
stained with HST at concentrations of 0 to 10pM alone or in combination with Py at 
concentrations of 0 to 1 pg/mi. Similar concentrations of these dyes in combination 
had been used previously, though it was necessary to establish optimal 
concentrations of both dyes using our FACS sorter. This allowed assessment of 
the minimum laser power setting required to produce acceptable FACS profiles, as 
it has been previously reported that increased laser power could be lethal to some 
cells (Shapiro HM 1981). 
The clonogenic assay input cell counts were adjusted for viability and for the 
percentage of CD34 positive cells so that the same number of viable stem cells 
was used to initiate each culture. 1x104 viable CD34 positive cells were plated in 
duplicate in methylcellulose containing a cocktail of cytokines designed to 
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stimulate both myeloid and erythroid colony growth. The GM colonies (1 colony= 
>40 cells) and BFU-e (single bursts) were counted after incubation at 37°C in a 
humidified incubator for 12 days. Counts were an average of two plates. The 
results are shown in table 3.3. 
NnPMAI 
Hoechst Pyronin Y % Viable GM BFUe TOTAL 
0 0 38.6 158 407 565 
5 0.5 40.7 89 335 424 
5 1 43.3 43 79 122 
10 0.5 43.6 62 382 450 
10 1 40.8 56 160 216 
10 0 38.5 49 404 453 
0 0.5 45.3 211 348 559 
CML 
Hoechst Pyronin Y % Viable GM BFUe TOTAL 
0 0 35.9 190 339 529 
5 0.5 40.1 106 177 283 
5 1 42.8 108 337 445 
10 0.5 39.5 56 512 568 
10 1 35.8 58 283 341 
10 0 39.1 105 351 456 
0 0.5 42.8 190 287 477 
Table 3-3 Table of colony counts for normal and CML cells stained with various 
concentrations of HST and Py. 
The cells were stained with the dyes as Indicated In the table and plated In 
colony assays as described In the text. The colonies were counted at day 12 
and GM scored as >40 cells and BFU-e as single bursts. The cell viabilities 
were assessed by PI exclusion by FACS following staining, and before plating 
In colony assays. 
Table 3.3 shows the percentage of total viable cells together with the GM, BFU-e 
and total colony counts (GM + BFU-e) for unstained and combinations of dyes at 
various concentrations. Results for both a normal and CML sample are shown. 
The total cell viabilities were determined by FACS following incubation of the cells 
with PI after staining with HST and Py as indicated in table 3.3. All combinations of 
stains were run on the FAGS sorter to establish the success of the staining 
procedure. This indicated that the HST stain was the least consistent especially at 
low concentrations. Increasing the incubation time with HST from 45to 90 minutes 
before the addition of Py, improved the reliability of staining. 
The results in table 3.3 indicate that compared to unstained cells, for both normal 
and CML, the staining had some effect on the total colony count. For normal cells, 
in most cases, the number of CFU-GM was reduced except in the Py only culture 
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where the number of CFU-GM colonies exceeded the control. The largest 
reduction in total colony count was seen in the 5pM HST/1 pg/ml Py combination in 
the normal sample, where the total colony count was reduced from 565 to 122. 
The 10pM HST/1 pg/ml Py would have been expected to show a greater reduction 
in colonies but only reduced the counts from 565 to 216. For CML cells, the large 
reduction in total colony count, identified in the normal sample with 5pM 
HST/1 pg/ml Py, was not observed, however there was a similar level of reduction 
in CFU-GM numbers from 190 to 108. Although there was a reduction in overall 
colony count, it was only from 529 to 445, most of which was attributed to the 
reduction in CFU-GM. 
Comparing the colony counts for the single stains, the numbers indicate that HST 
appears to affect the CFU-GM count preferentially. AT 10pM, HST alone reduces 
the CFU-GM count from 158 to 49 for the normal, and from 190 to 105 for the 
CML, whereas the BFU-e count remains at the same level. In contrast, Py appears 
to exert a greater effect on the BFU-e count. At 0.5pgIml the BFU-e count was 
reduced in the normal from 407 to 348 and in the CML from 339 to 287, while the 
GM count remained the same for the CML, and increased in the normal from 158 
to 211. This phenomenon is worthy of further investigation but was outwith the 
scope of this project. 
The results in table 3.3 also demonstrate that in the normal sample, increasing the 
Py concentration to 1 pg/ml in combination with either 5 or I OpM HST reduced the 
total number of colony counts to a level below any of the other combinations that 
used 0 or 5pg/m Py. In the CML example, the 5pmHST/ 0.5pg/ml Py combination 
appears to have a reduced overall count compared to both unstained and other 
combinations. This may be experimental error and these results represent one 
example of each combination, as availability of material limited replication of these 
experiments. The total population viability appears to be higher in the stained 
samples than in the unstained control. The lack of replicates in these experiments 
due to limitations in sample availability meant it was not possible to achieve 
statistical significance. However, the data gave an indication of the toxicity of the 
dyes and enabled examination of the FACS profiles. 
Following inspection of the FACS profiles of stained cells, the combination of 
IOpM HST/0.5pg/ml Py gave the most acceptable and reliable staining using our 
sorter set-up. Having demonstrated that this combination did not appreciably affect 
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the viability and clonogenicity, at least in terms of the total colony counts, this was 
the combination used in all subsequent experiments. In addition, similar 
concentrations of these dyes have been used previously to isolate stem cells, 
which retain full functional capacity, as demonstrated by their ability to reconstitute 
immuno-deficient mice (Holyoake T, Jiang X et al. 1999). 
Figure 3.6 shows an example of the FACS profile obtained using this combination 
of dyes. By manipulating the amplitude of the detectors it was possible to increase 
the level of the detector on the y-axis (Py) to identify cells with the lowest Py 
staining, which were also HST1°, as those being in GO. Figure 3.6 shows the 
corresponding profile obtained on the histogram plot of HST (FL4). This 
demonstrates the cell cycle distribution, with most of the cells in the 2n population, 
which includes GO and G1 The 4n population are cells which have reached the 
end of the cell cycle and are about to divide into two cells and either become 
quiescent by going back into GO, or continue to divide by moving into G1. The two 
daughter cells may have different fates depending on the environmental stimuli 
they receive. 
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Figure 3-6 FACS profiles of Hoechst and Pyronin Y staining. 
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The dot plot shows CD34+ selected cells from a normal sample stained with 
10NM HST and 0.5pg/ml Py. The cells have been gated on the viable PI" 
population. The histogram plot shows the HST profile for the same cells 
identifying the 2n and 4n populations. 
Overall, the combination of 10pM HST and 0.5pg/ml Py gave the most reliable cell 
staining by FACS and maintained acceptable levels of cell viability. Various 
staining strategies were employed to increase the reliability of the Hoechst stain, 
which could be inconsistent. Increasing the HST incubation time from 45 to 90 
minutes before the addition of Py resulted in almost 100% reliable profiles for HST. 
3.3.2 Comparison of Total Cell and Stem Cell Viability 
Following Hoechst and Pyronin Y Staining 
Since the availability of material precluded doing toxicity analysis on multiple 
samples, the viabilities of the total and stem cell populations were recorded for 
each subsequent experiment. This allowed the monitoring of the effects of staining 
with HST and Py on a larger sample group. Comparing a number of samples both 
normal and CML cells stained with 10NM HST and 0.5pg/ml Py, indicated that 
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neither the total cell, nor the stem cell viability was significantly affected by the 
staining procedure. Table 3.4 shows normal and CML samples stained with 10pM 
HST and 0.5pg/mI Py in combination, compared to unstained cells. The 
concentrations selected had been used previously for isolation of cells in various 
phases of the cell cycle (Gothot A, Pyatt R et at. 1997). The results in table 3.4 
show the mean total cell viability in the normal unstained cells was 46% compared 
to 47% for the mean HST and Py stained cells. The mean stem cell viability was 
82% for the unstained cells compared to 87% for the stained stem cells. For the 
CML samples the mean total cell unstained viability was 61 % compared to 62% for 
the stained cells. The mean stem cell viability was 92% for unstained compared to 
94% for stained stem cells. These results show that staining with this combination 
of HST and Py did not significantly affect the total cell or the stem cell viability in 
either the normal or CML samples. 
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% Viable of Total % Viable of CD34+ 
Unst HST! Py Unst HSTIPy 
I Normal1 48 44 83 78 
2 Normal2 46 49 82 95 
3 Normal3 44 48 81 89 
MEAN 46 47 82 87 
4 CML 1 74 72 91 93 
5 CML 2 63 69 94 95 
6 CML 3 58 57 77 83 
7 CML 4 44 51 96 99 
8 CML 5 48 41 99 99 
9 CML 6 56 67 90 91 
10 CML 7 81 78 97 98 
MEAN 61 62 92 94 
Table 3-4 Comparison of total cell and stem cell viabilities following staining with 
Hoechst and Pyronin Y. 
Following recovery from cryopreservation and an overnight Incubation In 
media with 5 growth factors, the cells were stained with 10NM HST and 
0.5pg, ml Py. The total cell and stem cell viabilities were assessed by FACS 
following additional staining with anti-CD34-FITC and Pl. 
For both CML and normal samples, the unstained stem cell viability (77-99%) was 
considerably higher than the unstained total cell viability (44-81%), suggesting that 
stem cells were less susceptible to damage by cryopreservation. 
It had been documented previously that exposing cells to increasing laser power 
rendered them non-viable. Historically, during the development of staining 
protocols, exposure to laser power of 100mV was common. This was not a 
problem until researchers wanted to obtain viable sorted cells for further 
experimentation. Studies revealed that acceptable FAGS profiles could be 
obtained using much lower settings and that cells could survive sorting on this 
basis (Shapiro HM 1981). For the experiments in this thesis, the laser power level 
for excitation of Hoechst was set at the minimum of 30mV using UV beads and 
verified with stained cells. 
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3.3.3 Sorting Using Hoechst and Pyronin Y 
To obtain populations of viable stem cells in different phases of the cell cycle it 
was necessary to use the HST and Py fluorescent stains described, which allowed 
discrimination of cell populations whilst maintaining viability, functional capacity 
and proliferative potential. Cells in the GO phase of the cell cycle were HSTb/Pybo, 
cells in the G1 phase were HST '°/Py+ and those in the S/G2/M phase were 
HSTb"9ht/Py+. By combining these two stains with a stem cell marker (CD34) and 
PI as a viable marker, it was possible to obtain pure populations of viable stem 
cells in three phases of the cell cycle. However, the sorter was only capable of 
collecting two populations of cells simultaneously, which meant the third 
population was resigned to waste. For this reason most sorts were set up to collect 
two parameters only, GO and dividing. Figure 3.7 shows the gating strategy used 
to sort the different fractions of the cell cycle. The HST and Py plot was gated on 
the viable, CD34+ cells. 
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Figure 3-7 FACS gating strategy for isolation of viable quiescent and cycling stem cells. 
Following overnight incubation in growth factor supplemented media, the 
cells were stained with HST, Py, CD34 and PI. A viable gate was set around the 
PI' cells (RI) and a further gate set around the CD34' cells (R2). This 
combination of gates was used to set further gates on the GO (R3) and cycling 
cells (R4). 
3.3.4 Assessment of Success of Cell Cycle Stage Sub- 
Selection 
It was not feasible to re-run sorted cells on the FACS to assess sort purity as the 
cells were collected in sheath fluid and would have effluxed the HST and Py dyes. 
Since the purity of the sort was operator controlled, it was necessary to verify the 
correct cell populations had been sorted. This was achieved by analysing the gene 
expression of sorted cells by PCR for genes specific to cell cycle position. For this 
experiment an additional gate was used to isolate the G1 population. It was not 
possible to commit any more than one CML sample to processing for PCR for 
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verification of sort purity, as cell numbers were prohibitive. Nor was it possible to 
repeat the PCR with a normal sample as these were in very limited supply. 
The cells were sorted into viable, CD34+, GO, G1 and S/G2/M fractions for PCR. 
Figure 3.8 shows the results of PCR with primers for Actin (control), CD34, PCNA 
and MCM5. Primers for the genes of interest were designed as described in the 
methods. Figure 3.9 illustrates that all samples showed a band for actin and for 
CD34. Although MCM5 is typically associated with proliferating cells, it was 
present in all of the sorted cells (discussed below). The band for proliferating cell 
nuclear antigen (PCNA), known to be synthesised in S phase, was clearly absent 
in GO and G1 and present in S/G2/M. All of the bands were excised from the gel 
and processed for sequencing at the Beatson Laboratories. The results of 
sequencing verified that the primers were specific for the genes indicated. 
This is strong evidence that the sorting strategy has indeed separated the relevant 
populations. Interestingly, the cells used were malignant (CML) cells and 
aberrations in MCM5 expression have been documented in cancer cells compared 
their normal counterparts (Going JJ, Keith WN et al. 2002). PCR on normal cells 
would have verified this observation, however as stated previously limited sample 
availability precluded these experiments being done. The results presented in 
chapter 6 of this thesis may explain this observation. 
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The cells were sorted into GO, GI, and S/G2/M phases of the cell cycle as 
described in the text. PCR was performed with primers specific for the genes 
indicated. 
3.3.5 Comparison of Relative Percentage of Cells in Different 
Cell Cycle Positions for Normal and CML Stem cells 
It was noted during the course of staining and sorting for quiescent cells, that there 
were differences in the proportion of cells in the GO and G1 phases of cell cycle 
between normal and CML samples. In particular the number of GO cells sorted for 
the CML samples was always lower than for normal samples. 
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Figure 3-9 FACS plots showing the proportion of cells in GO and G1 for normal and CML. 
The plots are gated on the viable CD34` cells as described in the text. The 
percentages are the mean for all samples, n=3 for the normals and n=9 for the 
CML samples. 
A number of normal and CML samples were compared to investigate this 
observation. Following an overnight incubation in a5 growth factor cocktail, to 
enable recovery from cryopreservation, the cells were removed from plates or 
flasks and washed in PBS2% before staining with HST and Py as described 
previously. Gates were set around the viable CD34+ cells and the percentage of 
cells in GO and G1 compared. The numbers represent the mean of 9 CML 
samples and 3 normal samples. The number of quiescent cells i. e. those in GO 
was significantly lower in the CML sample than in the normal sample, 1.9% 
compared to 3.8% (p=0.04). The difference in the percentage of cells in the G1 
gate, 70% in the normal compared to 50% in CML, was also significant (p=0.04). 
These observations suggest that CML cells exhibit greater cell cycle activation 
than normal cells, or that the CML cells are 'primed' to go into division. The 
observation that a greater proportion of CML cells were in the G1 phase of the cell 
cycle compared to normal does not necessarily mean that they were cycling at a 
greater rate. These data give no information on the time taken to complete the cell 
cycle, merely that there are fewer CML cells in GO and G1 compared to normal. 
Other studies have also documented that for CML CD34+ cells, a greater number 
are in the S/G2/M phase of the cell cycle compared with normal CD34+ peripheral 
blood stem cells. In addition, others have shown that CML cells do not cycle at a 
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faster rate than normal cells, and that this does not explain the increase in cell 
numbers observed for CML in chronic phase (Buckle AM, Mottram R et al. 2000). 
3.3.6 Summary 
The work described in this chapter documents the identification and isolation of 
quiescent haemopoietic stem cells from normal and CML patient samples. The 
success of the sorting strategy was confirmed by PCR analysis of the sorted cells. 
It was noted that for CML, the proportion of cells in the S/G2/M phase of the cell 
cycle was greater than for the normal samples, suggesting they display an 
increased cell cycle activation compared to normal cells. The following chapter 
describes experiments aimed at assessing the behaviour of CML quiescent stem 
cells in culture compared to normal cells, in an effort to gain a clearer 
understanding of the properties of CML stem cells. 
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Chapter 4 Results 2- Comparison of Normal and 
CML Stem Cell Division Characteristics In-Vitro 
4.1 Introduction 
Previous work by Buckle et al (Buckle AM, Mottram R et at. 2000) has shown that 
CML cells do not divide at a greater rate than normal cells. In contrast, Kramer et 
at (Kramer A, Loffler H et at. 2001) have shown that CML CD34+ cells display 
greater cell cycle activation than their normal counterparts with many more cells in 
S/G2/M. It remained a possibility that differences in the pattern of cell division 
within the stem cell population could shed some light on the abnormal cell 
behaviour exhibited by malignant cells. Having previously identified quiescent 
stem cells in both normal and CML samples, the aim of the work presented in this 
chapter was to further characterise the dynamics of the cell population by tracking 
the pattern of cell division in normal and CML stem cells under different conditions. 
It was also proposed that this approach could be used to monitor the division 
history of the cells in conjunction with their viability and stem cell status using 
CD34 expression as a stem cell marker. 
4.2 CFSE for High Resolution Tracking of Cell Division 
In order to follow the pattern of cell division in culture, it was necessary to devise a 
strategy that would allow discrimination of the number of cell divisions together 
with stem cell status in each division. Monitoring viability of the cells as they 
progressed through each division was necessary in order to obtain information on 
the proliferative status of the culture. A method of specifically tracking cell division 
in lymphocytes was developed by Lyons et al in 1994 (Lyons AB and Parish CR 
1994) using the fluorescent stain CFSE (carboxyfluorescein diacetate succinimidyl 
ester). CFSE is a non-polar molecule that passively enters cells where it is 
converted to a reactive dye by non-specific esterases. The amine-reactive 
coupling of CFSE to cellular proteins results in stable long-term intracellular 
retention. Thus, when the cell divides each daughter cell will have exactly half of 
the fluorescence of the parent cell. The effect is permanent, fluorescent, 
intracellular staining that can be used to track cell division over a period of time. Li 
et at (Li X, Dancausse H et at. 2003) have shown, using mixtures of stained 
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human and unstained rat cells in co-culture, that no dye leaks from stained cells 
and the fluorescence intensity of the undivided cells remains constant. These 
observations confirm the integrity of this technique for identification of undivided 
cells. Previous protocols have used a 5pM concentration of USE, which was 
highly fluorescent, allowing the cells to be monitored over a period of time. The 
disadvantage of such a high concentration of CFSE is that it makes compensation 
with other fluorescent dyes very difficult, and as monitoring of stem cell status and 
viability were an integral part of this study certain modifications to the protocol 
were necessary. Reducing the concentration of CFSE to 1 pM gave adequate cell 
staining but allowed FACS compensation with other dyes, for example CD34-PE. 
As the cells of particular interest in this study were the undivided ones i. e. the most 
brightly CFSE stained, it was important that compensation could be achieved at 
the highest concentration of USE When utilised with a sorting strategy to 
enhance resolution (described in detail in 4.4), the peaks of cell division could be 
clearly distinguished. By combining CFSE with cell surface markers such as 
CD34, this strategy could yield data unobtainable in any other way. It should be 
emphasised that the undivided cells identified by CFSE staining are not 
necessarily quiescent as recognised by HST and Py staining in the previous 
chapter, since their cell cycle position cannot be identified using this labelling 
technique. 
4.3 The Effect of CFSE Staining on Cell Viability 
Although higher concentrations of CFSE than the one proposed had been used 
previously with no deleterious effect on cell viability (Li X, Dancausse H et al. 
2003), it was essential to establish that, in this system, cell viability was not 
adversely affected by the staining protocol. To this end stem cell enriched 
samples, from either normal donors or CML patients, were recovered from frozen 
and stained with 1pM CFSE for 10minutes, before washing in PBS/2% and 
incubating in culture medium containing a5 growth factor cocktail as described in 
the methods. Following an overnight incubation, to allow excess stain to leach out, 
cells were recovered from petri dishes and further stained with PI as an indicator 
of viability. The total cell viability was measured by gating on the PI" population. if 
the samples used in the experiments were >94% (94-98.6%) CD34`, it was not 
normally a requirement to set a CD34} gate for the first sort, as all of the CD34+ 
cells were within the viable gate following overnight incubation. The cells which 
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failed to recover from cryopreservation, tended to be the CD34- cells. An example 
of the staining and gating strategy is shown in figure 4.1. The FACS plots show the 
viable PI- cells in (A) gated in R1, which were further gated on the CD34+ cells in 
R2 shown in (B). The histogram in (C) illustrates both the unstained and CFSE+ 
cells gated on R1 and R2, thus Pl-/CD34+. The histogram plot in (C) also shows 
the markers L (left) and R (right), representing the left and right sorting gates used 
in CFSE sort 1. 
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Figure 4-1 FACS gating strategy for first CFSE sort. 
FACS plots showing the gating strategy used in the first CFSE sort. The viable 
PI' cells are shown in RI (A). The CD34+ cells, which are already gated on the 
viable cell population, are contained in R2 (B). The histogram plots shown in 
(C) indicate the position of the unstained" control cells and the CFSE positively 
stained cells. The markers labelled L (left) and R (right) show the sorting gates 
used to obtain CFSE + homogenously stained cell populations. If the 
percentage of CD34+ cells was less than 95%, a combination of both R1 and R2 
were used. 
The stained and unstained populations shown on the histogram plot were gated on 
the viable (PI") cells. Table 4.1 shows the total cell viabilities from both normal and 
CML cells stained with CFSE, following an overnight incubation in 5 growth factor 
medium. Comparing 10 unstained and stained CML samples there was very little 
difference between them, with 7 out of 10 showing a slight increase following 
CFSE staining. The differences in viability were not statistically significant (p=0.3). 
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The small differences in the stained cells were most likely due to the washing 
steps following staining, which removed some of the dead cells. 
Unstained CFSE 
%Viabie %Viable 
CML 54.5 59.4 
CML 59.5 53.4 
CML 75.6 75.4 
CML 62.2 65.9 
CML 58.8 63.6 
CML 58.3 58.8 
CML 67.5 71.1 
CML 73.5 77.3 
CML 48.7 52.7 
CML 64.6 63.5 
Normal 65.9 60.7 
Normal 50.6 47.5 
Table 4-1 Viability of CFSE stained cells. 
Following recovery from cryopreservation, the cells were stained with 1pM 
CFSE. An aliquot of unstained cells was reserved as a FACS control. The total 
cell viabilities were measured by staining with PI after 16hours In culture with 
growth factors. 
A graphic representation of this data is shown in figure 4.2. For the 2 normal 
samples there was a slight decrease in the stained cell viability, however there 
were only two samples in this group due to the limited availability of material, 
therefore statistics were not possible. 
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Figure 4-2 Graph of CFSE viabilities for normal and CML. 
Viabilities of CFSE stained and unstained cells, for both normal and CML 
samples. The percentages were calculated by FACS on the basis of PI 
exclusion. 
If the cells were placed in culture at this stage and allowed to proliferate cell 
divisions could be identified, but due to overlap of the CFSE peaks shown in figure 
4.3, it was difficult to determine where one division began and ended. This made 
calculation of the numbers of cells in each division unfeasible, and it was not 
possible to set sorting gates on cell peaks in this instance. It was therefore 
necessary to develop a sorting strategy to enhance the resolution of the peaks of 
cell division, allowing more data to be obtained from these experiments. 
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Figure 4-3 FACS histogram showing unresolved peaks of cell division. 
Histogram plot of unsorted CFSE stained cells after 3 days in culture with 
growth factors. The histogram is gated on the viable CD34' cells with markers 
showing the position of the peaks and their values. Each peak has exactly half 
the fluorescence of the previous peak, however lack of resolution makes 
identification of the exact position of each peak difficult. 
4.4 Identification of the Undivided Cells 
As the main focus of the experiments contained in this work was the quiescent, 
undivided cells, it was important to be able to accurately identify the position of the 
undivided cell peak. Since the number of undivided cells could be so small that the 
first peak of division could be misinterpreted as undivided cells, accurate 
measurement was crucial. In order to precisely position the undivided peak it was 
essential to use the same cell population as the experimental one i. e. one left- 
sorted and one right-sorted (sort 1), to ensure the level of fluorescence was 
equivalent. A small number (typically 5x104) of the left and right-sorted cells were 
incubated in the presence of 0.4pg/ml colcemid, a known inhibitor of cell cycle 
progression (Taylor E 1965). Figure 4.4 shows a representative example of CFSE 
sorted normal cells cultured for 3 days and gated on the viable CD34+ cells This 
histogram plot illustrates the resolved peaks of cell division obtained following the 
first CFSE sort. The peaks of cell division are overlaid with the colcemid control 
from the same cell population. This clearly demonstrates the position of the 
undivided cells and allows a further markers to be set. Colcemid controls were 
included for each cell population (left and right-sorted) for every experiment. 
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An example of the peaks of cell division obtained after 3 days in culture, 
following CFSE staining and sort 1. The histogram is gated on the viable 
CD34` cells. The peak shown in green represents sorted cells Incubated in the 
presence of 0.4pg/ml colcemid to prevent further cell division. The colcemid 
control allows accurate identification of the undivided cell population. 
4.5 Sorting Strategy to Allow High Resolution Tracking 
of Cell Division 
In order to gain the maximum amount of information from these experiments it was 
necessary to devise a method which would allow calculation of the numbers of 
cells in each division together with their stem cell status. As can be seen in figure 
4.5 when cells were stained with CFSE a relatively broad spectrum of staining was 
observed and as detailed in section 4.3, further culture of these cells gave 
indistinguishable peaks of cell division. By reducing the width of the peak i. e. by 
sorting a homogenously CFSE-stained population of cells, the subsequent peaks 
of cell division were enhanced. To achieve this, two very narrow channels (19-22 
channel widths) were sorted left and right, and kept separate throughout 
subsequent culture. The channel widths were set by the operator using the FACS 
sorter software. Figure 4.5 shows the resultant peaks when the sorted cells were 
re-analysed; the figures in the table represent the channel widths for each marker. 
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CFSE stained cells 
Marker bounds 
Marker Left Right 
All 0,1023 
M1 611,797 total width of peak = 186 (channels) 
M2 662,710 width of L (sorted) = 48 
M3 678,727 width of R (sorted) = 49 
M4 664,729 total width of sorted = 65 
(left + right) 
Figure 4-5 Histogram showing analysis of sorted cells from first CFSE sort. 
A histogram plot showing the widths of fluorescence peaks of unsorted and 
sorted cells as defined by the marker bounds. The unsorted cells are the solid 
blue peak and the left and right-sorted peaks are green and pink respectively. 
The marker bounds indicate the fluorescent channel limits in each peak. 
The total width of the peak for unsorted cells was 186 channels, marker (Ml). M2 
(sorted left) and M3 (sorted right) were 48 and 49 channels respectively. Although 
the markers for sorting were set around 20 channels, in practice the resultant 
sorted channel widths were wider. This was due to the mechanics of sorting and 
the settings applied. The total width of the two sorted peaks (M4) was 65 
channels, which is considerably less than the starting width of 186 channels. If the 
channel widths were set beyond the limits described, the resolution in the peaks of 
cell division was not observed. In terms of recovered cell numbers, the 2-sorted 
peaks amounted to approximately 40% of the available viable stem cells. To 
obtain enough sorted cells for further culture it was necessary to sort around 3- 
4x107 cells in total. Taking the cell viabilities into account the number of sorted 
cells recovered was 4.5-7.8x106 in total for both peaks. 
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Having successfully achieved the desired resolution in the peaks of cell division, 
this technology was utilised to investigate the proliferative potential of normal and 
CML GO cells. Figure 4.6 shows examples of CML and normal cells first sorted 
into a homogenously stained population as described above and then placed in 
culture for 3 days. The cells were then stained with anti-CD34-PE and Pl. The 
CFSE histogram was gated on the CD34+/Pl" cells. The FAGS histograms show 
that the cells from both normal and CML samples have divided up to 5 times and 
that the individual peaks of cell division were clearly visible. Each histogram shown 
represents the left sorted cells; the right-sorted cells were also set up in culture for 
each experiment providing a duplicate. All of the numbers generated from these 
experiments were a mean of the left and right sorts. M1 represents the undivided 
cells as established with the colcemid control cells, and M2-M6 the peaks of cell 
division. The small numbers of cells to the right of the undivided cells in the normal 
example were probably doublets, however without access to doublet discriminator 
software it was not possible to confirm this. 
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Figure 4-6 CFSE histograms showing resolution of peaks of cell division for normal and 
CML cells. 
Histogram plots showing the peaks of cell division obtained following sort 1 
and 3 days in culture with growth factors for a normal and CML sample. The 
histograms are gated on the PI'CD34+ cells. The markers show the position of 
each peak including the undivided cells (MI) identified by the colcemid 
control. 
The precise identification of the division history in a population of cultured cells 
provides data unavailable otherwise. If the number of cells used to establish the 
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culture is known, as well as the number of cells recovered at the end point, it is 
possible to calculate the proportion of input cells recovered in each peak of cell 
division. In combination with a stem cell marker such as CD34 it is also possible to 
gain information on the stem cell status in each division under different conditions. 
For both normal and CML examples, shown in figure 4.6, a population of cells in 
MI i. e. undivided, is clearly visible. This indicates there is a degree of 
heterogeneity in the starting population with some of the cells "primed" to go into 
division under appropriate stimuli. Also in both examples, there are cells that have 
undergone different numbers of divisions (M2-M5) suggesting that there may be 
cells responding differently to the growth factor conditions in the culture or to 
products secreted by other cells. For both normal and CML, most of the cells 
appear to be in M3, M4 and M5, which show the largest peaks. The cells in both 
cultures have divided up to 5 times suggesting a division time of around 12 hours. 
It is interesting that the number of cell divisions is similar for both normal and CML, 
indicating that the CML cells are not dividing at a greater rate than the normal 
ones in this culture system. This observation is consistent with the findings of 
Buckle et al (Buckle AM, Mottram R et al. 2000) who observed little difference in 
cell cycle characteristics between normal and CML CD34 selected cells. It has 
been suggested that increased resistance to apoptosis, rather than faster cell 
division, allows accumulation of excessive CML cell numbers in the circulation 
(Bedi A, Zehnbauer B et al. 1994). 
4.6 Comparison of the Pattern of Cell Division in the 
Presence and Absence of Growth Factors for Normal 
and CML Stem Cells 
It is well documented in many cancers that malignant cells have the capacity to 
proliferate in the absence of exogenous growth factors (Rodeck U, et at. 1993). 
The development of a method for tracking cell division in stem cells allowed 
comparison of the properties of normal and CML cells in vitro. CD34 selected 
cells, from both normal and CML samples, were recovered from frozen, stained 
with 1 pm CFSE and incubated overnight in the presence or absence of a5 growth 
factor cocktail containing IL-3, IL-6, G-CSF, hSCF and FIt3-L as described in the 
methods. The following day the cells were stained with anti-CD34-PE and PI 
before sorting into two narrow channels as described above. Cells were then 
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incubated, again in the presence or absence growth factors, for a further 3 days. 
1-5x104 cells from each of the sorted populations were incubated in the presence 
of 0.4pg/ml colcemid as described. After the May culture period, the cells were 
stained with anti-CD34-PE and PI and sorted (sort 2) into divided and undivided 
populations. Figure 4.7 shows normal cells (as in fig 4.6) in the presence and 
absence of added growth factors. 
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Figure 4-7 CFSE histogram plots of normal cells with and without growth factors. 
Histogram plots of normal CFSE stained, sorted cells, following 3 days in 
culture in the presence or absence of growth factors. The histograms are 
gated on the PI"CD34+ cells. 
The histogram, which is gated on the viable stem cells, shows that in the presence 
of growth factors, normal stem cells were able to undergo up to 5 divisions in the 
3-day time period. However, in the absence of growth factors, normal cells were 
unable to divide and only a small undivided peak, representing the remaining 
viable stem cells was observed. 
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Figure 4-8 CFSE histogram plots of CML cells with and without growth factors. 
Histogram plots showing CML cells CFSE stained and sorted followed by 3 
days in culture in the presence and absence of growth factors. The green 
overlaid peak shows the position of the colcemid control i. e. the undivided 
cells. 
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Figure 4-9 Graph of the percentage of cells in each peak for CML cells with and without 
growth factor 
Graphic representation of the percentage of CML cells in each peak in the 
presence and absence of growth factors, as shown in figure 4.8. 
In the CML example shown in figure 4.8, the stem cells have divided a comparable 
number of times in the presence of growth factors as the normal cells, and with 
similar kinetics. In contrast, in the absence of growth factors, the CML cells have 
been able to divide up to 3 times as shown by the markers M2-M4, demonstrating 
growth factor independence. However, the percentage of cells in M1 is higher in 
the absence than in the presence of growth factors as shown in figure 4.9, 
M1 M] M4 MS Mi 
Peak number 
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suggesting that without added growth factors some of the cells either fail to enter 
cell division or there is a delay while autocrine growth factor production is 
established. A further possibility is that the stem cell population is heterogeneous 
and that some of the cells are not capable of growth factor independent 
expansion. Nevertheless, the cell divisions observed in the absence of growth 
factors demonstrate that a number of CML stem cells exhibit growth factor 
independence. 
Another question that arises as a result of these observations, is why, in the 
presence of growth factors, the cell divisions are asynchronous. In other words, if 
the stringent sorting strategy has produced a generally homogenous population, 
why are the cell cycles not synchronous? There are cells that have divided only 
once, while others have divided a number of times. Apart from the possibility that 
the cell population exhibits a significant degree of heterogeneity, another 
explanation may be that as the cells divide they respond to growth factor stimuli in 
a variety of ways. The implication being, that the population is becoming more 
heterogeneous with every division. For instance, all of the cells in M2 must have 
come from M1 so if some of the cells have gone through one division which has 
produced two different daughter cells i. e. one stem cell copy and one 
differentiating cell, these cells may be responsible for the further divisions 
observed. This may have further consequences if, for example, some of the cells 
are producing growth factors/inhibitors/chemokines etc which influence the 
behaviour of residual cells. 
4.7 The effect of Withdrawal of Growth Factors on 
Proliferation of CML Stem Cells 
The ability of CML stem cells to proliferate in the absence of exogenous growth 
factors could have implications for disease progression. If cells are able to thrive 
outwith the stem cell niche, and proliferate autonomously, then the capacity for 
maintenance of disease is escalated. In an effort to gain some understanding of 
the CML cells capability for proliferation, the culture period was extended to 12 
days. It was possible that prior to culture in conditions of growth factor starvation, 
the cells had gained mitotic signals from previous in vivo stimuli. By culturing cells 
for a longer time period and monitoring the behaviour of cells that had arisen 
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within the culture, a clearer picture of the extended proliferative capacity of the 
cells could be ascertained. 
Fold amplification 
(mean) 
+GF 
Da 3 18.2±7 
Da 6 107±41 
Day 12 233 ± 47 
-GF 
Da 3 7.6±4 
Da 6 6±4 
Day 12 32±19 
Table 4-2 Table of mean fold amplification for CML cells with and without growth factors. 
The table shows the mean fold amplification of CML cells cultured in the 
presence and absence of growth factors over a period of 12 days. The fold 
amplification was calculated as the total viable cell output proportionate to the 
input cell number. The figures represent the mean of 5 CML samples :t SEM. 
While the CML stem cells were able to divide up to 4 times in the absence of 
growth factors in the 3 day time period, there was a reduction in the overall 
recovery of viable cells. It remained a possibility that the assay, at 3 days, was 
selecting cells able to proliferate without growth factor stimulation, but unable to 
sustain the culture beyond this time period. To address these issues the cells were 
cultured for 12 days, with viability and cell recovery assessed on days 3,6, and 
12, in the presence and absence of growth factors. Table 4.2 shows that in the 
presence of growth factors the mean total viable cell number increased by 18.2-, 
107-, and 233-fold on days 3,6, and 12 respectively (p=0.06 between days 3 and 
6, p=0.05 between days 6 and 12). In the absence of supplementary growth 
factors the mean total viable cell number increased by 7.6-, 6-, and 32-fold on 
days 3,6, and 12. The figures in this table represent the mean of 5 CML samples 
± SEM based on an input number of 5x104 cells per assay in Iml medium. The 
figures did not achieve statistical significance in the absence of growth factors; 
p=0.2 between days 3 and 6, and p=0.16 between days 6 and 12, however there 
was considerable variation between patient samples, which is a consistent feature 
of CML. The slight fall in fold amplification on day 6 could be due to the death of 
cells that although Ph' may not be fully growth factor independent. There may be 
a lag period as the cells adjust to growth factor starvation either by producing 
autocrine growth factors or by circumventing the processes that require 
exogenous stimuli. By day 12 the fold amplification had increased to 32, 
demonstrating that growth factor independence is a typical characteristic of CML 
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stem cells and is in accordance with other published results (Pierce A, Spooncer E 
et al. 2002) (Witte 0N 2001). 
4.8 Expression of CD34 in CML Cells in the Presence 
and Absence of Growth Factors 
Having observed significant differences in the proliferation of stem cells from CML 
patients in the presence and absence of growth factors, the level of CD34 
expression was examined in these cultures. Clearly the stem cell status may well 
impact on their ability to maintain disease and is an important consideration for 
possible eradication of CML. 
A detectable difference in CD34 expression was observed in the presence and 
absence of growth factors for the CML samples. Figure 4.10 illustrates, in this 
representative example, in the absence of growth factors, cells that divided up to 4 
times retained high levels of CD34 expression, compared to cells undergoing 
division in the presence of growth factors. The difference in CD34 expression 
between the two sets of conditions was highly significant by division 3 (p=. 009). 
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Figure 4-10 FACS plots of CFSE versus CD34 expression for CML cells with and without 
growth factors. 
The plots are gated on the viable cells following 3 days in culture in the 
presence and absence of growth factors, after the first CFSE sort to enhance 
resolution of the peaks of cell division. The cells were stained with anti- 
CD34PE and Pl and analysed by FACS. 
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Figure 4-11. Graph of CD34+ percentage versus peaks of cell division in the presence and 
absence of growth factors. 
The graph shows the percentage of CML viable CD34` cells as a function of 
cell division. The cells were cultured for 3 days in the presence and absence of 
growth factors following the first CFSE sort, before being stained with anti- 
CD34PE and PI and assessed by FACS. 
The graph in figure 4.11 shows the percentage of cells that remained CD34+ for 
divisions 0-4, for CML cells cultured in the presence and in the absence of added 
growth factors. In the presence of growth factors the percentage of CD34+ cells 
has fallen from 90 to 42%, whereas in the absence of growth factors the CD34+ 
percentage was 75 after the same 4 divisions. This shows that the proportion of 
cells that retained CD34 expression was greater in the absence, than in the 
presence of growth factors. A possible explanation was that as cells differentiated 
and lost CD34 expression they disappeared from the culture, possibly due to cell 
death. Another reason may be that in the absence of added growth factors, cells 
preferentially undergo self-renewal divisions with retention of a primitive 
phenotype. It has been previously demonstrated by Jiang et al (Jiang X, Lopez A 
et al. 1999) that in primitive cells autocrine production of IL-3 fell as cells 
differentiated from CD34+CD45RA/71-, through the intermediate 
CD34+CD45RA/71+, to the more mature CD34- cells. Under the culture conditions 
described here, survival may perhaps depend on the retention of a primitive 
phenotype and possibly on autocrine production of growth factors. 
4.9 Demonstration of Leukaemic Status in the Undivided 
cells 
It was important to establish that the cells that survived in the undivided fraction 
were in fact Ieukaemic cells. It was a possibility that these cells could have been a 
12345 
Number of divisions 
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deeply quiescent normal population (known to co-exist in CML) that had failed to 
go into division. When normal cells were cultured in the absence of growth factors 
a very small number of viable stem cells was observed (see section 4.6) and it 
was essential to exclude this possibility in the case of the CML samples, since if 
these cells were normal stem cells, they represented no risk to the well being of 
the patient. 
Cells from the undivided peak (identified by colcemid controls), cultured in the 
presence and absence of growth factors, were sorted and fixed for FISH. Figure 
4.12 shows a representative example of the cells stained with the D-FISH probe 
for BCR-ABL and ABL-BCR. The detection of double signal i. e. recombinant 
genes established the presence of leukaemic cells, which were greater than 95% 
of the total sorted cells. The FISH picture is the D-FISH probe, which labels BCR, 
and ABL, red and green respectively. Two yellow fusion signals are observed on 
BCR-ABL and ABL-BCR. The double fusion signal reduces the chances of a false 
positive often observed when the chromosomes are in particularly close proximity. 
A positive is recorded only when two fusion signals are detected with both a red 
and green signal. 
Figure 4-12 FISH analysis of undivided cells. 
The cells have been cultured in the absence of growth factors for 3 days, 
before being sorted into divided and undivided populations and fixed for FISH. 
4.10 Discussion 
In conclusion, these experiments have confirmed that CML stem cells are clearly 
different from normal stem cells in their response to withdrawal of growth factors in 
this culture system. The ability of CML stem cells to divide in the absence of 
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exogenous growth factors is a feature of malignant cells that is not observed for 
normal cells. Although all of the CML samples had FISH performed prior to 
commencement of the experiments, it still remained a possibility that a very small 
number of normal stem cells were present in the CML population. The 
demonstration that normal stem cells were unable to divide in the absence of 
growth factors indicated that any cell division in growth factor deficient media was 
due to CML cell proliferation. It was possible that undivided cells in the CML 
population contained some normal cells, however sorting the undivided population 
and performing FISH confirmed that these cells were almost completely Ph 4* within 
the limits of detection. Therefore, proliferation in the absence of growth factors 
could be used as an indication of leukaemic cell division as opposed to normal cell 
division, not observed under these conditions. 
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Chapter 5 Results 3- The Effect of ST1571 on the 
Pattern of Cell Division in Normal and CML Stem 
Cells 
5.1 Introduction 
The molecular event that gives rise to the disease of chronic myeloid leukaemia is 
a reciprocal translocation between chromosomes 9 and 22 (Rowley JD 1973). The 
resultant product is a shortened chromosome 22, known as the Philadelphia 
chromosome, which in turn gives rise to the BCR-ABL oncogene (Shtivelman E, 
Lifshitz B et at. 1985). The fusion gene product is a p210 oncoprotein containing a 
constitutively activated tyrosine kinase (TK) that is responsible for the CML 
phenotype (Ben-Neriah Y, Daley GQ et at. 1986) (Lugo TG, Pendergast AM et at. 
1990). The TK activity of normal c-ABL is tightly regulated and shuttles between 
the nucleus and cytoplasm, whereas BCR-ABL is exclusively cytoplasmic. It is the 
deregulated TK activity of bcr-abl, together with the cytoplasmic location, that are 
considered to be the defining elements in the CML phenotype (Lugo TG, 
Pendergast AM et at. 1990). The bcr-abl TK phosphorylates a number of cellular 
proteins, that in turn impact on a myriad of downstream targets involved in many 
cellular processes, including cell growth, stromal interaction and apoptosis (Salgia 
R, Li JL et al. 1997; Deininger M, Vieira S et at. 2000) (Gordon MY, Dowding CR 
et al. 1987). With a defined molecular target, it was feasible to design specific 
inhibitors of the bcr-abl TK activity, potentially abrogating its downstream effects 
with minimal consequence for normal cells. 
As a result of synthesis and screening of a large number of small molecule TK 
inhibitors, Signal Transduction Inhibitor 571 (ST1571) was identified as a potential 
therapeutic agent for CML (Buchdunger E, Zimmermann J et al. 1996). From 
results of clinical trials, STI was very effective in chronic phase, reducing white cell 
numbers to within normal limits in a few weeks. With relatively few side effects for 
the patient, STI was well tolerated with none of the debilitating toxicity observed 
with other forms of chemotherapy, largely due to its selectivity for leukaemic cells 
(Druker BJ, Tamura S et al. 1996). On treatment with STI, 97% of patients 
achieved a complete haematological response and 75% achieved a complete 
cytogenetic response (Kantarjian H, Sawyers C et al. 2002). However, the results 
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in blast crisis were less encouraging, with only transient haematological responses 
observed, and few molecular responses recorded (Hughes T, Kaeda J et al. 
2002). There are now documented cases of relapse in patients who achieved a 
complete cytogenetic response on STI, which indicates that the disease 
progressed even in the presence of the drug (Sawyers CL, Hochhaus A et al. 
2002). Using very sensitive Q-PCR it has been observed that patients achieving 
remissions with STI still have detectable BCR-ABL transcripts and that few 
patients have been negative on treatment (Hughes T, Kaeda J et al. 2002). These 
observations lead to the premise that a small population of cells was able to 
survive exposure to the drug and could possibly contribute to relapse at a later 
date. It was proposed that one source of surviving leukaemic cells could be the 
quiescent population, identified in previous experiments in chapter 4. The aim of 
the next set of experiments was to determine the effect of STI on the pattern of cell 
division in CML stem cells and to assess which cells, if any, survived exposure to 
the drug. 
5.2 Effect of Different Concentrations of ST1571 on the 
Growth of CML Cells in Culture 
The objective was to determine the response of a number of CML samples to 
differing concentrations of STI. Since the clinically effective and achievable dose of 
STI in the initial trials was 1 pM (Buchdunger E, Zimmermann J et al. 1996; Druker 
BJ, Tamura S et at. 1996; Peng B, Hayes M et at. 2004), this was the starting 
concentration used in these experiments. CD34 enriched stem cells from 5 CML 
patient samples were recovered from cryopreservation and cultured in the 
presence and absence of a5 growth factor cocktail as described in the methods. 
The no growth factor arm was included as a selection for leukaemic cell 
proliferation, as normal cells were unable to proliferate under these conditions (as 
shown in chapter 4). 
All of the samples were from patients at diagnosis and before clinical intervention, 
and all were >95% BCR-ABL positive by FISH. STI was added on day 0 at 
concentrations of 0,1,5 and 10pM. On days 3,6 and 12 triplicate wells for each 
concentration were harvested, counted and assessed for viability by trypan blue 
exclusion. Figure 5.1 shows graphs of viable cell numbers on days 3,6 and 12 in 
the presence and absence of growth factors, with increasing concentrations of 
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STI. In the presence of growth factors (figure 5.1(A)), the mean total viable cell 
number continued to increase over the 12 day period in the absence of STI. 
However, in the presence of 1,5, and 10pM STI the total viable cell number was 
consistently lower than the control. In the absence of growth factors (figure 5.1(B)), 
or STI in parallel cultures, the total viable cell number was lower than in the 
presence of growth factors, but still showed an increase over time. The addition of 
STI at concentrations of 1-10NM reduced the viable cell number to a greater extent 
when no exogenous growth factors were present. In these cultures, the decrease 
in cell proliferation as a result of growth factor starvation and cell kill by STI were 
indistinguishable but the cumulative effect was a reduction in viable cell recovery. 
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Figure 5-1 Graphs of viable cell number with concentration of STI over time. 
The cells were cultured in the presence and absence of growth factors, with 
differing concentrations of STI. 5x104 cells in Iml of media were used to 
establish the cultures and the viable cell number assessed by typan blue 
exclusion on days 3,6, and 12 as described in the text. 
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0 MM ST1571 1 uM ST1571 5 uM ST1571 10 uM ST1571 
Fold 
amplification 
(mean) 
Fold 
amplification 
(mean) 
% 
Recovery 
(mean) 
Fold 
amplification 
(mean) 
% 
Recovery 
(mean) 
Fold 
amplification 
(mean) 
% 
Recovery 
(mean) 
+GF 
Day 3 18±7 11 t4 62 7±3 39 10±8 55 
Da 6 107±40 38±17 36 25±12 23 15±5 14 
Day 12 233±54 204±74 87 172±68 74 95 ±43 41 
-GF 
Day 3 7.6±4 1.8±0.6 24 1.4±0.7 18 1.611 21 
Day 6 6±4 1±0.3 17 0.6 ± 0.3 10 0.4 ± 0.2 7 
Day 12 32±19 2±1.4 6 1±0.6 3 0.8±0.3 2.5 
Table 5-1 Table of fold amplification and viable cell recovery±GF and i STI. 
The figures are the mean of 5 CML samples ±SEM. 
Table 5.1 shows the fold amplification for the same cultures ±STI and ±growth 
factors on days 3,6, and 12. For each culture 5x104 cells were added to 1 ml of 
media in 24 well plates and each well set up in triplicate. On days 3,6, and 12 the 
wells were harvested and viable cell recovery assessed by trypan blue exclusion. 
The fold amplification was calculated as the viable cell output proportional to the 
input number. The results in table 5.1 represent the mean of 5 CML patient 
samples ± SEM. The data shows that in the presence of growth factors, the mean 
total viable cell number increased by 18-, 107-, and 233-fold on days 3,6, and 12 
respectively (as detailed previously in chapter 4, section 4.7). The addition of 1,5, 
and 10pM STI reduced the total amplification to 11-, 7-, and 10-fold by day 3. By 
day 6 the total cell amplification was 38-, 25-, and 15-fold and by day 12 it had 
reached 204-, 172-, and 95-fold. In order to assess the effect of STI, the viable cell 
recovery was calculated as a percentage of the no drug control. The maximum 
effect of STI was observed on day 6 when the overall recovery of viable cells was 
reduced to 36%, 23%, and 14% of control for 1,5, and 10pM STI respectively. 
However, by day 12 the viable cell recoveries had improved to 87% and 74% of 
the control for I and 5pM STI. (p=0.048). For 10pM STI, although the viable cell 
recovery had improved from 14 to 41 % this did not achieve statistical significance. 
In the absence of growth factors and STI the mean total viable cell number 
increased by 7.6-, 6-, and 32-fold on days 3,6, and 12 respectively (as detailed 
previously in chapter 4 section 4.7). In the presence of 1,5, and I OpM STI the fold 
amplification of viable cells was reduced to 1.8-, 1.4-, and 1.6-fold by day 3, to 1-, 
0.6-, and 0.4-fold by day 6, and to 2-, 1-, and 0.8-fold on day 12. The maximum 
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effect of STI was observed on day 12 when the overall viable cell recoveries were 
6%, 3%, and 2.5% for 1,5, and 1 0pM STI respectively. 
In the presence of growth factors the mean viable cell recovery decreased 
between days 3 and 6 in the presence of 1,5, and 10pM STI but increased 
between days 6 and 12 suggesting that a subset of Ph+ cells were insensitive to 
STI at greater than clinically achievable concentrations. Figure 5.2 shows graphic 
representations of the recoveries of viable cells for each STI concentration 
±growth factors. As stated above, the recovery of viable cells in the presence of 
growth factors and STI at each concentration showed a decline on day 6 and an 
increase between days 6 and 12. In the absence of growth factors, although the 
fold amplification increased between days 6 and 12 for each concentration, as 
shown in table 5.1, the recovery of viable cells continued to decrease over this 
time period. The data generated in these experiments suggested that a small 
population of cells were able to survive exposure to STI, at 10pM. It was proposed 
that the CFSE assay described in the previous chapter could be used to identify 
which cells were able tolerate exposure to the drug and would generate further 
information on the stem cell status. 
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Figure 5-2 Graphs of cell recovery (growth factors and tSTI. 
The cells were cultured for 12 days as described in the text. The viable cell 
number was assessed on days 3,6, and 12 by trypan blue exclusion. The 
viable cell recovery was calculated as a proportion of the input cell number 
5x104) in 1ml of media ±GF. The results are the mean of 5 CML samples. 
5.3 The Effect of ST1571 on the Pattern of Cell Division 
in Normal and CML Stem Cells 
As demonstrated in the previous chapters, quiescent stem cells could be identified 
in all CML samples; it was consequently hypothesised that these cells may be the 
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ones that survive exposure to STI. Figure 5.3 shows a schematic outline of the 
experimental strategy used here, and illustrates that following the first sort to 
enhance resolution of the peaks of cell division (detailed in chapter 4, section 4.5), 
the sorted cells were incubated in serum free medium with or without a5 growth 
factor cocktail for a further 3 days. Although previous experiments had shown that 
normal cells failed to proliferate in the absence of growth factors, the introduction 
of STI into the culture may have influenced this; therefore control cells were 
treated in the same way as experimental ones. The cells were incubated in the 
presence or absence of 10µM STI, cultured for 3 days and further sorted into 
divided and undivided fractions. As 10pM had been the most effective 
concentration of STI in reducing the recovery of viable cells this was the 
concentration used for the rest of the experiments, although this was not clinically 
achievable. The three-day time point was chosen, as the effect of STI could be 
observed within this time frame. Figure 5.4 illustrates the sorting and gating 
strategy used for these experiments. For both sorts the cells were first gated on 
the viable (PI") population and on the CD34+ population, before setting the markers 
for sorting. 
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Figure 5-3 Schematic outline of the CFSE sorting and experimental strategy. 
Following recovery from cryopreservation, the cells were stained with 1pM 
CFSE and cultured overnight ± growth factors. The cells were then sorted (sort 
1) to obtain homogeneously stained CFSE' populations before being cultured 
for 3 days ± GF and ± STI. After 3 days the cells were further sorted (sort 2) 
into undivided (UD) and divided (DIV) cell populations identified by the 
colcemid control cells as described previously. 
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Figure 5-4 Gating strategies for CFSE sorts 1 and 2. 
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The cells were first gated on the PI" cells and then on the CD34' population. 
For sort 1, two markers (L and R) of -20 channels were set on the CFSE' cells 
to obtain homogeneously stained populations. Sort 2 was done after the cells 
had been in culture for a further 3 days. The colcemid control identifies the 
position of the undivided cells, and allows the markers to be set for sort 2. 
Figure 5.5 shows normal cells in the presence and absence of 10pM STI, and 
±growth factors. The histograms are gated on the viable (PI-) and CD34+ cells; 
therefore the peaks of cell division represent the viable, CD34+ cells in each 
culture. As previously shown in chapter 4 section 4.6, in the presence of 
exogenous growth factors, stem cells have undergone up to 5 divisions with a 
small, undivided peak observed. The addition of STI did not affect the cell cycle 
kinetics or the recovery of viable stem cells. The cells were able to undergo a 
similar number of divisions in the presence of STI as in the absence. This was not 
surprising, as STI had previously been shown to have little effect on the 
proliferation of normal stem cells at this concentration. It has however, been 
documented that at concentrations of >10µM STI, inhibition of proliferation in 
normal cells is observed, possibly due to the inhibition of other tyrosine kinases 
(Deininger MW, Goldman JM et al. 1997). 
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Figure 5-5 Normal CFSE stained and sorted cells ±GF and tSTI on day 3. 
The plots were gated on the PI", CD34' population. Normal cells were 
unaffected by the addition of STI to the culture with GF. In the absence of GF 
there were no cell divisions and only a small number of undivided cells 
remained viable 
In contrast to the normal example for CML 1 shown in figure 5.6, the addition of 
STI to the culture eliminated all of the dividing cells both in the presence and 
absence of growth factors. In both instances, a small, undivided peak was 
observed representing viable stem cells that had survived exposure to the drug. 
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Figure 5-6 CML I CFSE stained and sorted cells ±GF and ±STI on day 3. 
All plots were gated on the PI", CD34* population. STI has killed all of the 
dividing cells both In the presence and absence of growth factors. A small, 
undivided peak is observed ±GF following drug treatment. 
The CML undivided cells were sorted and processed for FISH and RT-PCR. 
Representative examples are shown in figure 5.7, which demonstrated that these 
cells were part of the leukaemic clone. The FISH picture shows the dual fusion 
signal, which gives two yellow signals when BCR-ABL and ABL-BCR are detected. 
The red and green signals are the single BCR and ABL genes. The PCR picture 
illustrates the presence of BCR-ABL transcripts in the sorted undivided cells from 
cultures ± growth factors following treatment with STI. It was important to exclude 
the possibility that these cells were a very small number of normal cells that had 
been unaffected by STI exposure. The previous observation that CML cells exhibit 
growth factor independence (chapter 4) is also evident in this example, which 
shows 4 peaks of cell division in the absence of added growth factors. 
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Figure 5-7 FISH and PCR on sorted undivided cells on day 3. 
Following sorting on day 3 as described in the text, the cells were fixed for 
FISH using the dual fusion signal probe. PCR was done (by H Jorgensen) 
using primers for BCR-ABL and cABL. 
This response to STI treatment was not observed for all CML patients. Figure 5.8 
illustrates another CML patient whose stem cells were less sensitive to the drug in 
this assay. In the presence of growth factors and 10pM STI, a number of cells 
have been able to undergo up to 4 divisions. In conditions of growth factor 
starvation, and 10pM STI, some of the cells have still been able to undergo 1 
division. The relative difference between the divisions ± growth factors may be 
attributable to the decline in cell proliferation at this early time point; as observed 
when the cells were cultured for 12 days in the absence of growth factors, detailed 
in the previous chapter. (Chapter 4, section 4.7). The differences in patient 
responses to STI exposure seen here may reflect a range of sensitivities to the 
drug, analogous to observations of in vivo responses. 
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Figure 5-8 CML 2 CFSE stained and sorted cells ±GF and iSTI. 
The histograms were gated on the PI', CD34; cells. The peaks of cell division 
with GF and STI are indicated showing that the cells have been able to divide 
up to 4 times in the presence of 10pM STI. In the absence of GF with STI, some 
cells have been able to undergo I cell division. 
Although STI is targeted to BCR-ABL; cells, published reports have suggested 
that inherent resistance occurs, possibly due to over-expression of BCR-ABL or to 
mutations in the ATP binding site on the tyrosine kinase. In all patient samples 
used in this study, a quiescent population was identified following STI exposure 
(n=5), and in all cases these cells were CD34+ and BCR-ABL+ by FISH. The CD34 
status of the cultures was recorded routinely and this allowed access to data on 
the expression of this stem cell marker under a range of conditions. As CIVIL is a 
stem cell disease with the capability for production of excessive cell numbers, the 
expression of a stem cell marker could serve as an indication of the replicative 
potential of the malignant cells. 
5.4 The Effect of STI Exposure on the Expression of 
CD34 in CML 
It was important to illustrate what happened to the stem cell status in the treated 
cultures. For example STI may have induced differentiation including loss of CD34 
and have exerted its effects in this way. It was also important to assess the 
proliferation potential of any cells, which survived exposure to the drug. If the 
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surviving cells were more mature then the risk of disease relapse may have been 
reduced, as these cells would be naturally exhausted through differentiation. 
Information on the stem cells status as a function of division could be gained by 
visualising CFSE (i. e. division) versus CD34 expression on a dot plot. The cells 
were first gated on Pl" viable cells, and cell division, identified by CFSE staining, 
with CD34 expression visualised on a dot plot. Figure 5.9 shows, for this STI- 
sensitive example also shown in figure 5.6, that the cells remaining following STI 
exposure were all CD34+. The dotted line indicates the position of the undivided 
cells, identified by the colcemid control. As shown previously in chapter 4, section 
4.8, growth factor starvation lead to increased retention of the CD34+ phenotype 
with cell division. The addition of STI to the cultures containing growth factors 
eliminated all of the dividing cells and all of the remaining viable cells were CD34+. 
In the second less sensitive example, shown in figure 5.10, where STI has not 
eliminated the dividing cells, the expression of CD34 remained high. This would 
suggest that the most primitive cells show increased resistance to the effects of 
the drug. Given that more primitive stem cells have the capacity for greater 
expansion, this could potentially lead to disease relapse. 
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Figure 5-9 CD34 expression with cell division. 
The plots are gated on the PI' cells and show cell divisions (CFSE) versus 
CD34 expression. This is the same sample shown in figure 5.6 (CML 1). The 
dotted line represents the position of the undivided cells. 
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Figure 5-10 CD34 expression versus cell division for CIVIL 2. 
The plots were gated on the P1' cells and show CD34 expression after 3 days in 
culture ± GF and ± STI. The events to the right of the dotted line are undivided 
cells, identified by the colcemid control as described in the text. 
To give an indication of the cells recovered in each cell division, the total number 
of viable cells in each culture, as well as the number of viable CD34+ cells was 
calculated as a percentage of the input number (corrected for the number of 
divisions). Figure 5.11 shows the gating strategy used to generate the CD34 
percentages used for these calculations. The cells were first gated on the viable 
population, then visualised on a dot-plot showing cell division (CFSE) and CD34 
expression. Good resolution of the cell divisions (achieved by the first CFSE sort) 
allowed markers to be set for measurement of CD34 percentages in each division. 
Table 5.2 shows the total cell i. e. CD34+ and CD34" (A), and CD34+ only (B) 
recoveries for each division ± growth factors and ± STI at 10pM (n=4). The figures 
illustrate that in the presence of growth factors, the mean total cell recovery was 
91% compared to 56% following the addition of STI. In the absence of growth 
factors, the total cell recovery was 47% compared with 22% on addition of 10NM 
STI. Considering the recoveries in each individual peak, 17% recovery was 
observed in M1 (undivided cells) with growth factors alone. Cell recovery in the 
presence of STI was 16%, which was not significantly different. It would appear 
that STI did not affect the recovery of viable cells until division 3, where the 
recovery decreased from 28% with growth factors alone to 1.6% with the addition 
of STI. In the absence of growth factors, the percentage of cells in the undivided 
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peak (Ml) was 14% compared to 11 % with the addition of STI. However, in this 
culture the effect of STI was observed in M2 where the recovery of viable cells fell 
from 21 % to 9%, suggesting that as soon as the cells entered cell cycle they were 
killed by STI, or that STI was preventing them from entering cell cycle. As would 
perhaps be expected, the overall recovery in the presence of STI was markedly 
lower, 22% versus 47%, with the effect again observed as soon as the cells 
entered cell division. If the calculations were done using the viable CD34+ cells as 
opposed to the total viable cells, the results were almost exactly the same for each 
of the 4 experimental arms (table 5.2 (B)) 
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Figure 5-11 FACS plot of cell division (CFSE) with CD34 expression. 
Gating for 
C D34 
percentages 
The cells were cultured for 3 days in the presence of GF, after initial sorting of 
CFSE stained cells as described in the text. Cells were then stained with anti- 
CD34-PE and gates set for each division to calculate the percentage of CD34+ 
and CD34' cells in each division. This plot was gated on the PI' population. R3 
and R14 represent the undivided cells identified by the colcemid control. 
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Conditions 
Recovery 
in M1 
(mean %) 
Recovery in 
M2 
(mean %) 
Recovery in 
M3 
(mean %) 
Recovery in 
M4 
(mean %) 
Recovery 
in M5 
mean % 
Total 
recovery 
(mean 
+GF 17 13 26 28 6 91 
+GF + STI 16 15 23 1.6 0.9 56 
-GF 14 21 10 1.4 - 47 
-GF+STI 11 9 2 0.2 - 22 
(B) Recovery of CD34+ cells 
Conditions 
Recovery 
in M1 
(mean %) 
Recovery in 
M2 
(mean %) 
Recovery in 
M3 
(mean %) 
Recovery in 
M4 
(mean %) 
Recovery 
in M5 
(mean %) 
Total 
recovery 
(mean 
+GF 11 13 28 28 6 85 
+GF + STI 15 16 23 1.6 0.9 55 
-GF 13 25 11 1.4 - 51 
-GF+STI 11 10 2 0.2 - 24 
Table 5-2 Table of total cell and CD34+ cell recoveries in each peak of cell division. 
Numbers are the mean (n=4) percentage recovery for the number of cells in 
each division peak, (corrected for the number of divisions) as a fraction of the 
input cell numbers. 
If the premise is that quiescent undivided cells in CML are the most difficult to 
eradicate, then any treatment which exerts an anti-proliferative effect, may 
potentially allow harbouring of quiescent leukaemic stem cells. These cells would 
have the capacity to cause relapse at a later date, as a consequence of their high 
proliferative potential. The total cell and CD34+ cell recovery in table 5.2 showed 
little difference in the mean recoveries of cells in M1 (undivided), with and without 
STI. However, anti-proliferative effects of STI treatment could be demonstrated in 
one particularly sensitive CML sample. This sample is shown in figure 5.6 where 
the cell divisions and CD34 status were identified (as discussed in section 5.4). If 
the number of cells recovered in the undivided peak, (as a proportion of the input 
number) was calculated, with growth factors alone, the recovery in M1 was 3.2%: t 
0.4% and in the presence of STI was 15.6%. ± 1.4% (p=0.014). This demonstrated 
that STI was exerting an anti-proliferative effect, as the cells had backed up in the 
undivided peak, i. e. the recovery of undivided cells had increased in the presence 
of the drug. It remained a possibility that the cells identified in the undivided peak 
were early apoptotic cells, however due to limitations in this assay it was not 
possible to confirm this. Further work by our group (not shown in this thesis), has 
established that the undivided cells, which survive STI exposure, have the 
capacity to proliferate upon removal of the drug and therefore retain the potential 
to cause disease relapse (Jorgensen HG, Allan EK et al. 2005). 
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Holtz et at (Holtz MS, Slovak ML et at. 2002) have demonstrated that STI 
selectively inhibits the proliferation of primitive CML progenitors and more recently 
Bhatia et at (Bhatia R, Holtz M et at. 2003) have shown that malignant progenitors 
persist in patients treated with STI. Studies within our group have shown that the 
anti-proliferative effect of STI can be enhanced or reduced by the introduction of 
other drugs in combination with STI in vitro (Jorgensen HG, Allan EK et at. 2005). 
Holtz et at have also demonstrated that haemopoietic progenitor cells persist in 
CML patients treated with STI who are in complete cytogenetic remission, and 
confirmed that BCR-ABL mRNA levels in the progenitor cells were higher than in 
the more mature MNC (Holtz MS, Forman SJ et at. 2005). However, it is still too 
early to assess whether these cells can ultimately contribute to relapse in patients 
treated with STI therapy. 
5.5 Summary 
In summary, the experiments presented in this chapter were aimed at assessing 
the sensitivity of a number of CML patient stem cells to differing doses of STI. 
These results established a range of sensitivities to the drug with one particular 
example, which was very susceptible. Having established test doses and a time 
frame for the protocol, further work investigated the pattern of cell division in the 
presence of the drug, together with the effects on the stem cell status. It was 
confirmed that some cells from every patient sample survived exposure to the drug 
at greater than clinically achievable doses. It was also established that these cells 
were part of the leukaemic clone by FISH, and expressed the stem cell marker 
CD34. It was further determined that the surviving cells were the undivided, 
quiescent cells and that STI exerted anti-proliferative activity (shown in one 
example) by causing the number of undivided cells to increase in the presence of 
the drug. Taken together it would seem likely that STI is not going to cure CIVIL as 
a single therapy. However, in combination with other agents aimed at inducing 
quiescent cells into cycle, or by increasing their susceptibility to other agents, a 
more effective treatment may be feasible. In an effort to identify potential 
therapeutic targets, an investigation of the gene expression profile of normal and 
CML quiescent cells compared to cycling cells was undertaken, and the following 
chapter describes the preliminary analysis. 
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Chapter 6 Results 4-A Comparison of the Gene 
Expression Profile of Normal and CML Quiescent 
and Dividing Stem Cells. 
6.1 Introduction 
Advances in the treatment of chronic myeloid leukaemic saw the first molecularly 
targeted therapy for a human cancer reach the clinic. STI571 (STI) was rationally 
designed to inhibit the constitutively active tyrosine kinase of the BCR-ABL 
oncoprotein. This in turn, is responsible for BCR-ABL-induced transformation in 
primitive haemopoietic stem cells typical of CML disease. Initial clinical trials with 
STI showed remarkable results particularly in chronic phase, with almost all 
patients achieving a haematologic response and many achieving major or 
complete cytogenetic responses. However, molecular remissions were rare and 
detectable levels of BCR-ABL transcripts were noted in patients achieving a 
complete cytogenetic response, with cases of disease relapse whilst on therapy 
documented. It was clear that some cells were resistant to the effects of STI and 
able to repopulate the haemopoietic system post-treatment. 
The results presented in the previous chapter identified a quiescent population of 
primitive stem cells that survived exposure to STI at concentrations in excess of 
those used clinically. Other reports have also documented progenitor cells that 
remain viable in vitro and in vivo following exposure to STI (Holtz MS, Slovak ML 
et al. 2002; Hughes TP, Kaeda J et al. 2003). In an effort to characterise the 
quiescent cells compared to cycling cells in both normal and CML, a microarray 
approach was used. Gene expression profiling had been used successfully in 
other studies of leukaemia, identifying a previously unrecognised class of mixed 
lineage leukaemia (MLL) (Armstrong SA, Staunton JE et al. 2002). It was 
anticipated that a microarray approach would yield important information not only 
concerning leukaemic cells, but also regarding normal haemopoietic stem cell 
biology. It was hoped that differences in the expression profiles would yield targets 
valuable for CML therapy alone, or perhaps in combination with other known 
cytotoxic agents. Quiescent cells were identified and sorted using the protocols 
described in chapter 3, then processed for RNA. The RNA was converted to 
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biotinylated cRNA, applied to Affymetrix U133A gene chips and the results 
analysed by two different methods. 
6.2 Sorting to Isolate Quiescent and Cycling Stem Cell 
Fractions 
It was of critical importance that the cell populations used for microarray studies 
were subject to consistent conditions, as any deviation in the protocol may have 
induced changes in gene expression related to procedure. The Hoechst (HST) and 
Pyronin (Py) sorting strategy (as described in chapter 3, section 3.1.3) was used to 
generate quiescent cells in GO and cycling cells in G1/S/G2/M from previously 
CD34 selected samples A representative CML sample is shown in figure 6.1. The 
plots illustrate the cells were first gated on the PI- viable cells and then on the 
CD34+ population. The gates on the HST/Py plot are set for sorting GO 
(HST1OPyIO) and cycling cells in G1/S/G2/M. This protocol was previously verified 
for sorting of cell cycle phases in chapter 3 section 3.14. 
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Figure 6-1 Sorting gates for isolation of GO and dividing cells. 
The cells were incubated overnight In growth factor medium to enable 
recovery from cryopreservation. The following day the cells were stained with 
Pi, anti-CD34FITC, HST and Py. The sorting gates were set firstly on the viable 
Pl' cells (RI), then on the CD34+ cells (R2). Further gates were set on the GO 
(R3) and dividing cells (R4). 
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To maintain consistency (essential for arrays), all of the samples were positively 
selected using the Isolex method described in section 3.2.1 of chapter 3. In total 5 
CML samples and 3 normal samples were sorted and processed for RNA as 
described in materials and methods section 2.3.4.12. Unfortunately, one of the 
normal GO samples failed to produce enough RNA for the microarray experiment, 
which meant that the normal GO set had only 2 samples; the corresponding normal 
divided cell sample was included. 
6.3 Generation of RNA for Application to Arrays 
The total number of sorted cells together with the amount of RNA obtained form 
each sample is shown in table 6.1. The cell numbers were from the sorter counts 
and in an effort to conserve cells no further counting was done. As shown in the 
table, the amount of RNA obtained varied considerably from 0.07pg to 45pg and 
did not appear to correlate well with starting cell number although this could be 
due in part, to the reduced accuracy of the sorter counts. The level of the least 
amount of RNA necessitated that an amplification protocol be employed in order to 
generate data on every sample. 
Sample Number of cells x106 
Total amount of 
RNA pg 
CML 1 GO 0.4 0.07 
CML 1 Div 11 17 
CML2GO 0.5 0.16 
CML 2 DIV 8 45 
CML 3 GO 0.4 0.38 
CML 3 DIV 11 37 
CML 4 GO 0.05 0.07 
CML 4 DIV 0.5 0.80 
CML5GO 0.4 0.09 
CML 5 DIV 10 10.2 
NORM 1 GO 0.8 0.34 
NORM 1 DIV 6 15 
NORM2GO 1 0.84 
NORM 2 DIV 10 3.3 
NORM 3 DIV 8 14 
Table 6-1 Table of sorted cell numbers and total RNA. 
Normal and CML cells were sorted to produce quiescent GO and cycling 
S/G21M cell populations. The cells were Immediately placed Into Trizol and 
stored at -80°C. When all of the samples had been sorted, RNA was extracted 
in a single batch. The concentrations of RNA were measured at the microarray 
facility using the Nanodrop machine. 
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lt was crucial that all of the samples were treated similarly, to enable comparison 
of the expression profiles. Although the samples were sorted on different days, the 
RNA processing was done in a single batch using the same reagents. The RNA 
samples were then handed over to the Sir Henry Wellcome Functional Genomics 
(SHWFG) facility at the University of Glasgow, where the remaining procedures 
were carried out. These included; measurement and quality assessment of RNA, 
generation of cDNA, amplification of RNA, labelling of cRNA, application to 
Affymetrix gene chips UI33A, generation of results and analysis of data. Analysis 
included normalization of the data, production of gene lists and clustering analysis. 
Additional analysis of the data was done by myself using the GeneSpring®(Silicon 
Genetics) program. 
The Affymetrix microarray methodology was chosen as the internal controls and 
reproducibility were robust and the system had been used in numerous previous 
studies. This study used the HU-133A GeneChip which contains 22,000 probes 
representing 12,600 well substantiated genes. The sequences were selected from 
GenBank®, dbEST, and RefSeq and sequence clusters created from UniGene 
database (build 133, April 2001) and refined by comparison with other public 
databases. It was decided at this early stage that only validated gene sequences 
would be used which incorporated a limited number of expressed sequence tags 
(EST), most of which are contained in the HU-133B chip. Affymetrix GeneChips 
contain reference standards for both gene expression and target intensity, which 
enable scaling and normalization of the data. Sets of genes known to be 
expressed in a diverse range of human tissues are included on the chip. This 
technology allows data from different experiments to be compared quantitatively. 
6.4 Production of Gene Lists 
Normalization of the data and generation of gene lists was done by the SHWFG 
facility at the University of Glasgow where the microarray experiments were 
carried out. Normalization was done using the robust multichip average (RMA), a 
published, validated method of normalization specific to Affymetrix GeneChip 
technology (Irizarry RA, Hobbs B et al. 2003). 
Lists of differentially expressed genes for the desired comparisons were produced 
using Rank Products (RP); a recently published method which sorts all genes 
according to their expression changes and provides statistical confidence levels 
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which are particularly applicable to small and noisy data sets (Breitling R, 
Armengaud P et al. 2004). A more sophisticated level of analysis was done using 
an innovative method for identification of functional gene classes known as 
Iterative Group Analysis (iGA). This method generates a biological summary of the 
physiological processes altered in a particular experiment and provides powerful 
statistical confidence measures (Breitling R, Amtmann A et al. 2004). These 
results will be discussed in detail later. 
6.5 Analysis of Data Using GeneSpring® 
Conducted by myself, the gene lists imported into the GeneSpring (Silicon 
Genetics) program were normalized data produced by SHWFG using RP as 
detailed above. 
The results were generated on the basis of defined comparisons. The sample 
groups of most interest were: 1. CML GO versus CML dividing, 2. Normal GO 
versus Normal dividing, 3. CML GO versus Normal GO, 4. CML dividing versus 
Normal dividing. Lists of genes were collated and ranked in order of fold change 
with an indication of false discovery rate (FDR) i. e. a conservative estimate of the 
expected percentage of false positives. For practical purposes an arbitrary cut-off 
of 5% was used, in the initial assessment of the data. As this was a relatively small 
sample group the FDR was quite high for many of the genes in the comparisons. 
Comparisons Regulated Number of Genes 
CML GO Vs CML DIV UP 1088 
CML GO Vs CML DIV DOWN 614 
Norm GO Vs Norm DIV UP 448 
Norm GO Vs Norm DIV DOWN 1676 
CML GO Vs Norm GO UP 1793 
CML GO Vs Norm GO DOWN 208 
CML DIV Vs Norm DIV UP 743 
CML DIV Vs Norm DIV DOWN 139 
Table 6-2 Table of the number of genes changed for each comparison. 
The results represented in the table are the numbers of genes changed either 
up or down, as Identified by RP analysis, for each comparison. 
Table 6.2 shows the number of consistently differentiated genes up- and down- 
regulated for each comparison. This illustrates that hundreds of genes were 
changed between the groups, which were accompanied by large differences in 
fold change and FDR. In addition, the lists were not clustered into functional 
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groups, which made identification of the most relevant genes more difficult. As with 
all global expression arrays the analysis yields very large amounts of data and to 
facilitate identification of the most significant genes, clustering analysis is required. 
The data was subsequently re-analysed using the GeneSpring® program. 
Normalized raw data from Affymetrix gene chips was imported into the program, 
which allowed the data to be manipulated such that genes could be grouped 
according to fold change. Analysis of the data using scatter plots generated 
groups of genes with >3, >4 and >5 fold changes. Table 6.3 shows the number of 
genes changed either increased or decreased, for each comparison. 
Comparison >3-Fold >4-Fold >5-Fold 
CML GO Vs CML DIV 37 21 10 
Norm GO Vs Norm DIV 188 92 47 
CML GO Vs Norm GO 168 85 49 
CML DIV Vs Norm DIV 49 27 8 
Table 6-3 Table of the numbers of changed genes with fold change. 
The genes changed and the level of fold change was generated by GeneSpring 
analysis of RP lists imported into the program. 
The greatest number of genes changed >3-fold (188) was in the Normal GO versus 
Normal dividing group and the least number >3-fold changed (37) was in the CML 
GO versus CML dividing. There was a large number of genes >3-fold changed 
between CML GO and Normal GO (168) suggesting that the normal GO cells were 
very different in their gene expression, from either their dividing counterparts or 
CML GO cells. Figure 6.2 shows a mathematical model of the relative distance in 
terms of gene expression between the samples. The Euclidean distance diagram 
represents the data (>3-fold change) plotted on a relative scale. Euclidean 
distance is plotted using the formula: distance (x, y) = sqrt( SUM(xi - yi)2 )%Z 
(where the sum is over all points i), which calculates the geometric distance in the 
multidimensional space. It gives an indication of how close the groups are in terms 
of gene expression. 
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Figure 6-2 Euclidean distance diagram of gene differences >3-fold changed. 
The model was created using the genes >3-fold changed, up or down, between 
the groups to give an Indication of how close each group was In gene 
expression. The height scale is arbitrary and Indicates the relative distance 
between the groups. 
The diagram in figure 6.2 shows that CML and normal dividing cells are closest in 
gene expression and that normal GO cells show the least homogeneity with the 
other sample groups, since they are separated by the greatest distance. The 
diagram also illustrates that CML GO cells are closer in gene expression to normal 
and CML dividing cells than to Normal GO cells. 
6.6 Analysis of Gene Expression in Normal GO Versus 
Normal Dividing Cells 
One of the particular areas of interest in terms of gene expression was the 
difference between Normal GO and Normal dividing cells. The gene expression of 
such specific populations of normal stem cells has not been previously 
investigated. It has been shown that most mobilised primitive stem cells are out of 
cycle i. e. in GO, and it was anticipated that this data set would shed some light on 
the gene expression profile of quiescent stem cells compared to cycling cells 
(Uchida N, He D et al. 1997). 
Given that the cells were sorted on the basis of cell cycle position, the change in 
expression of cell cycle genes was examined. Table 6.4 shows a list of cell cycle 
genes and their fold change between Normal GO and Normal dividing cells. The 
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list shows significant up-regulation of many cell cycle associated genes in dividing 
cells, which would be expected if the cells were accurately sorted into their cell 
cycle compartments. This was a further confirmation of the success of the sorting 
strategy using HST and Py for identification of cell cycle position. In addition, the 
dividing cells also showed up regulation of genes associated with transcription and 
translation, which would be anticipated in cells exhibiting greater cellular activity. 
Gene Fold up-regulation 
CDC2 8 
CDC20 6 
CCNB2 5 
CCN1 3.5 
CDC25 3.5 
MCM2 4 
MCM5 3 
CHEKI 4 
CDC6 5 
CDKN3 4 
Table 6-4 Table of cell cycle genes up-regulated in normal cycling cells. 
The table shows a selection of gene up-regulated in normal dividing versus 
quiescent cells. An indication of the fold change for each gene is also shown. 
Curiously, the greatest fold change in Normal GO versus Normal dividing cells was 
seen in a set of chemokine genes, specifically the ligands, not the receptors, which 
were between 5 and 10 fold up-regulated in the quiescent cells. The significance 
of this observation is not immediately obvious and no other published work on 
haematopoietic stem cells has suggested a role for these chemokines in 
maintenance of quiescence. These data will be discussed in more detail later. 
6.7 Analysis of Gene Expression in CML GO Versus CML 
Dividing Cells 
As the analysis of cell cycle genes in normal cells had shown good differential 
expression between GO and dividing cells it was anticipated that the same would 
hold true for the CML cells, since these had been sorted in the same way. 
However, similar differences in cell cycle associated gene expression were not 
observed in the CML samples. There appeared to be significant up-regulation of 
cell cycle genes in the CML sorted quiescent cells compared to normal GO, such 
that these more closely resembled dividing cells. One possible explanation may be 
that the sorted population of cells was heterogeneous and contained cycling cells 
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in the quiescent fraction. However, on the basis of the normal data, the sorting 
strategy would appear to be robust. Another potential explanation could be that the 
CML cells were more efficient in dye efflux by ABCG2 transporters, known to efflux 
Hoechst. This would place some cells in the GO gate when in fact they were 
cycling cells. Increased expression of the ABCG2 transporter in stem cells has 
been identified in primitive haemopoietic cells, specifically in side population (SP) 
cells (Scharenberg CW, Harkey MA et al. 2002). ABCG2 is responsible for 
Hoechst efflux, which places the SP cells in a particular position on a FAGS plot 
where dual fluorescence of Hoechst is analysed. However, the data generated in 
this microarray experiment does not show significant up regulation of ABCG2 in 
the CML GO versus CML dividing cells or indeed between the CML and normal 
cells. If expression of ABC transporter genes in CML cells were a factor in 
determining their position on the Hoechst and Pyronin FAGS plot, it would be 
expected to show some differential expression between CML and Normal cells. 
However, it was possible that the set level of 3 fold differential expression was too 
high to detect changes in ABCG2 transporter activity. The only way to exclude the 
possibility of the influence of ABCG2 would be to sort the cells using a different 
FAGS staining strategy and examine the expression of cell cycle genes. The fact 
remains that quiescent CML stem cells behave differently from CML cycling cells 
as demonstrated in chapter 5, where these cells were shown to survive exposure 
to STI. Such distinct differences in cell behaviour would not be expected if the cell 
cycle position identified as GO was an artefact of the staining and sorting strategy. 
Although expression of cell cycle genes in the GO CML cells has cast some doubt 
on the integrity of the sorting procedure, a similar up-regulation of the same group 
of chemokine genes observed in the Normal GO cells was also observed for the 
CML GO cells. This would suggest that these populations of cells share at least 
some similar characteristics. Figure 6.3 shows a Venn diagram of the comparisons 
of Normal GO versus Normal dividing and CML GO versus CML dividing cells. 
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Figure 6-3 Venn diagrams of differential gene expression between all comparisons. 
The Venn diagrams were created in GeneSpring by selecting all genes >3-, >4- 
and >5-fold, changed between the groups as illustrated. Genes common to 
both groups for >4-fold and >5-fold are shown in the boxes. 
Figure 6.3 illustrates that of genes showing >3-fold change, 188 genes were 
differentially expressed in Normal GO versus Normal dividing cells, 37 genes were 
expressed in CML GO versus CML dividing and that 19 genes were commonly 
expressed in both Normal and CML GO versus dividing cells. When the level of 
change is set at >4-fold, 9 genes were common to both groups. Significantly, 7 of 
the 9 genes encode chemokines. If a similar comparison is done with the fold 
change set at >5, as shown in figure 6.4,47 genes were changed in Normal GO 
versus dividing, 10 genes were changed in CML GO versus dividing, and 4 genes 
were common to both comparisons. The 4 common genes, >5-fold up-regulated in 
the GO cells were all chemokine genes, and this was a surprising finding. The 
particular chemokines identified have not been previously associated with stem 
cell quiescence. This may be an important observation, as the level of up 
regulation (5-10-fold) in quiescent cells, is significant compared to cycling cells. 
Also, although genes encoding the ligands were up regulated, there was no up- 
regulation of the corresponding receptors as shown in table 6.5, suggesting that 
this was not an autocrine mechanism. The involvement of these particular 
Genes changed >5-fold 
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chemokines in quiescent stem cells has not been documented and as such 
represents a novel observation, which merits further investigation. 
Receptor Present Comments 
CXCR1 + Norm vs CML 
CXCR2 - 
CXCR3 + 
CXCR4 + 3-fold in Norm GO 
CXCR5 - 
CCR1 - 
CCR2A - 
CCR4 + 
CCR5 + 
CCR6 - 
CCR7 - 
CCR8 - 
CCR10 - 
CCRL1 + lNorm vs CML 
Table 6-5 Table of gene expression of chemokine receptors. 
The table shows the presence or not of signals on the arrays for chemokine 
receptor genes. The levels of expression between the groups were similar 
unless otherwise indicated. 
6.8 Iterative group analysis (iGA) to Identify Functional 
Gene Classes for Each Comparison 
Iterative group analysis (iGA) is based on the premise that combined expression 
change of some or all members of a functional group is physiologically relevant. 
iGA uses statistics to identify functional gene classes that are significantly 
changed in an experiment, and at the same time determines which of the class 
members are most likely to be differentially expressed. iGA does not depend on 
fixed lists of differentially changed genes but instead uses an iterative procedure to 
determine the optimal threshold for each functional class. By concentrating on 
gene groups rather than single genes it is feasible to establish statistical 
significance even in the absence of experimental replication, as the group 
members serve as internal replicates. This is a powerful tool that enhances the 
sensitivity of gene detection especially in small data sets such as this one. A 
further advantage of this technique for the analysis of microarray experiments is 
that it allows comparison of data from different platforms or analytical techniques 
(Breitling R, Amtmann A et al. 2004). 
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Using the iGA method, the data from these experiments was further analysed to 
identify clusters of significantly changed genes. The list of genes and their 
functional class assignments is contained in Appendix 1. These results also 
identify the greatest changes in gene expression as being between the Normal GO 
cells and their dividing counterparts, with some 20 gene groups significantly 
changed. Interestingly, most of the changed groups in the dividing cell up- 
regulated cohort are related to cell cycle. The differential expression of cell cycle 
genes strongly suggests that the sorting strategy has indeed isolated quiescent, 
GO cells from cycling ones. 
Analysis of up-regulated genes in the Normal GO samples shows significant 
expression of chemokine genes identifying not only the ones found in the 
GeneSpring analysis, but a further 5 genes in this functional class. In addition, the 
gene groups are ranked in order of significance with chemokine genes at the top 
of the list. This analysis corroborates the GeneSpring data, and increases the 
significance of this observation. The relevance of this finding will be studied in 
further experiments, as no previously published work has established a role for 
these chemokines in stem cell quiescence. 
In the CML GO versus cycling cells, the consistent up regulation of genes 
associated with initiation of cell cycle observed in the normal samples, was not 
detected in this clustering analysis. However, there was significant up regulation of 
genes associated with the mitotic phase of the cell cycle and of those associated 
with spindle formation and chromosome assembly. This suggests that there were 
considerable differences in gene expression between the two CML cell 
populations. However, it would appear that cells identified as quiescent CML cells 
are not truly quiescent in the same way as normal cells are. The GO CML cells 
appear to have little differential expression of genes associated with early cell 
cycle events, but have increased expression of genes involved in the later mitotic 
phase. This would support the findings documented in chapter 3 of this thesis, 
which identified a significant increase in the proportion of cells in the S/G2/M 
phase of the cell cycle, for CML samples compared to normal. The CML GO cells 
were clearly very different from normal GO cells; however, the same up-regulation 
of chemokine genes was observed in the CML quiescent cells as in the normal 
ones, albeit at a slightly lower level. It is possible that the genes associated with 
expression of chemokines are a quiescent stem cell feature and the aberrant cell 
cycle gene expression is a consequence of malignancy. 
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In conclusion, the microarray study has confirmed that for normal cells, significant 
up-regulation of cell cycle genes was observed in sorted cycling compared to 
quiescent cells. For CML samples this differential cell cycle gene expression was 
not observed, suggesting that quiescent CML cells display altered expression of 
some cell cycle associated genes. Gene expression profiling also identified an 
unexpected cohort of chemokine genes 5-10-fold up-regulated in quiescent stem 
cells from both normal and CML samples. 
153 
Chapter 7 Discussion 
7.1 Introduction 
The aim of the work presented in this thesis was to isolate and characterise 
quiescent haemopoietic stem cells (HSC) from CML and normal patients. These 
isolated stem cell populations were used to determine if cell cycle position affected 
their sensitivity to a specifically targeted treatment, STI. These cell populations 
were further utilised in a microarray study in an effort to identify genotypic 
differences between quiescent and cycling stem cells, and between normal and 
CML stem cells. 
7.2 Identification and Isolation of Stem Cells in Different 
Phases of the Cell Cycle 
HSC comprise a very small proportion of the circulating progenitors, typically 
around 0.1% in normal individuals. Although there are no definitive markers for 
human stem cells, CD34 is the most commonly used. This sialomucin molecule is 
expressed on the surface of cells capable of rescuing a myeloablated host, and 
therefore possessing the capacity to generate every cell of the haemopoietic 
system. In practice, stem cell populations enriched by selection with this marker, 
have been used clinically for transplantation for a number of years. All samples in 
this study were enriched for CD34+ cells by either positive or negative selection, 
prior to sorting by flow cytometry. The different CD34 selection methods generate 
subtly different populations of stem cells. Positive selection separates cells bearing 
the CD34 antigen from the whole population. Negative selection uses a cocktail of 
antibodies to a variety of lineage markers, which allows removal of these cells 
leaving the immature CD34+ cells, which express no lineage markers. Generally 
the percentage of CD34+ cells is lower for the negative selection. If CD34'Lin" cells 
(possibly more immature than CD34+Lin) are present in the population, they will 
be retained by a negative selection but lost in a positive selection. However, all of 
the FACS sorting experiments described in this thesis included gating on the 
CD34+ population, which in effect excludes any CD34"Lin cells. 
Stem cells are generally accepted to be predominantly quiescent and enter cell 
cycle relatively infrequently. It is proposed that this affords them protection from 
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potentially damaging influences, and reduces the incidence of genetic mutation 
associated with DNA replication. It is possible that quiescence is a factor in the 
maintenance of malignant stem cell disease and the experiments described in this 
thesis were aimed at addressing the importance of a quiescent phenotype in 
leukaemic survival following cytotoxic therapy, and the possible implications for 
disease persistence. 
Previous work by Holyoake et at had demonstrated that a quiescent stem cell 
population existed in CP CML and that these cells could be isolated by FACS 
sorting (Holyoake T, Jiang X et at. 1999). Intracellular staining of DNA by Hoechst 
(HST) and RNA by Pyronin Y (Py) is the most commonly used method of isolating 
viable cells in different phases of the cell cycle. Most other dyes used in flow 
cytometry for discrimination of cell cycle phases (e. g. propidium iodide) are not 
able to distinguish the GO and G1 phases. In addition, most stains require the cells 
to be fixed and therefore non viable. Furthermore, HST and Py can be combined 
with additional stains, as described below, which allow more specific cell 
populations to be isolated. 
Using the HST and Py staining method, GO and dividing populations were 
identified (shown in figure 3.6). In addition, setting gates around the viable (PI) 
CD34'' cells allowed GO and cycling stem cells to be sorted separately (figure 3.7). 
Success of the sorting strategy was confirmed by PCR analysis of the CML sorted 
cells showing the presence of PCNA (synthesised in S-phase) in the cycling cells, 
which was absent in the GO and G1 cells. Interestingly, another cell cycle 
associated gene MCM5, which is synthesised when cells enter G1, was also 
observed in the GO cells. However, other studies have documented aberrant 
expression of MCM5 in malignant cells of the oesophagus, which may be related 
to disruption in cell cycle control in cancer cells (Going JJ, Keith WN et al. 2002). 
Unfortunately, due to limitations in the availability of material, it was not possible to 
repeat the PCR confirmation experiments with a normal sample. These preliminary 
results showed we could successfully isolate viable, quiescent and cycling, stem 
cell populations. 
One of the first observations following HST and Py staining, was that the 
proportion of cells in GO was lower in the CML samples. There was also a 
significant difference in the proportion of cells in G1,70.9% in normal compared to 
50.6% in CML. The percentage of cells in GO was consistently lower for CML 
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samples compared to normal, suggesting that there were fewer quiescent stem 
cells in CIVIL Given that all cells were stained following 24hrs in culture after 
recovery from cryopreservation, it would appear that the CIVIL cells displayed an 
increased cell cycle activation, with fewer cells in GO/GI than in the normal 
samples. Kramer et al have made similar observations for CD34" cells in both BM 
and PB from newly diagnosed CIVIL patients. They noted the proportion of cycling 
progenitor cells was higher in CIVIL PB and BM compared to matched samples 
from BCR-ABL' myeloproliferative disease, and concluded that BCR-ABL' CD34+ 
cells display an increased cell cycle activation (Kramer A, Loffler H et al. 2001). 
Although the results presented here, and those of Kramer et al, indicate that a 
greater proportion of the CIVIL cells are in the S/G2/M phase of the cell cycle, it 
does not imply that these cells are cycling more rapidly. Rather it suggests CIVIL 
cells are more likely to enter cell division, but does not give information on the time 
taken to complete the cell cycle. Furthermore, data on the division history of CIVIL 
and normal stem cells detailed in chapter 4, indicates that both populations 
undergo a similar number of divisions following 3 days in culture with growth 
factors, after the same initial 24 hours recovery from cyropreservation. Moreover, 
Buckle et al have also demonstrated that CIVIL stem cells do not exhibit increased 
cell cycling compared to normal stem cells (Buckle AM, Mottram R et al. 2000) 
These observations suggest similar cell cycle kinetics for CIVIL and normal CD34+ 
stem cells, at least in vitro. 
7.3 Comparison of Division History and Stem Cell Status 
in Normal and CML Cells 
The experiments described in chapter 4 investigated some of the characteristics of 
CML stem cells compared to normal stem cells in vitro. Culturing cells in the 
absence of exogenous growth factors identified distinct differences between 
normal and CML stem cells. To gain some understanding of the behaviour of stem 
cells under varying conditions, a method of tracking cell division and 'stem cell 
status was devised. By staining cells with a permanent, non-toxic cytoplasmic dye 
(CFSE) and developing a sorting strategy to enhance the resolution of cell division 
peaks, it was possible to precisely track the pattern of cell division. In addition, it 
was possible to calculate with some accuracy, stem cell amplifications together 
with the proportions of cells recovered in each peak of division relative to the 
number of input cells. When sorted CD34+ cells were cultured in the presence and 
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absence of a5 growth factor cocktail containing IL-3, IL-6, SCF, GCSF and FIt3L, 
there were distinct differences between normal and CML cells. In the presence of 
growth factors, both normal and CML cells have undergone up to 5 divisions in 3 
days. However, in the absence of growth factors, normal cells were unable to 
divide and only a very small proportion remained viable and undivided. It is 
possible that these cells represent a deeply quiescent population resistant to the 
detrimental effects of growth factor starvation, or that they are early apoptotic cells 
still able to exclude Pl. Unfortunately, it was not possible using this FACS staining 
strategy to confirm either status. 
In contrast, in the absence of growth factors, CML cells were able to divide up to 3 
times, demonstrating their growth factor independence. This is in accordance with 
other published data, which was recently convincingly substantiated when CD34' 
normal cord blood (CB) cells infected with retrovirus encoding p210BCR-ABL, 
displayed a growth factor independent phenotype (Chalandon Y, Jiang X et al. 
2004). The mechanism of growth factor independence in CML cells is not clearly 
defined. It has previously been shown that in primitive CML cells growth factor 
autonomous proliferation was associated with autocrine production of IL-3 and 
GCSF (Jiang X, Lopez A et al. 1999). In other studies, we have further 
demonstrated that whereas quiescent CML CD34+ cells have no detectable IL-3 
transcripts, following culture in the absence of growth factors these cells 
spontaneously up regulate IL-3 expression as they enter cell cycle (Holyoake T, 
Jiang X et al. 2001). Further experiments by Jiang et al demonstrated the rapid 
acquisition of autocrine IL-3 production by BCR-ABL transduced primitive murine 
BM cells, which was associated with immediate growth factor independence (Jiang 
X, Ng E et at. 2002). Chalandon et al also found that in p210BCRABL retrovirally 
transduced cells, growth factor independent proliferation was associated with 
autocrine production, not only of IL-3, but also of GCSF and erythropoietin. This 
evidence strongly suggests that bcr-abI confers a growth factor independent 
phenotype in association with autocrine growth factor production. Furthermore, 
proliferation in the absence of growth factors can be considered selective for Ph+ 
cells, as normal cells fail to divide under these conditions. 
Experimental analysis of CD34 status together with cell division showed CML cells 
preferentially maintained expression of CD34 following growth factor withdrawal. In 
the presence of added growth factors the percentage of CD34' cells declined with 
division, however, in the absence of growth factors, the cells retained significant 
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levels of CD34 expression. This suggests that in the absence of exogenous 
growth factors, the cells that are able to survive and divide are the most primitive 
i. e. expressing the CD34 stem cell marker, and that they maintain this status with 
division. 
Interestingly, both in the presence and absence of growth factors, a small number 
of undivided cells were observed in all CML samples, which displayed a high level 
of CD34 expression. It remained a possibility that these cells represented a small 
number of primitive normal cells, analogous to the in vivo population known to 
coexist alongside Ph"' cells. Sorting divided and undivided populations allowed 
FISH analysis, which showed that all of the undivided cells were in fact BCR-ABL;, 
confirming their leukaemic status. This data verified that, even when exposed to a 
potent growth factor cocktail, a number of CML stem cells remained undivided. 
This methodology does not allow assessment of cell cycle status, only division 
history. It is likely that the undivided cells were indeed quiescent, having failed to 
enter cell division after 3 days in the presence of growth factors, however it was 
not possible to confirm this using this experimental strategy. 
7.4 The Effect of STI571 on Cell Division in Normal and 
CML Stem Cells 
The central role of bcr-abl in leukaemic transformation presented an attractive 
target for drug therapy. A small molecule inhibitor, STI, was found to inhibit the 
constitutive tyrosine kinase activity of bcr-abl+ cells both in vitro and in vivo. 
However, in vitro studies with STI had revealed that some Ph+ cells were able to 
survive exposure to the drug (Deininger MW, Goldman JM et al. 1997). Clinical 
observations suggest that all BCR-ABL+ cells are not eliminated by STI treatment, 
and the potential for relapse exists in the majority of treated patients. One of the 
mechanisms of resistance to STI is the development of mutations in the kinase 
domain of bcr-abl, which inhibit STI binding and can be detected prior to treatment. 
It is possible that this could explain the differences in sensitivities to STI 
documented in the work presented in chapter 5 of this thesis, however only 
mutation analysis could confirm this. 
There are other proposed mechanisms to explain the resistance of CML cells to 
STI. For example, it has recently been reported that activity of the ABC 
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transporter, Pgp, can reduce intracellular concentrations of STI, leading to less 
effective inhibition of the tyrosine kinase activity (Illmer T, Schaich M et al. 2004). 
Mahon et at have also demonstrated that Pgp activity may be responsible for 
resistance to STI in cell lines, however it has not been conclusively established if 
overexpression of this transporter is a clinical feature of CML disease (Mahon FX, 
Belloc F et al. 2003). Conversely, others have shown that overexpression of Pgp, 
at least in BCR-ABL' cell lines, does not confer resistance to STI in vitro (Ferrao 
PT, Frost MJ et al. 2003). The evidence so far has not confirmed if drug efflux is a 
significant factor in STI resistance. 
Gene amplification and overexpression of BCR-ABL have also been described in 
STI resistant cells, and it is generally accepted that reactivation of the bcr-abl 
tyrosine kinase is required to induce a malignant phenotype. However these 
mechanisms remain controversial in the clinical setting. Although gene 
amplification has been described in some patients, whether this results in 
increased bcr-abl protein has not been established (Gorre ME, Mohammed M et 
al. 2001). 
It was possible that a quiescent phenotype could allow stem cells to escape the 
effects of cytotoxic therapy. In an effort to identify which CML cells (if any) could 
survive exposure to STI, the previous experimental strategy to identify division 
history and stem cell status was utilised. CML and normal CD34' cells were 
stained with CFSE and cultured in the presence or absence of STI, with a 
relatively short time frame (3days) to exclude the possibility of outgrowth of 
resistant mutant clones. Cultures of CML cells in the absence of growth factors 
were included in an effort to focus on leukaemic cell proliferation without the 
potential contribution of normal cells, unable to divide under these conditions. 
Preliminary experiments were aimed at establishing a test concentration of STI in 
excess of clinical doses, to determine if any CML cells were able to survive at 
greater than clinically achievable doses. Pharmacokinetic studies demonstrated 
that at the prescribed dose of 300mg/day, a peak plasma concentration of I pM 
was achieved in the patient. IOpM STI was selected for all subsequent studies as 
this represented 10x the clinically achievable dose at the time of the experiments. 
More recently, in vivo doses have been escalated to 600-800mg/day, giving peak 
plasma concentrations of 5-7pM (Peng B, Hayes M et al. 2004). 
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The experiments described in chapter 5 demonstrated that some CML stem cells 
could survive when cultured in the presence of 10pM STI, which had little effect on 
normal stem cell proliferation in this system. Effects of higher concentrations of 
STI (>lOpM) on normal cells have been observed, possibly due to inhibition of c- 
kit or other tyrosine kinases. Holtz et al have documented that whereas some 
effect of STI on normal CFC is observed at 5pM, it does not affect more primitive 
LTC-IC (Holtz MS, Slovak ML et al. 2002). It is worth mentioning that many of the 
early investigations into the effectiveness of STI as an agent that inhibited the 
proliferation of Ph* cells examined its effects on very heterogeneous cell 
populations or in cell lines. Work in this thesis focused specifically on the stem cell 
fraction, and the importance of this defined population will become evident as this 
discussion develops. 
Tracking the pattern of cell division by staining and sorting stem cell populations 
+/- STI revealed that in all CML samples, a population of undivided cells was able 
to survive exposure to STI at greater than clinically achievable doses. It was also 
evident that a range of sensitivities to STI existed among CML patients. In a 
particularly sensitive example all of the dividing cells, +/- growth factors were killed 
by STI. In less sensitive patients a number of cells were able to divide +/-growth 
factors and also in the presence of 10pM STI. A possible explanation for this 
heterologous response of patient cells may be that some patients harbour a small 
number of cells with a mutation, which renders them insensitive to STI treatment. 
Such mutations in either the ATP binding pocket or in other parts of the protein 
that confer conformational changes have been documented in cases of resistance. 
There is now evidence that these mutations exist in a small number of cells even 
before treatment, and that elimination of the STI-sensitive cells reveals their 
presence (Roche-Lestienne C, Lai JL et al. 2003). More recent evidence suggests 
that kinase domain mutations exist in around 22% of STI-naive CML patients. 
However, their existence does not correlate directly with resistance to STI therapy. 
The authors concluded that additional factors were required to induce a fully 
resistant phenotype (Willis S, Lange T et al. 2005). 
These data support the theory that innate or acquired resistance to STI is not the 
only explanation for disease persistence. Indeed, data presented in chapter 5 of 
this work offers an alternative explanation for the minimal residual disease 
observed in STI treated patients, namely, that it is the quiescent cells that are able 
to evade therapy. In support of this, it has recently been demonstrated that non- 
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proliferating CD34` BCR-ABL+ cells are resistant to the effects of apoptosis 
inducing stimuli including STI, and that only dividing cells display sensitivity to the 
effects of these agents (Holtz MS, Forman SJ et al. 2005). If quiescent cells can 
re-enter cell cycle then the potential for relapse exists and represents a genuine 
clinical problem. It is still too early to assess whether the remissions due to STI 
therapy will be durable. Evidence from patients who had to stop the drug due to 
complications, suggests that relapse from disease reactivation is a distinct 
possibility. 
Observations in the experiments described in this thesis may have implications in 
the therapeutic context. If quiescence or a non-dividing state allows cells to 
escape the effects of STI, then any treatment that induces quiescence has the 
potential to perpetuate disease. In the experiments described in chapter 5, 
analysis of the most STI-sensitive example revealed an increased recovery of cells 
in the undivided peak as a proportion of the input number, demonstrating that STI 
was exerting an anti-proliferative effect. A similar observation was made by Holtz 
et al. Using a similar FACS sorting strategy, they also found that exposure to 5pM 
STI increased the proportion (relative to the input number) of primitive undivided 
cells (Holtz MS, Slovak ML et al. 2002). In addition, they also observed that 
whereas increased proliferation was inhibited by STI, there was no concomitant 
effect in apoptosis, suggesting that STI was exerting a cytostatic and not a 
cytotoxic effect. 
These data raise concerns in relation to the clinical effectiveness of STI treatment. 
If one of the effects of STI therapy is to reduce the number of committed 
progenitors but also to induce the quiescence of primitive leukaemic stem cells, 
then long-term patient survival may be jeopardised. It has already been 
documented that most patients who achieve a complete cytogenetic response also 
harbour detectable BCR-ABL transcripts, and that molecular remissions are rare 
(Hughes TP, Kaeda J et al. 2003). 
In separate studies not included in this thesis, we have identified combinations of 
STI with other agents that reduce the quiescent fraction in vitro following 
treatment. Evaluation of the effects of treatment on the primitive CD34` BCR-ABL+ 
population revealed that STI in combination with lonafamib, a famesyl transferase 
inhibitor, reduced the number of undivided cells and inhibited their ability to 
proliferate on removal of the drug, which was not observed for other drug 
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combinations (Jorgensen HG, Allan EK et al. 2005). If leukaemic stem cells are 
able to evade STI therapy when they are quiescent, then only combinations of 
agents that induce cell cycle and target CML stem cells in concert are likely to be 
effective. Although there is accumulating evidence to suggest primitive quiescent 
CML stem cells are the most resistant to STI treatment in vitro, it is impossible to 
say if disease persistence in vivo is due to the same cell population. Clearly, in 
vivo stem cells are subject to microenvironmental stimuli impossible to mimic in 
vitro. 
7.5 Gene Expression Profiling of Quiescent Versus 
Cycling Normal and CML Cells 
Comprehensive analysis of gene expression by cDNA microarrays has become an 
important tool for research in many areas. This technology produces a snapshot of 
the gene expression profile of a cell and provides information on the relative levels 
of gene expression between different cells. Microarrays have been used 
extensively in the search for distinctions between subsets of cells; indeed a recent 
Pubmed search on "microarray" yielded over 10,000 references, a testament to 
the universal appeal of this relatively new methodology. Analysis of microarray 
data has moved on from single gene differences to the generation of "molecular 
signatures" or groups of genes consistently changed between samples. However, 
the enormous data sets generated by these types of analyses has emphasised the 
importance of ever more defined cell populations in the generation of meaningful 
data. Recently, microarrays have been used successfully to identify consistent 
gene differences between populations of haemopoietic stem cells (Manfredini R, 
Zini R et al. 2005), and to identify genes associated with CML disease (Nowicki 
MO, Pawlowski P et al. 2003). The potential to identify both known and novel gene 
differences using microarrays, together with the ability to sort very specific cell 
populations (as described in chapter 3), was the rational for the experiments 
presented in chapter 6 of this thesis. 
In an effort to gain insight into the properties of quiescent stem cells such as 
surface markers, receptors, and possible therapeutic targets, gene expression 
profiling was carried out using microarray technology. Utilising the HST and Py 
FACS sorting strategy developed in chapter 3, populations of viable, quiescent 
and cycling stem cells were isolated from normal and CML samples. Five CML 
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and three normal samples were sorted and processed for total RNA. Affymetrix 
GeneChip® U133A arrays were used and the processing carried out at the 
University of Glasgow. Affymetrix arrays were chosen, currently the gold standard 
in array technology, largely due to their stringent internal controls, which minimise 
the potential for false results. These data were analysed by two different methods, 
GeneSpring® and IGA (Iterative Group Analysis). The first level of analysis by 
GeneSpring generated lists of genes with fold change of >3-, >4- and >5-fold 
between comparative groups. Due to the large number of genes changed between 
samples in this study, a minimum arbitrary cut-off of 3-fold was used in the 
GeneSpring analysis. IGA is a recently published method of analysis generating 
gene groups and statistical significance of changed groups, and is particularly 
applicable to small data sets such as this (Breitling R, Amtmann A et al. 2004). 
The largest number of genes changed in this study was between normal quiescent 
(GO) and cycling cells. Analysis showed that these populations exhibited 
significant differences in their expression profiles. One of the most interesting was 
the extent of cell cycle associated genes that were up-regulated in normal cycling 
cells compared to quiescent cells, e. g. MCM2,4,5,6, and 7. CDC2,6,7, and 20, 
Cyclin A2 and E2, PCNA and CDC25. This expression profile verified the sorting 
strategy for the isolation of GO and cycling cells. Interestingly, examination of the 
expression profile of CML GO cells revealed that these cells were much closer in 
expression to both normal and CML cycling cells. Indeed a mathematical model 
(Euclidean distance) of the differences in gene expression of all genes (not just 
cell cycle genes) >3-fold changed, demonstrated that normal GO cells exhibited 
the greatest differences in gene expression when compared to the other three 
groups. 
Further analysis revealed that the differential gene expression in cell cycle genes 
observed for normal GO versus cycling cells was different for CML, indicating that 
CML GO cells were expressing many cell cycle associated genes, notwithstanding 
they appeared in the GO sorting gate. It is possible that overexpression of the 
Hoechst efflux pump ABCG2 in CML cells could have placed them in the GO gate. 
Initial analysis revealed a slight increase in expression of ABCG2 of 1.5-fold in the 
CML GO cells compared with their cycling counterparts. However, this was 
associated with a false discovery rate of 11 %, which suggests this finding was not 
universal for all samples, indicating it was unlikely to be a significant factor. In 
addition, ABCG2 did not appear as statistically significant in the IGA analysis. 
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These findings suggest that CML cells may not be quiescent in the same way that 
normal GO cells are and that they already exhibit activation of a number of cell 
cycle genes. This could explain the results shown in chapter 3 which indicated 
greater cell cycle activation for CML cells in culture compared to normal cells. It 
may be that CML GO cells, although they are not actively dividing, are 'primed' to 
go into division in a way that differs from normal stem cells. 
IGA analysis of the genes up-regulated in the normal cycling versus GO cells 
identified genes associated with DNA replication initiation as the most significantly 
changed gene group. In total, 20 gene groups were identified as significantly 
changed for these samples with mitosis, DNA replication and genes associated 
with early cell cycle events identified as the most important statistically. These 
data again increased confidence in the sorting methodology for isolation of cells in 
different phases of the cell cycle. Conversely, for the CML cycling versus GO cells, 
the top changed group was genes associated with mitosis and spindle formation, 
later cell cycle events, than for the normal cells. These data confirm the 
observation in chapter 3, that in the CML samples, there were significantly more 
cells at the later S/G2/M phase of the cell cycle compared to normal cells, where 
most were in G1. IGA analysis of genes up-regulated in CML GO versus normal 
GO again identified cell cycle genes as significantly changed between these 
groups, indicating increased cell cycle activation in the CML GO cells compared to 
normal GO. These results are in accordance with the work of other groups 
identifying greater cell cycle activation in CML cells (Kramer A, Loffler H et al. 
2001; Kronenwett R, Butterweck U et al. 2005). 
These observations suggest that strategies to induce CML quiescent cells into 
active cell cycle, thereby reducing resistance to drug therapy, may be relatively 
easy if they already exhibit activation of a number of cell cycle genes. This would 
result in more effective bcr-abl+ cell kill by STI. Anecdotal evidence that this may 
occur in vivo comes from studies of patients on STI therapy, who undergo 
concurrent stem cell mobilisation with GCSF to obtain stem cells for future 
autologous transplant. A recent study by Le Coutre's group has shown that 
following simultaneous GCSF mobilisation and STI treatment, one patient 
achieved a complete molecular remission, rare in patients treated with STI alone, 
and that most stem cell harvests were free of detectable BCR-ABL mRNA 
transcripts (Kreuzer KA, Kluhs C et al. 2004). Another recent study concluded that 
GCSF treatment increased the response to STI in 62% of patients. This also 
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included patients with a previous history of extended (median 22 months) STI 
treatment without a major cytogenetic response (CCR), notwithstanding the 
chances of patients achieving CCR after 12 months of therapy is extremely low. 
They concluded that the improved responses were due to reduced neutropenia, 
which allowed sustained STI treatment (Quintas-Cardama A, Kantarjian H et at. 
2004). It would be difficult to reproduce these results in vitro if mobilisation from 
the BM is preceded by induction of cell cycle, before reverting to a quiescent state 
in the PB, as reported by Wright et al, and this is a factor in STI response (Wright 
DE, Cheshier SH et al. 2001). 
Comparison of the significantly up-regulated genes in normal GO versus cycling 
cells yielded a completely unexpected group of chemokine genes as the top 
changed group. The most significantly up-regulated chemokine genes in the 
quiescent cells included CXCL1,2,3,6,8,10,11,13, and CCL19. Interestingly, 
although the ligands were up-regulated, the corresponding receptors were not. 
Many chemokines have been shown to play a role in both positive and negative 
regulation of haemopoiesis. However, cellular context and maturity almost 
certainly influence specific responses to individual and/or combinations of 
chemokines. In addition, it has been shown recently that the effects of the 
chemokine SDF-1 (secreted by BM cells) can selectively reverse the inhibitory 
effect of a range of myelosuppressive chemokines on haemopoietic progenitor 
cells (Broxmeyer HE, Cooper S et al. 2005). This may be one mechanism that 
allows differential responses in a context dependant manner and may represent a 
further level of proliferative control in stem cells. 
To our knowledge, the significance of the up-regulation in chemokine genes 
identified in the microarray study in the maintenance of stem cell quiescence has 
not been reported and as such represents a novel finding. The differential 
expression observed in these samples could be a consequence of GCSF 
mobilisation prior to sample collection, and only a comparison with matched 
samples from resting BM would address this question. Other microarray studies 
that compared BM and MPB have not identified differences in expression of any of 
these chemokine genes. Either there are no differences in expression of these 
genes between BM and MPB, or the subsets we have sorted represent such a 
small proportion that their differential expression is lost in the milieu. 
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A possible explanation for these findings may be that quiescent cells produce 
these chemoattractant chemokines to recruit neutrophils, which in turn increase 
the local concentration of proteases and facilitate exit from the BM niche. 
Surprisingly, CML GO cells also showed up-regulation of the same chemokine 
genes compared to their cycling counterparts, albeit at slightly lower levels than 
normal GO cells. CML patients have not been exposed to GCSF, and it is 
interesting to speculate that perhaps this is one mechanism which allows the 
premature release of CML progenitors into the circulation, characteristic of CML 
disease. In support of this, expression of CXCR4, the receptor for SDF-1 
expressed by stromal cells, was 2.9-fold lower in the quiescent CML cells than in 
normal GO cells, suggesting that these cells display altered adhesive interactions, 
which again may promote their release into the circulation. In addition, Cashman 
et al documented that addition of SDF-1 to normal long-term BM cultures inhibited 
cell cycle entry of primitive quiescent CFC, and the addition of a CXCR4 
antagonist prevented activated CFC from re-entering a quiescent state. 
Interestingly, this effect was not observed for CML CFC and could perhaps be 
explained by the lower levels of CXCR4 expression observed in this study for 
quiescent CML cells (Cashman J, Clark-Lewis I et al. 2002). A recent microarray 
study by Kronenwett et al compared CD34+ cells from CML BM and PB to normal 
CD34+ BM and GCSF mobilised PB. Although these populations are 
heterogeneous compared with the sorted populations we have used, they include 
the subsets we have separated and demonstrate certain similarities. For example, 
these researchers also identified enhanced cell cycle gene expression in the CML 
CD34* cells compared to normal CD34+ cells. In addition they also identified lower 
expression of CXCR4 on CML CD34+ cells compared to normal (Kronenwett R, 
Butterweck U et al. 2005). These findings increase our confidence in the array 
data and further increase the significance of the novel gene expression profiles we 
have identified. To date there is no published data on such specifically isolated 
stem cell populations as those used in this study. Although sample numbers were 
small, sophisticated statistical methods allowed us to generate significant data 
sets, which also identified genes observed in other published gene lists. 
One of the aims of this work was to identify possible CML targets that could be 
exploited in a therapeutic context. Although the analysis so far has not yielded 
specific gene differences that are immediately obvious as targets, the data 
analysis is not complete and will be subject to further investigation. 
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Conclusions and Future Aims 
The data presented in this thesis has focused on isolation of specifically defined 
stem cell populations from normal and CML patients. Culture of CML stem cells 
has identified a population of quiescent cells resistant to a specific targeted 
therapy, analogous to an in vivo population known to evade this therapy. The 
development of FACS sorting strategies allowed separation of stem cell 
populations on the basis of their cell cycle position and enabled microarray 
analysis of these specific cell subsets. Aberrant cell cycle gene expression was 
identified in the CML GO cells compared to normal cells. Importantly, a group of 
chemokine genes was identified as being up-regulated in quiescent cells from both 
normal and CML samples and signifies a novel finding which may be of major 
consequence in the understanding of haemopoietic stem cell biology. 
The data generated by these experiments have both answered and raised a 
number of questions. It is clear that a quiescent phenotype, especially in malignant 
cells, confers certain survival advantages. It is also apparent that some therapies 
induce quiescence, exacerbating the problem of disease persistence. Microarray 
analysis has yielded a significant amount of data, which has yet to be fully 
analysed. The results presented in this thesis represent the first round of analysis 
and further work will almost certainly identify other genes of significant importance. 
The unexpected up-regulation of a cohort of chemokine genes in quiescent cells 
deserves further investigation. One of the first questions is whether this is a 
product of G-CSF mobilisation. This will be addressed by examining gene 
expression in sorted, quiescent BM stem cells, initially by real time PCR and 
possibly by microarrays. Independent validation of the genes identified by 
microarrays will be required and this will be done by real time PCR, to enable 
relative quantitation of gene expression. The limited amount of patient material 
obtained following the stringent sorting reduces the opportunities for further 
experimentation. 
Some of these problems could be resolved by repeating the experiments in an 
animal model e. g. mouse. If microarray results for normal cells can be reproduced 
in the murine system it is anticipated that a considerable amount of data regarding 
normal stem cell biology would be obtained. Furthermore, these data could be 
used to identify possible targets in CML quiescent cells, which could be exploited 
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to increase the effectiveness of cytotoxic therapies. We anticipate experiments 
essential to verify biological function will be performed. For the chemokines 
identified, ELISA or protein analysis would confirm their presence in cultures of 
quiescent versus cycling cells. Once again the problem of limited patient material 
restricts the options for further experimentation, which could also be resolved by 
using an animal model. There is no doubt that studies which elucidate stem cell 
properties contribute appreciably to our understanding of malignant stem cell 
disease. 
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Experiment report 
Software 
This refers to software that actually runs the whole analysis 
automatically. In particular it: 
"" Generates a directory structure for a project and its 
experiments 
"" Manages the security of the project 
"" Performs RMA low-level analysis 
"" Performs RP identification of differentially expressed genes 
for a number of between-group comparisons 
"" Functionally annotates the list of RP-identified top genes 
"" Performs iGA to find differentially expressed functional 
classes of genes (written by Rainer Breitling). 
"" Presents the RP and iGA results in form of web pages 
and/or downloadable tab-delimited text files suitable for reading 
in Excel. 
The software has been written and implemented by Pawel Herzyk in 
the Autumn 2003 - Spring 2004. 
Project 
Project refers to data that belongs to a particular researcher or a group 
of researchers. Each PI (principal investigator) can only have one 
project that can be divided into many experiments. Each project has 
associated: 
" Name - this is usually constructed from the PI's name e. g. 
j ohn_dav would be a name of a project owned by John Davis. 
. Class - this could be Microarray or Proteomics 
"" Type - e. g. Affymetrix or spotted depending on the 
type of microarrays used 
Experiment 
Each project can be divided into experiments. Each experiment 
contains data from a number of replicated (or not) samples 
corresponding to different conditions. 
Array 
This refers to an identifiable type of array e. g. U133 is the Affymetrix 
human array HG-U 133. 
Chip 
Some Affymetrix arrays may consist of several subarrays. E. g. HG- 
U133 array is in fact represented by two arrays HG-U133A and HG- 
U133B. In this case we say that the array has two chips A and B. If the 
array has only one chip it is denoted as N (for none). 
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Normalisation 
This really is a shorthand for low-level analysis. In case of Affymetrix 
data this consists of 
" Background correction 
" Multichip normalisation on the probe level 
" Summary of the log-normalised probe level data into a 
probe-set level data 
By default we use Robust Multichip Average (RMA) method 
implemented in module Affe in the Bioconductor microarray analysis 
software. 
Differential Expression 
A method of identification of differentially expressed genes between 
two groups of replicated samples. We use the RankProducts 
method(RP) developed in University of Glasgow. 
Differentialy expressed gene classes 
A method for identification of functional gene classes that are 
differentially expressed in a given comparison. We use the Iterative 
Group Analysis method developed in the University of Glasgow. 
Baseline 
For every comparison between two groups of replicated samples we 
select one of the groups as a reference (baseline). This is usually done 
upon suggestion from a researcher who owns the data. 
Treatment 
This refers to the group of replicated samples that has not been 
selected as baseline. The software analyses the expression of a 
treatment group with respect to the baseline. 
Direction 
This refers to the direction of the differential expression of the 
treatment with respect to the baseline: 
"" Positive - means a list of genes with significantly higher 
expression in the treatment group than in the baseline group 
"" Negative - means a list of genes with significantly lower 
expression in the treatment group than in the baseline group 
RPhtml 
Results of RP in html format 
RPtext 
Results of RP in tab-delimited text format 
iGAcla 
Results of iGA in Classic mode (html format). Look at paragraph Mode 
in section iGA report for more explanations. 
iGArep 
Results of iGA in Representative mode (html format). Look at 
paragraph Mode in section iGA report for more explanations. 
RP report 
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Comparison 
This refers to a comparison between two groups of replicated samples. 
E. g.: Samples: A, B, C vs samples: D, E, F means that samples 
A, B, C correspond to the treatment group and D, E, F correspond to the 
baseline group. 
Probe-set ID 
The Affymetrix probe-set identificator 
RPscore 
This is a measure of differential expression calculated by the RP 
method. For every gene this is calculated as a geometric mean of fold- 
change ranks over the number of all possible between-chip 
comparisons contributing to a given between-group comparison. 
FDR 
This is a conservative estimate of False Discovery Rate. If you cut the 
differentially expressed gene-list at the particular position associated 
with a particular FDR then it shows the expected percentage of false 
positives. 
FCrma 
Before FunAlyse version 1.4.1 this is a mean fold-change over all 
possible between-chip comparisons contributing to a given between- 
group comparison. 
From FunAlyse version 1.4.1 onwards this is calculated as an antilog of 
a mean log-fold-change over all possible between-chip comparisons 
contributing to a given between-group comparison. 
In both cases if you have two groups of three Affymetrix chips the 
FCrma is calculated over all nine comparisons. 
FCnom 
It has been demonstrated in the experiment where selected genes 
were spiked-in at known concentrations on the HG-U95A chip that the 
fold-changes calculated after RMA low-level analysis are significantly 
lower than the nominal fold-changes calculated from the spiked-in gene 
concentrations. The relation between these two fold-changes was 
calculated by a fitting procedure: 
log2(rma FC) = 0.61 x log2(nominal FC) 
Consequently, the FCnom corresponds to the mean nominal fold- 
change obtained from the rma fold-changes using the above equation 
over all possible between-chip comparisons contributing to a given 
between-group comparison. Please, treat it with caution as it is not 
known how universal the above equation is. Consult Figure 6 in the 
original paper Cope et al. 2003 (PubMed abstract . 
Gene annotation database 
This is a database that contains functional annotation of your genes. 
Every gene in the reported list of differentially expressed genes has a 
hyperlink to it. Currently, we use the following databases: 
" Human, Mouse and Rat - SOURCE database 
" Arabidopsis - MIPS and TAIR databases 
Drosophila - FlyBase 
Yeast - SGD database 
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Gene symbol 
Common gene symbol used by biologists. 
Gene ID 
Publicly used gene identificator. 
Title 
Short functional annotation of a gene. This is very brief, you shouldn't 
rely on it too much. 
iGA report 
Mode 
The iGA module in the FunAlyse software can work in two modes: 
Classic - all probe-sets on the chip are taking part in the iGA 
calculations. Representative - only one probe-set per gene is 
selected. This is to remove a bias towards a particular groups in case 
more then one probe-set represent a gene contributing to this group. A 
probe set producing the best RPscore in a given comparison 
(calculated seperately for positive and negative expression) is selected 
as a representative for that gene. The non-redundant set of genes is 
defined differently for different organisms. For Human, Mouse and Rat 
they are defined using Unigene IDs, for Arabidopsis and Yeast they are 
defined on the base of gene IDs whilst for Drosophila it is based on 
gene symbols. 
Number of probe-sets on the chip 
A number of Affymetrix probe-sets on a given chip. In the Classic 
mode some probe-sets may refer to the same gene. 
Number of annotated probe-sets 
A number of probe-sets on a given chip that have functional annotation 
in the current Affymetrix annotation file that has been used for 
functional group construction. 
Number of groups 
A total number of functionally annotated gene-groups. They are pre- 
constructed independently of the microarray experiment. Usually we 
use GeneOntology (GO) annotations present in the Affymetrix 
annotation file but you may advise us to use other annotation sources. 
Number of singletons 
A number of functionally annotated gene-groups that contain a single 
gene. These are not particularly useful for iGA. 
Significance threshold 
A threshold for P-value changed. P-values lower than the threshold 
are considered statistically significant. (see also P-value changed) 
File Name 
A name of the input file that contains full list of genes sorted by 
RankProducts score RPscore that is our measure of gene differential 
expression. 
Annotations 
This is a name of the Affymetrix functional annotation file used for the 
functional group construction. 
Top changed groups 
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A list of significantly differentially expressed gene-groups. 
Group Members 
Number of probe-sets that belong to a particular group. 
Changed Members 
Number of group members that have actually contributed to achieving 
a given P-value changed for this group. 
P-value changed 
This tells you what is a probability of a random event that'that many' of 
changed members out of 'that many' group members has been 
found 'that high' on the RP list of 'that many' sorted genes. This is 
calculated from the hyper-geometric distribution. Consult Figure 1 in 
the original paper 
P-value 
Going down from the top of the RP list, for every encountered subset of 
a particular gene group we calculate the p-value that tells you how 
probable a random event is that such subset was found 'that high' on 
the RP list. This is calculated from the hyper-geometric distribution. In 
this context P-value changed is a smallest p-value over all the above 
subsets. Consult Figure 1 in the original paper 
Percent changed 
This is simply changed members over group members times 100. 
Rank 
This is rank of a particular gene in the list of differentially expressed 
genes. This list was created from the RP list by exclusion of genes that 
are not assigned to the functional gene-groups. 
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iGA report on the differentially expressed functional gene 
classes: up-regulated CML GO vs Normal GO 
General 
Mode Representative 
12698 
9533 
3991 
1649 
Number of genes on chip 
Number of annotated genes 
Number of groups 
Number of singletons 
Significance threshold 
File name 
F 2.5e-04 
TCML GO Vs N GO 
Top Changed Groups 
Group Changed P-Value Percent 
Members Members Changed Changed 
5833 - hemoglobin complex 935.7e-10 33.33 
------------ --------- 
- oxygen transport 935.7e-10 33.3i-- 15671 
5344 oxygen transporter 11 3 1.1 e-09 27.27 activity 
7067 - mitosis 74 7.7e-09 
[ 12.16 
5819 -spindle 11 4 . 
5e-06 36.36 
79 - regulation of cyclin 
dependent protein kinase 34 5 3.0e-06 14.71 
activity 
6260 - DNA replication 76 7 9.8e-06 9.21- 
9440 - cyanate catabolism 224.4e-05 100.00 
4792 - thiosulfate 224.4e-05 100.00 
sulfurtransferase activity 
5638 - lamin filament 222.3e-04 100.00 
9113 - purine base biosynthesis 
r442.4e-04 100.00 
Changed group breakdown: 
P- Probe-set Gene 
Group 
value ID 
Rank Gene ID Symbol Title 
5833- 
hemoglobin 04 209116 x at 
1 M25079 HBB hemoglobin, beta 
complex 
707 213515 x at 2 Al133353 j HBG1 hemoglobin, gamma A 
show the whose group 
53e- 206834 at 
-1 
3 ; NM 000519 10 HBD hemoglobin, d delta 
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15671 - oxygen 
transport 
9.4e- 209116 x 04 at 1 M25079 HBB hemoglobin, beta 
7 9e- 
. 07 2x 07 at 2 AI133353 HBG1 hemoglobin, gamma A 
5 
show the whole group 206834 10 at 3 NM 000519 HBD hemoglobin, delta 
5344 - oxygen 1_ 
transporter 03 209116 x 
1 
at 1 M25079 HBB hemoglobin, beta 
activity 
1.2e- 213515 x 06 at 
2 Al133353 HBG1 hemoglobin, gamma A 
show the whole group 
F1 ý9 - 206834 at 3 
! NM 000519 HBD hemoglobin, delta 
7067 - mitosis 
8.9e- 
1 202870 s at 12 NM 001255 CDC20 
CDC20 cell division cycle 20 
homolog (S. cerevisiae) 
1 Oe- f 
. 02 202705 at 
20 NM 004701 CCNB2 cyclin B2 
103- ( 203213 at 28 AL524035 CDC2 cell 
division 
and G21to21ýG1 
to S 
2 Oe- 
04 219306 at 
38 NM 020242 KNSL7 kinesin-like 7 
r- -- 
3 6e SMC2 structural maintenance 
. 204240 s at 49 NM 006444 SMC2L1 of chromosomes 2-like 1 05 (yeast) 
2.7e- 203968 s at 52 NM 001254 CDC6 
CDC6 cell division cycle 6 
06 homolog (S. cerevisiae) 
1 9e- 
. 204695 at 55 AI343459 CDC25A cell division cycle 25A 
. 
1e 1218662 s at 57 NM 022346 HCAP-G 
chromosome condensation 
08 protein G 
BUBI budding uninhibited by 
show the whole group 
7 7e- 209642 09 at 
78 AF043294 BUB1 benzimidazoles 1 homolog 
(yeast) 
5819 - spindle 
1.4e-1 202870 s at 12 NM 001255 CDC20 
CDC20 cell division cycle 20 
02 homolog (S. cerevisiae) 
5.5e- 207828 s 
( 
at 31 NM 005196 CP 
centromere protein F, 
04 350/400ka (mitosin) 
3.6e- 204444 at 59 NM 004523 KIF11 kinesin family member 11 05 
1 5e- 
show the whole group 06 217879 at 
81 AL566824 CDC27 cell division cycle 27 
79 - regulation of c clip-de endent kinase 
cyclin dependent 1.0e- 1209714 s at 30 AF213033 CDKN3 inhibitor 3 (CDK2-associated 
protein kinase 01 dual specificity phosphatase) 
activity 
6.4e- 218723 s at 34 NM 014059 RGC32 response gene to complement 03 32 
1 8-1 P-203968 s at 52 NM 001254 CDC6 [ Cfl A cell riivicinn nvnla F 
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04 homolog (S. cerevisiae) 
4 
05 204695 at 55 A1343459 CDC25A cell division cycle 25A 
show the whole group 
3. Oe 205394 at 65 I NM 001274 CHEM 
CHK1 checkpoint homolog (S. 
06 pombe) 
660DNA 0 3.2e- 209773 s at i 4 B0001886 RRM2 reductase 
tase M2 ribonucleotide 
replication 2 PoyP P e 
6 203968 
-- 
s at 52 
, 
NM 001254 CDC6 
_ CDC6 cell division cycle 6 
02 homolog (S. cerevisiae) 
MCM5 minichromosome 
1.0e- 201755 at 56 , NM 006739 MCM5 
maintenance deficient 5, cell 
02 division cycle 46 (S. 
cerevisiae) 
2.5e- 205909 at 72 NM 002692 POLE2 polymerase 
(DNA directed), 
03 epsilon 2 (p59 subunit) 
[6.3e- 
204127 at 87 B0000149 RFC3 replication 
factor C (activator 
04 1) 3,38kDa 
8 7e- 204767 s at 92 B0000323 FEN1 
flap structure-specific 
05 endonuclease 1 
snow the wh 204126 s at 95 
' NM 003504 CDC45L CDC45 cell division cycle 45- 
U° 11Ke ko. cerevisiae) 
03 
thiosulfate sulfurtransferase 9440 - cyanate te 2.7 e- 209605 at 13 D87292 TST (rhodanese) 
4.4e- 1203524 
s at 64 NM 021126 MPST mercaptopyruvate 05 sulfurtransferase 
4792 - thiosulfate 
sulfurtransferase 
2.7e- 209605 at 13 D87292 TST 
thiosulfate sulfurtransferase 
activity 
03 (rhodanese) 
4.4e- 203524 s at 64 NM 021126 MPST mercaptopyruvate 05 sulfurtransferase 
5638 - lamin 3.8e- 1203411 s at 18 NM 005572 LMNA lamin A/C filament 03 
2.3e- 203276 at 109 NM 005573, LMN61 lamin B1 04 
phosphoribosylaminoimidazolE 
9113 - purine 7.8e- carboxylase, base 02 201014 s at ! 191 NM 006452 PAICS phosphoribosylaminoimidazolE b biosynthesis succinocar oxamide 
synthetase 
7.7e- 214431 at 347 
ý NM 003875 GMPS guanine monphosphate 03 synthetase 
phosphoribosylglycinamide 
formyltransferase, 
7.3e- 212378 at 492 NM 000819 j GART phosphoribosylglycinamide 04 synthetase, 
phosphoribosylaminoimidazole 
synthetase 
705 A1457 433 2 I phosphoribosyl pyrophosphate s at 04 
209 120 PPAT 
amidotransferase 
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iGA report on the differentially expressed functional gene 
classes: up-regulated Normal GO vs CML GO 
General Information 
'_; 
t'n 
'r 
Functional 
Genomics 
Facility J 
4' 
Top Changed Groups 
19884 - antigen presentation, 
exogenous antigen 
19886 - antigen processing, 
exogenous antigen via MHC 
class II 
45012 - MHC class II receptor 
activity 
8009 - chemokine activity 
6935 - chemotaxis 
9596 - detection of pest, 
pathogen or parasite 
Mode Representative 
Number of genes on chip 12698 
Number of annotated genes 9530 
Number of groups F 3988 
Number of singletons T 1644 
Significance threshold 2.5e-04 
File name I 1N GO vs CML GO 
Group r Changed P Value Percent 
Members Members Changed Changed 
13 5 7.1e-12 38.46 
14 5 1.6e-11 35.71 
14 5 16e-11 35.71 
-- r- 40 ------------ 7 - 8.9e-08 [ 17.50 
- -- -- 86 -- ------ 7 - ----- 1. e-5 8.14 
4 2 7.4e-05 50.00 
Changed group breakdown: 
Group P-value 
Probe-set Rank Gene ID 
Gene 
Title 
ID Symbol 
19884 - major 
antigen 
presentation, 1.4e-03 209480 at 11 M16276 
HLA- histocompatibility 
DQB1 complex, class II, 
exogenous DQ beta 1 
antigen 
major 
2e-06 X212671 s at '3 BG397856 
HLA- histocompatibility 
5 . DQA1 complex, class II, 
DQ alpha 1 
HLA- major 
9e-09 213831 at 4 X00452 
DQA2 /// histocompatibility 7 
. HLA- complex, class II, 
DQA1 no atnha 9 /// 
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major 
histocompatibility 
complex, class II, 
DQ alpha 1 
major 
HLA- histocompatibility 
2.4e-1 1 209728 at 5 B0005312 DRB4 complex, class II, 
DR beta 4 
major 
show the whole 7.1e-12 213537 at 7 Al128225 
HLA- histocompatibility 
group DPA1 complex, class II, 
DP alpha 1 
19886- 
antigen 
---- 
major 
processing, HLA- histocompatibility 
exogenous 
1.5e-03 209480 at 1 M16276 DQB1 complex, class II, 
antigen via DQ beta 1 
MHC class II 
major 
6.0e-06 212671 s at 3 BG397856 
HLA- histocompatibility 
DQAI complex, class II, 
DQ alpha 1 
major 
histocompatibility 
HLA- complex, class II, 
1. Oe-08 213831 at 4 X00452 
DQA2 /// ! DQ alpha 2 /// 
HLA- major 
DQA1 histocompatibility 
complex, class II, 
DQ alpha 1 
r-- ----- major 
HLA- histocompatibility 
3.5e-11 209728 at 5 B0005312 DR64 complex, class II, 
DR beta 4 
major 
show the whole 1.6e-11 213537 at 7 A1128225 
HLA- histocompatibility 
group DPA1 complex, class II, 1 DP alpha 1 
--r major 45012 - MHC 
class II 1.5e-03 209480 at 1 M16276 
HLA- histocompatibility 
receptor DQB1 complex, class II, 
activity DQ beta 1 
major 
HLA- histocompatibility 
6. Oe-06 
r212671 
sat 3 BG397856 DQA1 complex, class II, 
DQ alpha 1 
major 
HLA- histocompatibility 
complex, class II, 
1. Oe-08 213831 at 4 X00452 
DHLA /ll DQ alpha 2 /ll 
DQA1 major histocompatibility 
cömnIPx class II 
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DQ alpha 1 
major 
3.5e-11 209728 at 5 B0005312 
HLA histocompatibility 
DRB4 complex, class II, 
DR beta 4 
major 
show the whole 1.6e-11 213537 at 7 Al128225 
HLA- histocompatibility 
group DPA1 complex, class II, 
DP alpha 1 
8009 
chemokine 9.2e-02 210163 at 23 AF030514 CXCL11 
chemokine inine e (C-X-C 
ligand 11 
activity 
1.5e-02 204533 at 45 NM 001565 CXCL10 chemokine 
(C-X-C 
motif) ligand 10 
9.8e-04 209774 x at 47 M57731 CXCL2 chemokine 
(C-X-C 
motif) ligand 2 
chemokine (C-X-C 
1.4e-04 205242 at 64 NM 006419 CXCL13 motif) 
ligand 13 
(B-cell 
chemoattractant) 
chemokine (C-X-C 
motif) ligand 6 
1.2e-05 206336 at 73 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
chemokine (C-X-C 
motif) ligand 1 
1.9e-06 204470 at 91 001511 CXCL1 (melanoma growth 
stimulating activity, 
alpha) 
show the whose 92 NM 002090 CXCL3 chemokine (C-X-C 8.9e-08 207850 at uot> motif) ligand 3 
6935 - chemokine (C-X -C 1.9e-01 210163 at 23 AF030514 CXCL11 
chemotaxis motif) ligand 11 
r6.2e-02 
204533 at 45 NM 001565 CXCL10 
chemokine (C-X-C 
motif) ligand 10 
8.6e-03 1209774 x at 47 M57731 
chemokine (C-X-C CXCL2 
motif) ligand 2 
chemokine (C-X-C 
2.6e-03 205242 at 64 NM 006419 CXCL13 motif) 
ligand 13 
(B-cell 
chemoattractant) 
chemokine (C-X-C 
motif) ligand 6 
4.9e-04 206336 at 73 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
chemokine (C-X-C 
204470 at 91 NM 001 motif) 
ligand 1 1.6e-04 511 CXCL1 (melanoma growth 
stimulatinn antivity 
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alpha) 
show roerwhole 1.8e-05 207850 at 92 I NM 002090 CXCL3 chemokine 
(C-X-C 
motif) ligand 3 
9596- 
detection of major 
pest, 1.4e-02 203932 at 33 NM 002118 HLA- histocompatibility 
pathogen or DMB complex, class II, 
parasite DM beta 
- ---i -ý 
major 
show the whole 7 4e-05 217478 s at 34 X76775 
HLA- histocompatibility 
group DMA complex, class II, 
i DM alpha 
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iGA report on the differentially expressed functional gene 
classes: up-regulated CML Divided vs Normal Divided 
L J L C b Jý ___ 
General Information 
Mode 
Number of genes on chip 
Number of annotated genes 
Number of groups 
Number of singletons 
Significance threshold 
File name 
Representative 
12698 
9532 
3990 
1648 
2.5e-04 
TCML DIV vs N DIV 
Top Changed Groups 
Group Changed P-Value Percent 
Members Members Changed Changed 
F 2.0e-06 36.36 5819 - spindle 11 F4 
626i-- DNA topological 17211.4e-04 28.57 
change I 
,, nangeu group uredKuuwn- 
Grou P-value 
Probe-set Rank Gene ID SGymbol Title p 
centromere protein 5819- 
pindle 
4.0e-02 207828 s at 35 ; NM 005196 CENPF F, 350/400ka s (mitosin) 
1.2e-03 204444 at 46 {NM 004523 KIF11 
kmembeam1y 
- ---- ---- --- cell division cycle 3.8e-05217878 sat 60 A1203880 CDC27 27 
CDC20 cell 
show the whole 2.0e-06 202870 s at 
I 
87 NM 001255 CDC20 
1 division cycle 20 
group I homolog (S. 
cerevisiae) 
6- DNA 265 topoisomerase 
topological 1.3e-02 201292 at 18 AL561834 TOP2A (DNA) II alpha 
change 170kDa 
show the whole topoisomerase 
group 1.4e-04 208900 s at 25 AW025108 TOP1 (DNA) 
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iGA report on the differentially expressed functional gene 
classes: up-regulated Normal Divided vs CML Divided 
General Information 
Mode Representative 
--- ' Number of genes on chip 12698 
Functional Number of annotated genes 9532 
Gnonsics _- --- 
Facility Number of groups 3988 
Number of singletons 1646 
s"-' Significance threshold 2 5e-04 . 
ý, ý--= File name TN DIV vs CML DIV 
Group Changed P-Value Percent Top Changed Groups Members 
I 
Members Changed Changed 
19884 - antigen presentation, 13 7 2. Oe-12 53.85 exogenous antigen 
19886 antigen processing, 
exogenous antigen via MHC 14 6 2.9e-1 1 42.86 
class II 
45012 - MHC class II receptor 
activity 
14 6 2.9e-11 42.86 
8009 - chemokine activity 40 8 5.7e-09 20.00 
6935 - chemotaxis 86 8 6e-06 9.30 
9596 - detection of pest, 4 2 1.9e-04 50 00 
pathogen or parasite . 
Changed group breakdown: 
Group P-value 
Probe-set Rank Gene ID Gene ID Symbol 
h 
400QA 
major 
I IJU V- HLA- complex, class II 
antigen nnn--) iii nn ni., º, n ýýý 
presentation, 1.4e-03 213831 at 1 X00452 
exogenous 
HLA- 
antigen 
DQA1 
1.7e-06 209480 at 2 M16276 qHLA- B1 
HLA- 7.9e-09 212671 s at 4 BG397856 DQA1 
vý. [ cý1r1iCI c. ni 
major 
histocompatibiliý 
complex, class II 
DQ alpha 1 
major 
histocompatibility 
complex, class II, 
DO beta 1 
major 
histocompatibility 
complex, class II, 
DQ alpha 1 
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major 
6.3e-09 209728 at 18 B0005312 
HLA- histocompatibility 
DRB4 complex, class II, 
DR beta 4 
-___--- major 
HLA- histocompatibility 1.8e-10 211991 s at 28 M27487 DPA1 complex, class II, 
DP alpha 1 
major 
HLA- 
1.2e-1 1 208894 at 31 M60334 
histocompatibility 
DRA complex, class II, 
DR alpha 
major 
show the whole 2.0e-12 201137 s at 50 NM 002121 
HLA- histocompatibility 
group DPB1 complex, class II, 
DP beta 1 
major 
19886 - histocompatibility 
antigen HLA- complex, class II, 
processing, 1.5e-03 213831 at 1 X00452 
DQA2 DQ alpha 2 
major exogenous HLA- 
antigen via DQA1 histocompatibility 
MHC class II complex, class II, 
DQ alpha 1 
major 
HLA- histocompatibility 
2.0e-06 209480 at 2 M16276 DQB1 complex, class II, 
DQ beta 1 
major 
1.0e-08 
1212671 
s at lH 
LA 
4 BG397856 
histocompatibility 
DQA1 complex, class II, 
DQ alpha 1 
major 
8.8e-09 209728 at 18 B0005312 
HLA- histocompatibility 
DRB4 complex, class II, 
DR beta 4 
----f-----. _---- - major 
3.1e-10 211991 s at 28 M27487 
HLA- histocompatibility 
DPA1 complex, class II, 
DP alpha 1 
major 
HLA- histocompatibility 
show the whole 
ý 
M60334 
group 
2.9e-1 1 208894 at 31 DRA complex, class II, 
DR alpha 
major 
histocompatibility 
45012 - MHC 
HLA- complex, class II, 
class II 1.5e-03 213831 at 1 X00452 
DQA2 DQ alpha 2 
receptor HLA- major 
activity DQA1 histocompatibility 
complex, class II, 
DQ alpha 1 
2. Oe-06 209480 at 2 M16276 HI A- mainr 
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DQB1 histocompatibility 
complex, class II, 
DQ beta 1 
major 
1.0e-08 1212671 s at 4 BG397856 
HLA- histocompatibility 
DQA1 complex, class II, 
DQ alpha 1 
ý _I 
major 
8.8e-09 209728 at 18 B0005312 
HLA- histocompatibility 
DRB4 complex, class II, 
DR beta 4 
major 
HLA- histocompatibility 3.1e-10 ! 211991 s at 28 M27487 DPA1 complex, class II, 
DP alpha 1 
major 
show the whole 2.9e-11 208894 at 31 M60334 
HLA- histocompatibility 
group DRA complex, class II, 
DR alpha 
8009 [NM 
chemokine (C-X-C 
chemokine 4.5e-02 204533 at 11 001565 CXCL10 motif) ligand 10 
activity 
2.8e-03 
1 
210163 at 19 1 AF030514 
r CXCL11 chemokine (C X-C 
motif) ligand 11 
x at 35 NM 000584 lL8 r 202859 4.1 e-04 interleukin 8 
rr chemokine (C-X-C 
motif) ligand 1 
4.5e-05 204470 at 48 I NM 001511 CXCL1 (melanoma growth 
stimulating activity, 
alpha) 
chemokine (C-X-C 3.6e-06 207850 at 57 NM 002090 CXCL3 motif) ligand 3 
chemokine (C-X-C 3.1 e-07 i 209774 x at 
r67 
M57731 CXCL2 
motif) ligand 2 
chemokine (C-X-C 
motif) ligand 6 
4.4e-08 206336 at 83 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
show the whole 5.7e-09 
r 
210072 a9 8 U88321 
[ 
CCL19 chemokine 
(C-C 
group motif) ligand 19 
6935- 9.5e-02 204533 at 11 NM 001565 CXCL10 chemokine 
(C-X-C 
chemotaxis motif) ligand 10 
1.2e-02 210163 at r 19 AF030514 CXCL11 chemokine (C-X-C motif) ligand 11 3.8e-03 202859 x at I 35 NM 000584 IL8 interleukin 8 
chemokine (C-X-C 
motif) ligand 1 8.9e-04 204470 at 48 NM 001511 CXCL1 (melanoma growth 
Stimulatinn artivity 
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alpha) 
04 207850 57 ! NM chemokine (C-X-C 1.5e- at 002090 CXCL3 
motif) ligand 3 
2.9e-05 209774 x at 67 M57731 CXCL2 chemokine 
(C-X-C 
motif) ligand 2 
chemokine (C-X-C 
motif) ligand 6 
9.1e-06 206336 at 83 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
show the whole 2.6e-06 210072 at 98 U88321 CCL19 chemokine (C 
C 
group motif) ligand 19 
9596- 
detection of 
pest, 2.2e-02 203932 at 52 NM 002118 
HLA- 
major 
histocompatibility 
DMB complex, class II, 
pathogen or DM beta 
parasite 
show the whole 9e-04 1 217478 s at 54 X76775 
HLA- 
major 
histocompatibility 
group . DMA complex, class II, 
DM alpha 
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iGA report on the differentially expressed functional gene 
classes: up-regulated Normal Divided vs Normal GO 
General Information 
Mode Representative 
Number of penes on chip 12698 
------ -------- ----- Number of annotated genes 9532 
Number of groups F 3990 
Number of singletons I 1648 
Siqnificance threshold 2.5e-04 
File name 1N DIV vs N GO 
Top Changed Groups 
Group Changed ý'_ P-Value Percent 
Members Members Changed Changed 
6270 - DNA replication initiation 17 7 1.4e-10 41.1-8-- 
7.067 - mitosis 
1 74 11 r 1.5e-10 14.86 
6260 - DNA replication 76 11 1.7e-10 14.47 
8094 - DNA-dependent ATPase 13 
- ---- 
6 
- ---- - 
6.3e-10 
- 
46 15 activity . 
79 - regulation of cyclin 
I 
dependent protein kinase 34 6 1.4e-07 17.65 
activity 
6281 - DNA repair 96 
_ 9 _ P6. Oe-07 9.38 
5660 -delta-DNA polymerase 3 3 8.7e-07 - 100 00 
cofactor complex . 
3684 - damaged DNA binding 35 6 1.2e-06 
r 17.14 
5833 - hemoglobin complex 9 3 2.1e-06 33.33 
15671 - oxygen transport 9 3 2.1 e-06 33.33 
5344 - oxygen transporter 11 3 4.1 e-06 27 27 activity i . 
4(4ö - rioonucieosiue- 2 2 1 le-05 100 00 
diphosphate reductase activity . . 
7089 - traversing start control 6 3 1 5e-05 50 00 
point of mitotic cell cycle j . . 
r76 
- DNA replication checkpoint 4 2 2.3e-05 50.00 
776 - kinetochore 14 3 2.6e-05 21.43- 
5876 - spindle microtubule 4 2 4.0e-05 
x50.00 
8156 - negative regulation of 4 2 4 6e-05 00 50 DNA replication . . 
Susan M Graham 2005 
6189 -'de novo' IMP 
thesis bi 
3 3 
osyn 
9113 - purine base biosynthesis 4 4 
5762 - mitochondrial large 4 4 
ribosomal subunit 
166 - nucleotide binding 91 6 
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1.8e-04 100.00 
2.2e-04 100.00 
2.2e-04 100.00 
2.4e-04 6.59 
replication 
3.3e- j 204126 s at 19 
I 
NM 003504 CDC45L CDC45 cell division cycle 45-like 
initiation 1 
02 (S. cerevisiae) 
2.6e- 
MCM2 minichromosome 
03 202107 s at 
43 NM 004526 MCM2 maintenance deficient 2, mitotin 
(S. cerevisiae) 
MCM4 minichromosome 7.3e- 222037 at 47 A1859865 MCM4 maintenance deficient 4 (S. 05 i 
cerevisiae) 
1 4 ma maintenance 6 MISS . e 201930 at 49 NM 005915 MCM6 ( 06 i homolog, S. pombe) (S. 
cerevisiae) 
5 61 AA807529 MCM5 
MCM5 minichromosome 
i t 08 216237 s at n ma enance deficient 5, cell 
division cycle 46 (S. cerevisiae) 
83 AF279900 MCM7 
MCM7 minichromosome 
i t 
09 210983 s at ma n enance deficient 7 (S. 
cerevisiae) 
show the whole group 
[14 
, 204510 at 88 NM 003503 CDC7 
CDC7 cell division cycle 7 (S. 
10 cerevisiae) 
3.1e 203213 7067 - mitosis at 4 AL524035 CDC2 . 
cell division cycle 2, G1 to S and 
G2 t M 02 o 
1.2e-202870 
s at 7 NM 001255 CDC20 
CDC20 cell division cycle 20 
li 03 homolog (S. cerevisiae) 
7.1e- 203968 s at 11 NM 001254 CDC6 
ion cycle 6 CDC6 cell division ll -ivi 
05 homolog (S. cerevisiae) 
4 3e 
. 202705 at 15 NM 004701 CCNB2 cyclin B2 06 
0 3. e- 219306 06 at 
30 NM 020242 KNSL7 kinesin-like 7 
[7e-142 
at 33 AF043294 BU 131 
BUB1 budding uninhibited by 
07 benzimidazoles 1 homolog (yeast) 
- -- 1.1 e- -- ý - 7 
--- - 
8 MAD2L1 MAD2 mitotic arrest 
deficient-like 1 
NM 0023 203362 s 
( ý08 
at 3 5 (yeast) 
. 
Oe 203418 
ý 
at 
-39 
NM 001237 CCNA2 A2 c 10 
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BUB1 budding uninhibited by 1.9e- 203755 at 41 NM 001211 BUB1B benzimidazoles 1 homolog beta 10 
(yeast) 
1.6e- 
10 204695 at 42 A1343459 CDC25A cell division cycle 25A 
1.5e- 1218662 
sat 45 NM 022346 HCAP-G chromosome condensation protein show the whole group 10 G 
6260 - DNA 8.0e- ribonucleotide reductase M2 
replication 03 
209773 s at 1 B0001886 RRM2 polypeptide 
3.3e- 203968 s at 11 NM 001254 
CDC6 cell division cycle 6 
03 CDC6 homolog (S. cerevisiae) 
204126 s at 
CDC45 cell division cycle 45-like 19 NM 003504 CDC45L 
04 (S. cerevisiae) 
replication factor C (activator 1) 3, 205 204127 at 21 B0000149 RFC3 38kDa 
6.7e- DNA re lication complex GINS 
07 221521 s at 
22 B0003186 Pfs2 pp 
protein PSF2 
6Ö8 208955 at 28 AB049113 DUT dUTP pyrophosphatase 
3.6e- Ir 31 NM 004111 
flap structure-specific 204768 s at 09 
FEW 
endonuclease 1 
ribonucleotide reductase M1 11 210.2e 32 NM 001033 ! RRM1 
polypeptide 
1.8e- 
MCM2 minichromosome 
10 202107 s at 
43 NM 004526 MCM2 maintenance deficient 2, mitotin 
(S. cerevisiae) 
1.7e- 205909 at I 46 NM 0026921 POLE2 
polymerase (DNA directed), 
10 epsilon 2 (p59 subunit) 
MCM4 minichromosome 
( show the whole group 
1.7e- 222037 at 47 AI859865 MCM4 maintenance deficient 4 S. 10 
cerevisiae) 
8094 - DNA- 5 7e- 
MCM2 minichromosome 
dependent 02 202107 s at 
43 NM 004526 MCM2 maintenance deficient 2, mitotin 
ATPase activity (S. cerevisiae) 
1.8e j 47 -1859865 MCM4 
MCM4 minichromosome 
maintenance deficient 4 (S. 03 222037 at 
cerevisiae) 
MCM6 minichromosome 
3.5e 201930 at 49 NM 005915 MCM6 
maintenance deficient 6 (MISS 
05 j homolog, S. pombe) (S. 
cerevisiae) 
MCM5 minichromosome 
. 
0e-216237 
s at 61 AA807529 MCM5 maintenance deficient 5, cell 06 division cycle 46 (S. cerevisiae) 
3. Oe- 209849 sat 74 AF029669 
IRAD51C 
! RAD51 homolog C (S. cerevisiae) 08 
MCM7 minichromosome 
show the whole group 
6.3e3 
s at 83 AF279900 MCM7 maintenance deficient 7 (S. 1" 
ýi cerevisiae) 
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79 - regulation 
of cyclin 
dependent 3 9e- 203968 s at 11 NM 001254 CDC6 
CDC6 cell division cycle 6 
protein kinase 
02 homolog (S. cerevisiae) 
activity 
3 205394 at 23 NM 001274 CHEK1 
CHK1 checkpoint homolog (S. 
03 pombe) 
1 0e- cyclin-dependent kinase inhibitor 3 . 04 209714 s at 26 AF213033 CDKN3 (CDK2-associated dual specificity 
phosphatase) 
1Oe- 
05 203418 at 39 NM 001237 CCNA2 cyclin A2 
3.3e- 
07 204695 at 42 Al343459 CDC25A cell division cycle 25A 
1 4e- 
07 205034 at 70 NM 004702 CCNE2 cyclin E2 
6281 DNA 3 7e 205909 at 46 NM 002692 POLE2 polymerase 
(DNA directed), 
repair 01 epsilon 2 (p59 subuni 
1 5e- 201202 at 69 NM 002592 PCNA proliferating cell nuclear antigen 01 
3 8e- 209849 s at 74 AF029669 RAD51C RAD51 homolog C (S. cerevisiae) 02 
8 9e- 
03 205733 at 81 NM 000057 BLM Bloom syndrome 
1 5e- 205024 s at 84 NM 002875 RAD51 
RAD51 homolog (RecA homolog, 
03 E. coli) (S. cerevisiae) 
3 2e 203209 at 92 B0001866 RFC5 replication 
factor C (activator 1) 5, 
04 - 36.5kDa 
48e mat 96 B0005264 RPA3 replication protein A3,14kDa 05 
5 5e 203564 at 97 NM 004629 FANCG 
Fanconi anemia, complementation 
06 group G 
6 0e- 
, n4'(_` s ý! 99 NM 002452 NUDT1 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 1 
5660 - delta- 
DNA 
polymoraso 
6 6e 204127 a 21 B0000149 RFC3 
replication factor C (activator 1) 3, 
38kDa 
cofactor 
03 
complex 
1 5e- 201202 at 69 NM 002592 PCNA proliferating cell nuclear antigen 04 
8 7e- replication factor C (activator 1) 5, 
07 203209 at 92 
B0001866 RFC5 36.5kDa 
3684 - 1 le- flap structure-specific damaged DNA 
01 2047 at 31 
NM 004111 FEN1 
endonuclease 1 binding 
1 9e- mutS homolog 2, colon cancer, 
0; O(A21 at - 
58 U04045 MSH2 
nonpolyposis type 1 (E. coli) 
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2.5e- 
03 209849 s at 74 ý 
AF029669 ! RAD51 C RAD51 homolog C (S. cerevisiae) 
1 Ö4 204531 s at 77 NM 007295 BRCA1 breast cancer 1 earl onset , y 
ý. 2e 205024 s at 84 NM 002875 RAD51 
RAD51 homolog (RecA homolog, 
05 E. coli) (S. cerevisiae) 
show the whole group 
06 203564 at 97 NM 004629 FANCG 
Fanconi anemia, complementation 
group G 
. 5833 - 28 
hemoglobin e- 206834 03 at 3 NM 000519 HBD hemoglobin, delta 
complex 
605 - 213515 x at 13 Al133353 HBG1 hemoglobin, gamma A 
2 - , Iio : use whole group 
06 20-9116 x at 29 M25079 HBB hemoglobin, beta 
15671 -oxygen 
transport 
2.8e- 206834 03 at 3 NM 000519 HBD hemoglobin, delta 
le- 6 
05 213515 x at 
13 Al133353 HBG1 hemoglobin, gamma A 
06 209116 x at 
29 M25079 HBB hemoglobin, beta 
5344 - oxygen _ 3 transporter 
03 206834 at 3 NM 000519 HBD hemoglobin, delta 
activity 
X 1 9 at 213515 05 
13 Al133353 HBG1 hemoglobin, gamma A 
show the whoirý'J". p 
ý406 
209116 x at 29 M25079 HBB hemoglobin, beta 
4748- 
ribonucleoside- 2.1e- ribonucleotide reductase M2 diphosphate 209773 s 04 at 
1 B0001886 RRM2 
polypeptide reductase 
activity 
- ------------ 1.1e- 201477 s at 32 NM 001033 RRM1 ribonucleotide reductase 
M1 
05 
----- -- -- 
polypeptide 
7089- ý 
start traversing ll di l i i 2 G 
control point of 
2 5e- 203213 at 4 AL524035 CDC2 
ce v s on cyc e , 
1 to S and 
mitotic cell 
03 G2 to M 
cycle 
1.8e- 203968 s at 11 NM 001254 CDC6 
CDC6 cell division cycle 6 
05 homolog (S. cerevisiae) 
show the whole group 
1.5e- 204510 05 at 88 NM 003503 CDC7 
CDC7 cell division cycle 7 (S. 
cerevisiae) 
7 -DNA 
i 
4.6e- 203968 t 11 
- 
NM CDC6 cell division cycle 6 p replication s 03 a 001254 CDC6 homolog (S. cerevisiae) 
checkpoint 
show the whoEEe <J 0uP 
205 1204126 s at 19 NM 003504 CDC45L 
CDC45 cell division cycle 45-like 
cerevisiae) S ( . 
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776 - 4.7e 209642 at 33 AF043294 BUB1 
BUB1 budding uninhibited by 
kinetochore 02 benzimidazoles 1 homolog (yeast) 
103 203362 s at i 37 NM 002358 MAD2L1 
MAD2 mitotic arrest deficient like 1 
t (yeas ) 
2 ! 
BUB1 budding uninhibited by 
show the whose group ý 203755 05 at 41 NM 001211 BUB1B 1 benzimidazoles 1 homolog beta 
(yeast) 
5876 - spindle 53 218009 s 03 at 14 NM 003981 PRC1 protein regulator of cytokinesis 1 
ýnow t 1( whole qt 
4. Oe- 202095 s 05 at 25 NM 001168 BIRC5 
baculoviral IAP repeat-containing 5 
i i (surv v n) 
81 56 - negative 
regulation of 4.6e- 203968 s at 11 NM 001254 CDC6 
CDC6 cell division cycle 6 
DNA ( 03 homolog (S. cerevisiae) 
replication 
4 
show the whole group 
5 218-5- 0 at 27 NM 895 015 GMNN geminin, DNA replication inhibitor 
6189 -'de novo' 
phosphoribosylaminoimidazole 
IMP 1 
3.3e- 201014 s at 107 NM 006452 PAILS 
1 carboxylase, 
biosynthesis 
02 1 phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
phosphoribosylglycinamide 
ý formyltransferase, 
6.0e- 212378 at 117 1 NM 000819 GART phosphoribosylglycinamide 04 synthetase, 
phosphoribosylaminoimidazole 
synthetase 
1.8e- phosphoribosylformylglycinamidine 
04 213302 at 251 AL044326 PFAS synthase (FGAR 
amidotransferase) 
9113 - purine 
phosphoribosylaminoimidazole 
base 4.4e- 201014 s at' 107 NM 006452 PAICS carboxylase, 
biosynthesis 
02 phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
phosphoribosylglycinamide 
formyltransferase, 
1.1e- 212378 at 117 ' NM 000819 GART Phosphoribosylglycinamide 03 , synthetase, 
phosphoribosylaminoimidazole 
synthetase 
2.3e- 214431 at 176 NM 003875 GMPS guanine monphosphate 04 synthetase 
2.2e 209434 s at 461 U00238 PPAT phosphoribosyl pyrophosphate 04 amidotransferase 
5762 - 
mitochondrial 
large ribosomal 
4.1e- 218049 s 02 at 98 NM 014078 MRPL13 
mitochondrial ribosomal protein 
L13 
subunit 
1.5e- 
03 
(203931 
s at 144 NM 002949 MRPL12 mitochondria) ribosomal protein L12 
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204 208787 at 196 B0003375 MRPL3 mitochondrial ribosomal protein L3 
2 
. 
2e- 213897 sat 493 AI832239 MRPL23 mitochondria) ribosomal protein 04 
166- 
nucleotide 
1. Oe- 203968 s at 11 NM 001254 i CDC6 
! 
CDC6 cell division cycle 6 
binding 
01 homolog (S. cerevisiae) 
1.1e- 204033 at 17 NM 004237 TRIP13 
thyroid hormone receptor 
02 interactor 13 
f 9.9e 204127 at 21 B0000149 RFC3 replication 
factor C (activator 1) 3, 
04 38kDa 
_f 1 
MCM4 minichromosome 
03 222037 at 47 
A1859865 MCM4 maintenance deficient 4 (S. 
cerevisiae) 
1.1e- 3 AF279900 MCM7 
MCM7 minichromosome 
03 210983 s at 8 maintenance deficient 7 (S. 
cerevisiae) 
show the whole group 
2.4e- 
i 203209 at 92 B0001866 RFC5 
replication factor C (activator 1) 5, or C 
04 3 . 5kDa 
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iGA report on the differentially expressed functional gene 
classes: up-regulated Normal GO vs Normal Divided 
Functional 
4anoinics 
Facility 
General Information 
Mode Representative 
Number of genes on chip 12698 
Number of annotated genes 9529 
Number of groups 3990 
Number of singletons 1646 
Significance threshold 2.5e-04 
File name IN GO vs ND 
Group Changed P-Value Percent 
Top Changed Groups Members Members Changed Changed 
8009 - chemokine activity 40 
-1 9 2.4e-10 I 22.50 
6935 - chemotaxis 86 10 8.7e-09 11.63 
7001 - chromosome organization 
and biogenesis (sensu 54 7 5.5e-08 12.96 
Eukaryota) 
786 - nucleosome 42 5 2.8e-07 
1 11.90 
5 6334 - nucleosome assembly 
T 47 5 
. 
Oe-07 1 10.64 
569 94 - chromosome 37 4 7.3e-06 
--- 10.81 
6928 - cell motility 99 7j 5.9e-05 7.07 
8219 - cell death 16 3 1.2e-04 18.75 
9596 - detection of pest, 4 4 2.4e-04 100.00 
pathogen or parasite 
16126 - sterol biosynthesis 3 3 2.4e-04 100.00 
OVuV 
chemokine 1.7e-02 210163 at 4 AF030514 CXCL11 
chemokine (C X-C 
motif) ligand 11 
activity 
6e-04 1209774 x at 7 10 M57731 CXCL2 
chemokine (C-X-C 
. motif) ligand 2 
1.1e-04 204533 at 23 NM 001565 CXCL10 chemokine 
(C-X-C 
d 10 li f gan moti ) 
205242 at 3.2e-06 25 ! NM 006419 CXCL13 chemokine 
(C-X-C 
mntifl linanrl 1 (R- 
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- ----- cell 
chemoattractant) 
4. Oe-07 207850 at 37 NM 002090 CXCL3 
I chemokine (C-X-C 
motif) ligand 3 
chemokine (C-X-C 
motif) ligand 6 
1.7e-08 206336 at 42 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
chemokine (C-X-C 
motif) ligand 1 
2.7e-09 204470 at 56 NM 001511 CXCL1 (melanoma growth 
stimulating activity, 
alpha) 
1.4e-09 202859-x at 82 NM 000584 IL8 interleukin 8 
show the whole 2.4e-10 210072 at 88 U88321 CCL19 
chemokine (C-C 
group I motif) ligand 19 
chemokine (C-X-C 6935 -- 
chemotaxis 
3.6e02 210163 at 4 AF030514 CXCL11 motif) ligand 11 
3.5e-03209774 x at 10 M57731 CXCL2 
chemokine (C-X-C 
motif) ligand 2 
1.1 e-03 204533 at 23 
!; 
NM 001565 chemokine 
motif) ligand 
(C-X-C CXCL10 
10 
chemokine (C-X-C 
6.8e-05 205242 at 25 NM 006419 
motif) ligand 13 (B- CXCL13 
cell 
chemoattractant) 
--- ------ ----- - r-- -- - ----- -- --- --- 
1.8e-05 207850 at 37 NM 002090 CXCL3 
chemokine (C-X-C 
motif) ligand 3 
chemokine (C-X-C 
motif) ligand 6 
1.8e-06 206336 at 42 1 NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
chemokine (C-X-C 
motif) ligand 1 
6.2e-07 204470 at 56 NM 001511 CXCL1 (melanoma growth 
stimulating activity, 
alpha) 
interleukin 8 6.6e-07 1202859 x at 
r 82 [NM 000584 IL8 
[8.3e 
08 210072 at 88 U88321 CCL19 
chemokine (C-C 
motif) ligand 19 
v-ral simian 
show the whole 
leukemia viral 
group 
8.7e-09 214435 x at 92 NM 005402 RALA oncogene homolog 
A (ras related) 
7001 - 
----------- i 
chromosome 
organization 
1.1e-02 1215071 s at j2 AL353759 HIST1 H2AC histone 1, H2ac 
and 
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biogenesis 
(sensu 
Eukaryota) 
9.4e-05 X202708 s at r3 NM 003528 HIST2H2BE histone 2, H2be 
6. Oe-05 209806 at 14 80000893 HIST1 H2BK histone 1, H2bk 
9.0e-06 214290 s at, 24 A1313324 HIST2H2AA , histone 2, H2aa 
stone f 1.0e-06 208886 at 33 B0000145 H1 FO H1 
hi 
m ember 
p ily, 
alpha 
thalassemia/mental 
retardation 4.7e-07 208859 s at 53 A1650257 ATRX 
syndrome X-linked 
1 
(RAD54 homolog, 
S. cerevisiae) 
show 
group 
whole 5.5e-08 
x209911 
x at 
p63 (B0002842 
HIST1H2BD histone 1, H2bd 
786 - 
nucleosome 
8.8e-03 215071 s at 2 AL353759 HIST1H2AC histone 1, H2ac 
5.7e-05 202708 s at 3 NM 003528 HIST2H2BE histone 2, H2be 
209806 a1 4 B0000893 HIST1H2BK 
r histone 1, H2bk ý- - -f 2.8e-05 
[ 
. 
3e-06 1214290 s at 24 r A1313324 HIST2H2AA histone 2, H2aa 
tone family, show the whol? 
f H1 his le 
He 
-07 208886 at 33 B0000145 H1FO group I member 0 
6334 - 
nucleosome 9.8e-03 215071 s at 2 AL353759 HIST1 H2AC histone 1, H2ac 
assembly 
7.1e-05 202708 s at 3 NM 003528 HIST2H2BE histone 2, H2be 
-3.9e-05 209806 at 14 B0000893 HIST1H26K histone 1, H2bk 
5.1e-06 1214290 s at 24 A1313324 HIST2H2AA ' histone 2, H2aa 
show the whole 
[oe07 H1 histone family, 
208886 at 33 B0000145 H1 FO group member 0 
5694 - 7.8e-03 215071 s at 2 AL353759 HIST1 H2AC histone 1, H2ac 
chromosome 
4.4e-05 X202708 s at 
F3 NM 003528 HIST2H26E histone 2, H2be 
1.0e-04214290 s at 
l 24 A1313324 HIST2H2AA histone 2, H2aa 
show the whole 7.3e-06 208886 at 33 B0000145 H1 FO 
H1 histone family, 
member 0 
6928 - cell chemokine (C-X-C 2.1e-01 204533 a 
motility 
23 NM 001565 CXCL10 
motif) ligand 10 
prostaglandin- 
endoperoxide 
3.6e-02 204748 at 29 NM 000963 PTGS2 
synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
1.3e-02 transmembrane 4 209108 at 47 AF053453 TM4SF6 
I cunPrfamily 
Susan M Graham 2005 Appendix 1.28 
member 6 
1.6e-03 203476 at 49 
[NM 
006670 TPBG trophoblast 
glycoprotein 
[1.3e-03 205844 at 1 78 ! NM 004666 VNN1 vanin 1 
2. Oe-04 1202859 x at 82 NM 000584 i- 1 IL8 interleukin 8 
Show the whose 5.9e-05 201005 at 96 I NM 001769 
group 
CD9 CD9 antigen (p24) 
8219 - cell 
epithelial 
death 
1.0e-02 201324 at 6 NM 001423 EMP1 membrane protein 
1 
optineurin 2.3e-03 202073 at 43 AV757675 OPTN 
amyloid beta (A4) 
show the whole 1.2e-04 200602 at 59 'NM 000484 APP 
precursor protein 
group (protease nexin-II, 
Alzheimer disease) 
- 9596- 
detection of 
pest, 1.8e-01 205101 at 463 NM 000246 MHC2TA 
MHC class II 
pathogen or 
transactivator 
parasite 
major 
1.4e-02 217478 s at 472 X76775 HLA-DMA 
histocompatibility 
complex, class II, 
DM alpha 
major 
8.5e-04 1 203932 at 525 ! NM 002118 ' HLA-DMB 
2.4e-04 210514 x at 695 AF226990 
---16126- 
213577 at 150 AA639705 sterol 4.6e-02 
biosynthesis 
2.6e-03 209146 at 273 AV704962 
2.4e-04 211423 s at 415 D85181 
HLA-G 
histocompatibility 
complex, class II, 
DM beta 
HLA-G 
histocompatibility 
antigen, class I, G 
SALE squalene 
epoxidase 
SC4MOL sterol-C4-methyl 
oxidase-like 
sterol-C5- 
desaturase (ERG3 
SC5DL delta-5-desaturase 
homolog, fungal)- 
like 
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7.4e-06 203418 at 17 NM 001237 CCNA2 cyclin A2 
hepatocyte 
5.8e-07 210997 at 22 M77227 HGF growth 
factor 
(hepapoietin A; 
scatter factor) 
CDC20 cell 
7.4e-08 202870 s at , 
29 NM 001255 CDC20 division cycle 20 
homolog (S. 
cerevisiae) 
chromosome 
3.8e-09 218663 at 32 NM 022346 HCAP-G condensation 
protein G 
7.3e-10 219306 at 40 : NM 020242 j KNSL7 kinesin-like 7 
coronin, actin 
1.8e-10 209083 at 43 U34690 COROIA binding protein, 
1A 
show the whole 1 5e-10 202240 at 44 NM 005030 PLK1 polo-like 
kinase 1 
g oup . (Drosophila) 
5819 - spindle 2.6e-02 204444 at 23 NM 004523 KIF1 1 
kinesin family 
b 11 mem er 
-_--- - - ý - I --- - --- --- ! CDC20 cell 
8e-04 4 202870 s at 29 NM 001255 CDC20 
division cycle 20 
. homolog (S. 
cerevisiae) 
2.0e-05 1204709 s at 49 NM 004856 KIF23 
kinesin family 
b mem er 23 
0e-07 3 208079 s at 54 NM 003158 STK6 serine/threonine . kinase 6 
TPX2, 
microtubule- 
show the whole whole 5.7e-09 210052 s at 65 AF098158 TPX2 associated g 
protein homolog 
(Xenopus laevis) 
5871 - kinesm 
f kinesin family 
complex 
2.2e-02 204444 at 23 NM 004523 KIF11 member 11 
1e-04 9 204709 s at 49 NM 004856 KIF23 
kinesin family 
. member 23 
snow she whole 8e-05 2 209408 at 68 U63743 KIF2C 
kin esin family 
group . member 2C 
775- 
chromosome, 8 5e-03 204162 at 9 NM 006101 KNTC2 
kinetochore 
pericentric . associated 2 
region 
-- _-_-- 
11 NM 0 
-- centromere 4.3e-05 204962 s at 01809 CC ENPA 
I protein A, 17kDa 
show the whole 8e-05 2 209408 at 68 U 63743 KIF2C 
kinesin family 
. member 2C 
3777- 6.3e-02 1 204444 at 23 NM 004523 KIF11 
kinesin family 
microtubule member 11 
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iGA report on the differentially expressed functional gene 
classes: up-regulated CML Divided vs CML GO 
General Information 
Mode 
Number of genes on chip 
Number of annotated genes 
Number of groups 
Number of singletons 
Significance threshold 
File name 
I Representative 
12698 
9531 
3990 
1648 
2.5e-04 
ICML GO vs CML DIV 
Grou Changed P-Value Percent 
Top Changed Groups Members Members Changed Chanqed 
7067 - mitosis 74 10 1.5e-10 13.51 
5819 -spi4e 11 5 5.7e-09 45.45 
5871 - kinesin complex 9 3 2.8e-05 33.33 
775 - chromosome, 9 3 2.8e-05 33.33 
pericentric region 
3777 - microtubule motor 
1 
4 4 5 05 1 27 e- . 4.81 activit 
4869 - cysteine protease 16 3 4 6 05 18 75 
inhibitor activity 
e- . . 
278 - mitotic cell cycle 3 2 7.1e-05 66.67 
776 - kinetochore 14 3 1 1e-04 21.43 
5876 - spindle microtubule 4 3 2.1 e-04 75.00 
22 - mitotic spindle 2 2 2.2e-04 100.00 
elongation 
Changed group br eakdown: 
Group 
P-value e-set 
Prob Rank Gene ID Gene Title D Sy 
cell division cycle 
7067 - mitosis 5.3e-02 203213 at i7 AL524035 CDC2 2, G1 to S and G2toM 
2.1 e-03 204162 at 9I NM 006101 KNTC2 
kmetochore 
associated 2 
ubiquitin- 
5.2e-05 202954 at 10 NM 007019 UBE2C conjugating 
enzyme E2C 
Susan M Graham 2005 
motor activity 
8.4e-03 , 204709 s at 
9.0e-04 1 209408 at 
whole show the 5.4e-05 218355 at 75 NM 012310 KIF4A 
kinesin family 
O1 p member 4A 
4869 - 
cysteine c statin A (stefin protease 5.0e-03 204971 at 3 NM 005213 CSTA y A) inhibitor 
activity 
2 5e-03 210140 at 45 AF031824 CST7 cystatin 
F 
. (leukocystatin) 
show the whole 
baculoviral IAP 
6.4e-05 202095 s at 48 NM 001168 BIRC5 repeat-containing group 
5 (survivin) 
chromosome 278 - mitotic 1. Oe-02 218663 at 32 NM 022346 HCAP-G condensation 
cell cycle , protein G 
show the whole 7 1e-05 212949 at 47 D38553 BRRN1 
barren homolog 
4rOUp . (Drosophila) 
BUB1 budding 
776 7 1e-02 209642 at 50 AF043294 BUB1 uninhibited by kinetochore . benzimidazoles 1 
homolog (yeast) 
MAD2 mitotic 
3.6e-03 11203362 s at! 62 NM 002358 MAD2L1 I arrest deficient- 
like 1 (yeast) 
BUB1 budding 
uninhibited by 
up hole show rh 1.1e-04 203755 at 66 NM 001211 BUB1 B benzimidazoles I o 
1 homolog beta 
(yeast) 
baculoviral IAP 
5876 - spindle 2. Oe-02 202095 s at , 48 I NM 001168 I BIRC5 repeat-containing microtubule 5 (survivin) 
kinesin family 3.6e-04 218355 at 75 NM 012310 KIF4A member 4A 
show the whole 1 e-04 2 1218009 s at 104 NM 003981 PRC1 
protein regulator 
group , of cytokinesis 1 
22 - mitotic 
spindle 1. Oe-02 204709 s at 49 NM 004856 KIF23 
kinesin family 
member 23 
elongation 
1 protein regulator 2.2e-04 218009 s at 04 NM 003981 PRC1 of cytokinesis 1 
Appendix 1.31 
I 
49 NM 004856 KI F23 
menesin 
fa 
mber 23 
68 U63743 KIF2C kinesin family 
member 2C 
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iGA report on the differentially expressed functional gene 
classes: up-regulated CML GO vs CML Divided 
General Information 
Mode Representative 
Number of genes on chip 12698 
Number of annotated genes 9532 
Number of groups 3991 
Number of singletons 1649 
Significance threshold [ 2.5e-04 
File name I ICML GO vs CML DIV 
Group Changed P-Value Percent 
Top Changed Groups Members Members Changed Changed 
8009 - chemokine activity 
I 40 7 4. Oe-11 I-17.50 
6935 - chemotaxis 86 9 
F 2.0e-08 [10.47 
5833 - hemoglobin complex 9 3 5.7e-05 33.33 
47115 - trans-1,2-dihydrobenzene- 3 2 1.3e-04 66 67 
1 2-diol dehydrogenase activity . 
15125 - bile acid transporter 3 2 1.3e-04 66 67 
activity . 
Changed group breakdown: 
Group P-value 
Probe-set Rank Gene ID Gene Title 
ID Symbol 
8009 - chemokine (C-X- 
chemokine 11.7e-02 210163 at 4 AF030514 CXCL11 C motif) ligand 
activity 11 
chemokine (C-X- 
2.5e-04 204533 at 6 NM 001565 CXCL10 C motif) ligand 
10 
interleukin ý2.4e-06 [202859 x at ;7 NM 000584 IL8 8 
chemokine (C-X- 1.3e07 207850 at 12 NM 002090 CXCL3 C motif) ligand 3 
chemokine (C-X- 
C motif) ligand 1 
9e-09 204470 at 15 NM 001511 CXCL1 
(melanoma 2 . growth 
stimulating 
activity, alpha) 
05114 s at 18 NM 002983 '', MGC12815 rhamnkine (C-(' 8.7e-11 : 205114-s- 
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motif) ligand 3- 
like, centromeric 
show the whole group 4. Oe-11 209774 x at 24 M57731 CXCL2 chemokine 
(C-X- 
C motif) ligand 2 
6935 - 
chemotaxis 
3.6e-02 210163 at 4 AF030514 CXCL11 C motif) ligand 
11 
chemokine (C-X- 
1.2e-03 204533 at 6I NM 001565 CXCL10 C motif) ligand 
10 
ý2 4e-05 202859 x at 7 NM 000584 r IL8 interleukin 8 
2.9e-06 207850 at chemokine (C-X- 12 NM 002090 CXCL3 C motif) ligand 3 
chemokine (C-X- 
1.5e-07 1 204470 at 
C motif) ligand 1 
15 NM 001511 CXCL1 (melanoma 
growth 
stimulating 
activity, alpha) 
X- [5. -4e-08 209774 x at 24 M57731 CXCL2 C 
che 
motif) 
mokine (C- 
ligand 2 
chemokine (C-X- 
C motif) ligand 6 
1.3e-07 206336 at 45 I NM 002993 CXCL6 (granulocyte 
chemotactic 
protein 2) 
chemokine (C-X- 3.7e-08 214974 x at 57 AK026546 CXCL5 C motif) ligand 5 
r- - chemokine (C-X- 
show the whole group 2.0e-08 205242 at 75 NM 006419 CXCL13 
C motif) ligand 
13 (B-cell 
chemoattractant) 
5833- 
hemoglobin 2.8e-02 209116 x at 30 M25079 HBB beta 
complex 
hemoglobin, 
2.7e-03 204419 x at 
! 85 NM 000184 HBG1 
gamma A 
erythroid 
show the whole group 5.7e-05 219672 at 86 NM 016633 ERAF associated 
factor 
47115 - trans- 
1,2- 
dihydrobenzene- 
1,2-diol 
dehydrogenase 
activity 
1.2e-02 ! 204151 x at 37 I NM 001353 
aldo-keto 
reductase family 
1, member C1 
(dihydrodiol 
AKR1C1 dehydrogenase 
1; 20-alpha (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
show the whole group 1.3e-04 216594 x at 64 S68290 
AKR 1 C1 
AKR1C2 
chemokine (C-X- 
C motif) ligand 
11 
aldo-keto 
rpdiiu: taca family 
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1, member C1 
(dihydrodiol 
dehydrogenase 
1; 20-alpha (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
/// aldo-keto 
reductase family 
1, member C2 
(dihydrodiol 
dehydrogenase 
2; bile acid 
binding protein; 
3-alpha 
hydroxysteroid 
dehydrogenase, 
type III) 
aldo-keto 
reductase family 
1, member Cl 
(dihydrodiol 
dehydrogenase 
1; 20-alpha (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
[-F- Fi- 
15125 - bile acid 
transporter 1.2e-02 204151 x at 37 jNM 001353 AKR1C1 
activity 
show the whole group 1.3e-04 ý 216594 x at 64 S68290 
AKR 1C1 
AKR1C2 
aldo-keto 
reductase family 
1, member C1 
(dihydrodiol 
dehydrogenase 
1; 20-alpha (3- 
alpha)- 
hydroxysteroid 
dehydrogenase) 
/// aldo-keto 
reductase family 
1, member C2 
(dihydrodiol 
dehydrogenase 
2; bile acid 
binding protein; 
3-alpha 
hydroxysteroid 
dehydrogenase, 
type III) 
